



# Bharat Parenterals Limited

Registered Office & Works:

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,  
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: 25<sup>th</sup> June, 2024

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai -400 001

Scrip Code: 541096

Dear Sir / Madam,

**Sub: Submission of Annual Report under clause 34 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**


We herewith submit revised Annual Report of the company for the FY 2023-2024 in line with Corrigendum to Notice 31<sup>st</sup> AGM circulated on 22<sup>nd</sup> June, 2024. This revision incorporates necessary amendments and corrections, particularly in light of our ongoing application for in-principle approval with the Bombay Stock Exchange ("BSE") for recent transactions involving the acquisition of equity stake in Varenym Healthcare Pvt Ltd ("VHPL") and Varenym Biolifesciences Pvt Ltd ("VBPL"). Additionally, it includes details regarding the issue of equity shares on a preferential basis for the swap of equity shares of the Company, along with the Notice of 31<sup>st</sup> Annual General Meeting of the company scheduled to be held on 2<sup>nd</sup> July, 2024 at 11:00 A.M. through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs (MCA) and SEBI.

The said Annual Report along with the Notice is also available on the website of the company [www.bplindia.in](http://www.bplindia.in).

A copy of the Annual Report is being mailed to all the shareholders of the company whose E-Mails IDs are registered with the company/R&T Agents & DPs.

You are requested to take note of the same.

**FOR BHARAT PARENTERALS LIMITED**



**Krutika Bhattbhatt**  
Company Secretary & Compliance officer





**Bharat Parenterals Limited**

*Harnessing Science For Life*

**Annual Report**

**2023 - 2024**

Registered Office :

Survey No : 144-A, Jarod Samlaya Road,  
Vill. Haripura, Ta. Savli, Dist. Vadodara - 391520(Guj)

Ph. No : +91 9909928332

E-mail : [cs@bplindia.in](mailto:cs@bplindia.in), [info@bplindia.in](mailto:info@bplindia.in)

Web : [www.bplindia.in](http://www.bplindia.in)





**BOARD OF DIRECTORS:**

Mr. Bharat R. Desai, Managing Director  
Mr. Hemang J. Shah, Executive Director  
Mr. Shailesh Gabhawala, Independent Director  
Mrs. Zankhana Sheth, Independent Director  
Mr. Mukesh Patel, Independent Director  
Mr. Sanjay Shah, Non Executive Director

**CHIEF FINANCIAL OFFICER :**

Mr. Jignesh Shah

**COMPANY SECRETARY &  
COMPLIANCE OFFICER :**

Ms. Krutika Bhattbhatt

**AUDITORS:**

CNK & Associates LLP, Chartered Accountants  
(Firm Registration No.: 101961)

**BANKERS**

Axis Bank Limited

**REGISTRARS AND  
TRANSFER AGENTS :**

Adroit Corporate Services Private Limited  
18-20, Jafferbhoy Industiral Estate, 1st Floor,  
Makwana Road, Marol Naka, Andheri  
East, Mumbai, Maharashtra, 400059

**REGISTERED OFFICE &  
FACTORY :**

Survey No. 144-A, Jarod- Samlaya Road, Village  
Haripura, Taluka Savli, Dist. Vadodara –  
391520

**31<sup>st</sup> AGM NOTICE****BHARAT PARENTERALS LIMITED**

NOTICE is hereby given that the 31<sup>st</sup> Annual General Meeting (“AGM”) of the members of **Bharat Parenterals Limited (CIN: L24231GJ1992PLC018237) (“the Company”)** will be held on Tuesday, **the 2<sup>nd</sup> July, 2024 at 11:00 A.M. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”)** to transact the following business:

**ORDINARY BUSINESS:**

1. To receive, consider and adopt the audited
  - a. Standalone and Consolidated Financial Statements of the Company for the financial year ended 31<sup>st</sup> March, 2024, together with the Reports of the Board of Directors and Auditors thereon.
  - b. Consolidated Financial Statements of the Company for the Financial year ended 31<sup>st</sup> March, 2024 together with the Report of the Auditors thereon
2. To declare final dividend of ₹1/- (10%) per Ordinary (equity) Share of ₹10/- each for the Financial Year 2023-24.
3. To appoint a Director in place of **Mr. Hemang J Shah (DIN: 03024324)**, who retires by rotation in terms of Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment.

**SPECIAL BUSINESS:**

4. **TO CONSIDER AND RATIFY THE REMUNERATION PAYABLE TO CMA CHETAN GANDHI, COST ACCOUNTANTS FOR THE FINANCIAL YEAR ENDING MARCH 31, 2025.**

To consider and if thought fit, to pass with or without modification(s), the following resolution as an “**ORDINARY RESOLUTION**”:

**“RESOLVED THAT** pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013, read with Rule 14 of Companies (Audit and Auditors) Rules, 2014 and other rules, if any, made there under (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the Company be and is hereby ratify the remuneration of Rs. 75,000/- (Rupees Seventy Five Thousand only) plus applicable taxes and out of pocket expenses incurred in connection with the cost audit as approved by the Board of Directors of the Company, payable to M/s. Chetan Gandhi & Associates, Cost Accountants (Firm Registration No. 101341), Proprietor- Mr. Chetan Gandhi (Membership No. 22096) for conducting Cost Audit of the cost records maintained by the Company for manufacturing of pharmaceutical formulations for the financial year ending March 31, 2025.”





**FURTHER RESOLVED THAT** the Board of Directors or the Company Secretary of the Company, be and are hereby severally authorised to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient to give effect to this resolution.”

**5. TO APPROVE RELATED PARTY TRANSACTIONS:**

To consider and if thought fit, to pass with or without modification(s), the following resolution as an **“ORDINARY RESOLUTION”**:

**“RESOLVED THAT** pursuant to the provisions of Section 188 and other applicable provisions, if any of the Companies Act, 2013 (“Act”), read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), including any statutory modification(s) or re-enactment thereof for the time being in force and the Company’s policy on Related Party Transactions and subject to such approvals, consents, sanctions and permissions as may be necessary, and basis of approval and recommendation of the Audit Committee and the Board of Directors of the Company, approval of the members of the Company be and is hereby accorded to enter into contract(s)/ arrangement(s)/ transaction(s) with parties as detailed in the table(s) forming part of the Explanatory Statement annexed to this notice as mutually agreed between related parties and the Company, notwithstanding that such transactions may exceed 10% of the Consolidated Turnover of the Company in any financial year or such other threshold limits as may be specified under the Listing Regulation from time to time, up to such extent maximum value of Related Party Transactions with such parties in aggregate, does not exceed value as specified in the explanatory statement to this resolution and on such terms and conditions as the Board of Directors may deem fit, in the normal course of business and on arm’s length basis,;

**RESOLVED FURTHER THAT** the Board of Directors of the Company (hereinafter referred to as “Board” which term shall be deemed to include the Audit Committee of the Company and any duly constituted/ to be constituted committee of Directors thereof in exercise its powers including powers conferred in this resolution) be and is hereby authorised to do or cause to be done all such acts, matters, deeds and things and to settle any queries, difficulties that may arise with regard to any transaction with the related party and execute such agreements, documents and writings and to make such filings as may be necessary or desirable for the purpose of giving effect to this resolution, in the best interest of the Company.”

**6. TO INCREASE IN THRESHOLD LIMITS FOR GRANTING LOANS/ GUARANTEES, PROVIDING SECURITIES AND MAKING INVESTMENTS IN SECURITIES UNDER SECTION 186 OF THE COMPANIES ACT, 2013:**



To consider and if thought fit, to pass with or without modification(s), the following resolution as a **“SPECIAL RESOLUTION”**:

**“RESOLVED THAT** pursuant to the provisions of Section 186 of the Companies Act, 2013 and any other applicable provisions of the Companies Act, 2013 and Rules made there under (including any statutory modification(s) or re-enactment thereof for the time being in force) and in supersession of all the earlier resolutions passed in this regard, based on the recommendation of the Board of Directors of the Company, the consent of the members of the Company be and is hereby accorded to the Board of Directors (hereinafter referred to as the “Board” which term shall include any Committee constituted by the Board or any person(s) authorized by the Board to exercise its powers, including the powers conferred by this Resolution) to (a) give any loan to any person or other body corporate; (b) give any guarantee or provide security in connection with a loan to any other body corporate or person; and (c) acquire by way of subscription, purchase or otherwise, the securities of any other body corporate from time to time in one or more tranches as the Board of Directors as in their absolute discretion deem beneficial and in the interest of the Company, for an amount not exceeding Rs. 150 Crores (Rupees One hundred and Fifty crores Only), in aggregate, notwithstanding that such investments, outstanding loans given or to be given and guarantees and/or security provided may collectively exceed the limits prescribed under Section 186 of the Companies Act, 2013 but in any case, shall not exceed the limit as stated above.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, the Board of Directors of the Company be and is hereby authorized to take from time to time all decisions and such steps as may be necessary for giving loans, guarantees or providing securities or for making such investments and to execute such documents, deeds, writings, papers and/or agreements as may be required and do all such acts, deeds, matters and things, as it may in its absolute discretion, deem fit; necessary or appropriate.”

**7. TO APPROVE ISSUANCE OF EQUITY SHARES ON PREFERENTIAL BASIS FOR CONSIDERATION OTHER THAN CASH:**

To consider and if thought fit, to pass with or without modification(s), the following resolution as **“SPECIAL RESOLUTION”**:

**“RESOLVED THAT** pursuant to the provisions of Sections 23, 42, 62(1)(c) and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”), the Companies (Prospectus and Allotment of Securities) Rules, 2014, the Companies (Share Capital and Debenture) Rules, 2014 and other applicable rules and regulations made thereunder (including any amendments, statutory modification(s)



and/or re-enactment thereof for the time being in force) and in accordance with the provisions of the Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the “SEBI ICDR Regulations”), and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “SEBI Listing Regulations”), as amended from time to time, the Memorandum and Articles of Association of the Company and any other rules / regulations/ guidelines, if any, prescribed by any other statutory regulatory authority; and subject to the approval(s), consent(s), permission(s) and/or sanction(s), if any, of the appropriate authorities, institutions or bodies as may be required, and subject to such conditions as may be prescribed by any of them while granting any such approval(s), consent(s), permission(s), and/or sanction(s), and as agreed to by the Board of Directors of the Company (hereinafter referred to as the “Board” which term shall be deemed to include any committee which the Board may have constituted or hereinafter constitute to exercise its powers including the powers conferred by this resolution), consents which may be accepted by the Board of Directors of the Company (“Board”, which term shall include any committee which the Board may have constituted to exercise its powers including the powers conferred by this resolution); the consent of the shareholders of the company be and is hereby accorded to create, offer, issue allot 3,67,516 (Three Lakhs Sixty-Seven Thousand Five hundred and Sixteen) fully paid-up Equity shares of face value of INR. 10/- each at price of INR.1479.90/- (Rupees One Thousand Four hundred and Seventy-Nine Point Ninety) which includes Face value of INR. 10/- per shares along with premium of INR. 1469.90/- (Indian Rupees One thousand and Sixty-nine point ninety only) aggregate amounting to INR. 54,38,86,928.40/- based on price determined as per regulation 164 of SEBI ICDR Regulation for consideration other than cash (i.e. Swap of Equity shares), against purchase of shares of Varenyam Health care Pvt Ltd and Varenyam Biolifesciences Pvt Ltd Companies from the proposed allottees as stated in explanatory statement, on such terms and conditions as applicable to this proposed transaction (‘Preferential issue of Equity shares’)

**RESOLVED FURTHER THAT** in terms of the provisions of Chapter V of the SEBI (ICDR) Regulations, the “Relevant Date” for determining the floor price for the preferential issue of the Equity Shares is Friday, May 31<sup>st</sup>, 2024, being the date 30 (thirty) days prior to the date of this 31<sup>st</sup> Annual General Meeting i.e. Tuesday, 2<sup>nd</sup> July, 2024 for the proposed Preferential Issue.

**RESOLVED FURTHER THAT** for the purpose of giving effect to the offer, issue, allotment of the proposed Equity Shares, any Director, Chief Financial Officer and the Company Secretary be and are hereby severally authorized to do all such acts, deeds, matters and things as they may in their absolute discretion deem necessary and desirable for such purpose, including without limitation, preparing, signing, executing, and filing applications with the appropriate authorities for obtaining



requisite approvals for the issuance of the Equity Shares, as may be required, issuing clarifications on the issue and allotment of the Equity Shares, resolving any difficulties, effecting any modifications, changes, variation, alterations, additions and/or deletions to the foregoing conditions as may be required by any regulator, or other authorities or agencies involved in or concerned with the issue of the Equity Shares and as the Board may in its absolute discretion deem fit and proper in the best interest of the Company without being required to seek any further consent or approval of the members or otherwise.

**RESOLVED FURTHER THAT** for the purpose of giving effect to the resolution, the Board be and is hereby authorized to engage depositories, registrars, bankers, and other consultants and advisors to the issue and to remunerate them by way of fees and/or other charges and also to enter into and execute all such arrangements, agreements, memoranda, documents, etc. with such agencies, as may be required and as permitted by law.

**RESOLVED FURTHER THAT** for the purpose of giving effect to the resolution, the Board be and is hereby authorized to delegate any or all of the powers conferred upon it by this resolution to any committee of directors, any other director(s), and/or officer(s) of the Company.

**FOR AND ON BEHALF OF DIRECTORS**

Sd/-

Date: 10/06/2024

Place: Vadodara

Mr. Bharat Desai  
Chairman

Registered office:

BHARAT PARENTERALS LIMITED

CIN: L24231GJ1992PLC018237

Add: Survey No. 144-A, Jarod-Samlaya Road, Vill. Haripura, Tal. Savli, Vadodara-391520, Gujarat, India

Tel: +91 9909982332

Website: [www.bplindia.in](http://www.bplindia.in)

E-mail: [info@bplindia.in](mailto:info@bplindia.in) , [cs@bplindia.in](mailto:cs@bplindia.in)

**IMPORTANT NOTES: -**

1. The Ministry of Corporate Affairs ("MCA") has vide its General Circular No. 20/2020 dated May 5, 2020 read with General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 02/2021 dated January 13, 2021, General Circular No. 21/2021 dated December 14, 2021, General Circular No. 2/2022 dated May 5, 2022, General Circular No. 10/2022 dated December 28, 2022, General Circular No.



09/2023 dated September 25, 2023 (collectively referred to as “MCA Circulars”) and Securities and Exchange Board of India (“SEBI”) vide its Circular Nos. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022 and SEBI/HO/CFD/PoD-2/P/ CIR/2023/4 dated January 5, 2023 (collectively referred to as “SEBI Circulars”), have permitted the holding of AGM through Video Conferencing (“VC”) or Other Audio-Visual Means (“OAVM”), without the physical presence of the Members at a common venue vide the above MCA circulars and provided relaxation to companies from dispatching physical copy of annual report vide above SEBI circulars. In compliance with the provisions of the Companies Act, 2013 (“Act”), amended provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), MCA Circulars and Secretarial Standard on General Meetings issued by The Institute of Company Secretaries of India (“SS-2”), the AGM of the Company will be held through VC / OAVM. The venue of the meeting shall be deemed to be the Registered Office of the Company situated at Survey No. 144-A, Jarod-Samlaya Road, Vill. Haripura, Tal. Savli, Vadodara-391520, Gujarat, India.

2. The relevant details, pursuant to Regulations 36(3) of the SEBI Listing Regulations and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Director seeking reappointment at this AGM is annexed.
3. Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Circulars issued by MCA and SEBI, the AGM of the Company shall be conducted through VC/OAVM. National Securities Depository Limited (NSDL) will be providing facility for remote e-voting, participation in the AGM through VC / OAVM and e-voting during the AGM.
4. As the AGM shall be conducted through VC/ OAVM, physical attendance of the members has been dispensed with. Accordingly, the facility for appointment of Proxy by the Members is not available and hence, Proxy Form, Attendance Slip and Route Map of the venue of the meeting are not annexed to this Notice.
5. The relative Explanatory Statement pursuant to the provisions Section 102 of the Companies Act, 2013 (“Act”) setting out material facts concerning the Special Business under Item Nos. 4 to 6 of the accompanying Notice, is annexed hereto.
6. Shareholders attending the AGM through VC/OAVM shall be reckoned for the purpose of quorum for the AGM as per Section 103 of the Companies Act, 2013 (Act).



7. The Register of Members and Shares Transfer Books for the Equity shares of the Company shall remain closed from 26<sup>th</sup> June, 2024 to 02<sup>nd</sup> July, 2024.
8. As per SEBI Notification No. SEBI/LAD-NRO/GN/2018/24 dated June 8, 2018 and further amendment vide Notification No. SEBI/LAD-NRO/GN/2018/49 dated November 30, 2018, requests for effecting transfer of securities (except in case of transmission or transposition of securities) shall not be processed from April 1, 2019 unless the securities are held in the dematerialized form with the depositories. With the said change coming into effect from April 1, 2019, Equity Shares of the Company shall be eligible for transfer only in Dematerialized form. Therefore, the Shareholders are requested to take action to dematerialize the Equity Shares of the Company, promptly.
9. Members holding shares in more than one folio in the same name(s) are requested to send the details of their folios along with the share certificates so as to enable the Company to consolidate their holdings into one folio.
10. Members desirous of obtaining information / details about the accounts, are requested to write to the Company at least one week before the meeting, so that proper information can be made available at the time of meeting. The Members desirous of inspection of documents may write to the Company through E-mail and the same shall be sent to them electronically.
11. As By virtue of Section 72 of Companies Act, 2013 and SEBI circular SEBI/HO/MIRSD/MIRSD\_RTAMB/P/ CIR/2021/655 dated November 3, 2021, securities holders holding shares in physical mode are required to comply with the requirements of registration/updation of valid Permanent Account Number (PAN) and Know Your Customer (KYC) details in form ISR – 1 and/or form ISR – 2 as the case maybe with the Registrar and Transfer Agents of (RTA) the Company, Adroit Corporate Services Private Limited. The facility for nomination is available for the members of the Company in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting the Form No. SH-13. If a Member desires to opt out or cancel the earlier nomination and record a fresh nomination, he/she may submit the same in Form No. ISR-3 or Form No. SH-14, as the case may be. Further the folios wherein any one of the document/ details are not available on or after April 1, 2023, shall be frozen by the RTA. Members are requested to submit the said details to Company's (RTA).
12. As per SEBI Directive, in case of failure to register the PAN and bank account details as aforesaid, any transaction in the securities of the Company shall be subject to enhanced due diligence by the Company/ RTA, as may be prescribed.
13. The shareholders are hereby informed that all the correspondence in connection with the shares is addressed to the Registrar & Share Transfer Agent: - Adroit Corporate Services Private Limited situated at 18-20,





Jafferbhoy Industrial Estate, Makwana Rd, Marol Naka, Andheri East, Mumbai, Maharashtra 400059.

14. Members are requested to send their queries, if any, at least seven days in advance of the meeting on Email id-[cs@bplindia.in](mailto:cs@bplindia.in) along with query.
15. Corporate members intending to authorize their representatives to participate and vote at the meeting are requested to mail to [cs@bplindia.in](mailto:cs@bplindia.in), a scanned copy (PDF format) of the Board Resolution authorizing their representatives to attend and vote at the AGM.
16. In compliance with MCA Circular No. MCA General Circular No. 02/2022 Dated 05th May, 2022 and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/79 dated May 12, 2021 and owing to the difficulties involved in dispatching of physical copies of the financial statements including Board's Report, Auditor's report or other documents required to be attached therewith (together referred to as Annual Report), the Annual Report for FY 2023-2024 and Notice of AGM are being sent in electronic mode to Members whose e-mail address is registered with the Company or the Depository Participant(s) and the same is available on the company and BSE website.
17. Members are requested to intimate changes, if any, pertaining to their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney etc to their DPs in case the shares are held by them in electronic form and to the Company in case the shares are held by them in physical form.
18. To prevent fraudulent transactions, members are advised to exercise due diligence and notify the Company of any change in address or demise of any member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the Concerned Depository Participant and holdings should be verified.
19. Members holding shares in physical mode and who have not registered / updated their email addresses with the Company are requested to update their email addresses with the company by providing the Folio No., No. of shares held and details of Email ID to be registered to [cs@bplindia.in](mailto:cs@bplindia.in). Members holding shares in dematerialized mode are requested to register / update their e-mail addresses with the relevant Depository Participant(s).
20. To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their DPs in case the shares are held by them in electronic form and with the Company in case the shares are held by them in physical form.
21. The Shareholders who have not registered their email ID with the Company can access the Annual Report on the website of the Company [www.bplindia.in](http://www.bplindia.in) and website of the stock exchange i.e. BSE Limited [www.bseindia.com](http://www.bseindia.com) and the



EGM/AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) [i.e. www.evoting.nsdl.com](http://www.evoting.nsdl.com).

22. Shareholder who would like to obtain pdf copy on their email ID may write an email to [cs@bplindia.in](mailto:cs@bplindia.in). Pursuant to the Circulars mentioned above, the Company has not printed the Annual Reports and hence no hard copies of the Annual Report will be provided.
23. Pursuant to Section 108 of Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of SEBI LODR, 2015, the Company is pleased to provide the facility to members to exercise their right to vote on the resolutions proposed to be passed in the AGM by electronic means. The members whose names appear in the Register of Members/ List of Beneficial owners as on 25<sup>th</sup> day of June 2024 i.e. the cut-off date, are entitled to vote on the Resolutions set forth in this Notice. Members may cast their votes on electronic voting systems from any place other than the venue of the meeting (remote e-voting). The remote e-voting will commence at 9:00 a.m. on 28<sup>th</sup> June, 2024 and will end at 5:00 p.m. on 1<sup>st</sup> July, 2024. In addition, the facility of voting through electronic voting system shall also be made available at the AGM and the members attending the AGM who have not cast their vote by remote e-voting shall be eligible to vote at the AGM. The Members desiring to vote through remote e-voting are requested to refer to the detailed procedure given hereinafter.

The requirement to place the matter relating to appointment of statutory auditors for ratification by Members at every AGM has been done away by the Companies (Amendment) Act, 2017 with effect from May 07, 2018. Accordingly, no resolution is being proposed for ratification of appointment of Statutory Auditors at the 31<sup>st</sup> AGM.

24. The Company has fixed 25<sup>th</sup> day of June 2024 as the “record date” for determining the eligibility of Members to receive the dividend for the financial year ended 31<sup>st</sup> March, 2024, if approved at the AGM.
25. The dividend when sanctioned will be made payable on or before 1<sup>st</sup> August, 2024, electronically through various online transfer modes to those members who have updated their bank account details. For members who have not updated their bank account details, dividend warrants / demand drafts / cheques will be dispatched to their registered addresses. To avoid delay in receiving the dividend, members are requested to update their bank details by following the process mentioned at point no. 27 below.
26. In accordance with the prevailing provisions of the Income Tax Act, 1961, the Company is required to deduct tax at source (TDS) at the prescribed rates on the dividend paid to its shareholders. The TDS rate would vary depending on the residential status of the shareholder and the documents submitted by them and accepted by the Company. Therefore, the members are requested to



update their PAN and upload applicable documents to avoid deduction of tax at higher rate by complying with the process mentioned herein under.

27. Members are requested to visit the website of Company's Registrar & Share Transfer Agent, Adroit Corporate Services Private Limited ("ACSPL") and provide the applicable documents such as Form 15G/15H and other applicable documents at <https://www.adroitcorporate.com/RandTServices.aspx> in order to enable the Company to determine the appropriate TDS / withholding tax rate applicable.
28. As per the provisions of Section 125 of the Act read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 as amended ("IEPF Rules, 2016"), the amount of dividend remaining unpaid or unclaimed for a period of seven years from the date of transfer to Unpaid Dividend Account, shall be transferred to the Investor Education and Protection Fund ("IEPF"), a fund constituted by the Government of India under Section 125 of the Act. Further, in accordance with the provisions of Section 124(6) of the Act and IEPF Rules, 2016, shares on which dividend has not been paid or claimed for seven consecutive years or more, are liable to be transferred to IEPF Account.
29. All the work related to share registry in terms of both physical and electronic, are being conducted by Adroit Corporate Services Private Limited ("ACSPL") at 17-20, Jafferbhoy Industrial Estate, Makhwana Rd, Marol, Andheri East, Mumbai-400059, Maharashtra, Tel: 022-42270418, Email ID: [info@adroitcorporate.com](mailto:info@adroitcorporate.com). The members are requested to send their communication to the aforesaid address.

**30. THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER: -**

The remote e-voting period begins at 9.00 am on 28<sup>th</sup> June, 2024 and will end at 5:00 p.m. on 01<sup>st</sup> July, 2024. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the cut-off date i.e. 25<sup>th</sup> June, 2024 may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being 25<sup>th</sup> June, 2024.

Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

**Please refer the EVENT NO. is 128797**







**The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:**

**Step 1: Access to NSDL e-Voting system**

**A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility. Login method for Individual shareholders holding securities in demat mode is given below:

<b>Type of shareholders</b>	<b>Login Method</b>
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"> <li>1. Existing <b>IDeAS</b> user can visit the e-Services website of NSDL Viz. <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. On the e-Services home page click on the “<b>Beneficial Owner</b>” icon under “<b>Login</b>” which is available under ‘<b>IDeAS</b>’ section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “<b>Access to e-Voting</b>” under e-Voting services and you will be able to see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>2. If you are not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “<b>Register Online for IDeAS Portal</b>” or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li> <li>3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company</li> </ol>

	<p>name or <b>e-Voting service provider i.e. NSDL</b> and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p> <p>4. Shareholders/Members can also download NSDL Mobile App “<b>NSDL Speede</b>” facility by scanning the QR code mentioned below for seamless voting experience.</p> <p style="text-align: center;"><b>NSDL Mobile App is available on</b></p> <div style="display: flex; justify-content: center; gap: 20px;">   </div> <div style="display: flex; justify-content: center; gap: 20px; margin-top: 10px;">   </div>
<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<ol style="list-style-type: none"> <li>1. Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on New System Myeasi.</li> <li>2. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of <b>e-Voting service provider i.e. NSDL</b>. Click on <b>NSDL</b> to cast your vote.</li> <li>3. If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/EasiRegistration">https://web.cdslindia.com/myeasi/Registration/EasiRegistration</a></li> <li>4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. <b>NSDL</b> where the e-Voting is in progress.</li> </ol>



Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Once login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on options available against company name or <b>e-Voting service provider-NSDL</b> and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
--	--

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.**

<b>Login type</b>	<b>Helpdesk details</b>
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at 022- 23058738 or 022-23058542-43

**B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

**Steps to Log-in to NSDL e-Voting website:**

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTF and a Verification Code as shown on the screen.  
Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :





<b>Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical</b>	<b>Your User ID is:</b>
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID  For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID  For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company  For example if folio number is 001*** and EVEN is 126232 then user ID is 121808001***

5. Password details for shareholders other than Individual shareholders are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- c) How to retrieve your 'initial password'?
  - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
  - (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered



6. If you are unable to retrieve or have not received the “ Initial password” or have forgotten your password:
  - a. Click on “**Forgot User Details/Password?**”(If you are holding shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - b. **Physical User Reset Password?** (If you are holding shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - c. If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
  - d. Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to “Terms and Conditions” by selecting on the check box.
8. Now, you will have to click on “Login” button.
9. After you click on the “Login” button, Home page of e-Voting will open.

### **Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.**

#### **How to cast your vote electronically and join General Meeting on NSDL e-Voting system?**

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on “VC/OAVM” link placed under “Join General Meeting”.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

#### **General Guidelines for shareholders**

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to [csjigartrivedi@gmail.com](mailto:csjigartrivedi@gmail.com) with a copy marked to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in).



2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “[Forgot User Details/Password?](#)” or “[Physical User Reset Password?](#)” option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to Mr. Sachin Kareliya at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in)

**Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:**

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to [cs@bplindia.in](mailto:cs@bplindia.in)
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to respective DP. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**
3. Alternatively shareholder/members may send a request to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

**THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE EGM/AGM ARE AS UNDER: -**

1. The procedure for e-Voting on the day of the EGM/AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.



3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

**INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:**

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of “VC/OAVM link” placed under **“Join General meeting”** menu against company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at [cs@bplidnia.in](mailto:cs@bplidnia.in). The same will be replied by the company suitably.

**FOR AND ON BEHALF OF DIRECTORS**

Date: 10/06/2024  
Place: Vadodara

Sd/-  
Mr. Bharat Desai  
Chairman

**EXPLANATORY STATEMENT IN RESPECT OF THE SPECIAL BUSINESS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013****Item No. 4**

Pursuant to Section 148 of the Companies Act, 2013 (“the Act”) read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, the Board of Directors at its Meeting held on May 22, 2024, based on the recommendation of the Audit Committee, had appointed CMA Chetan Gandhi, Cost Accountants (Registration No. 101311) for conducting Cost Audit of the cost records maintained by the Company for manufacturing of pharmaceutical formulations for the financial year ending March 31, 2025, at a remuneration of Rs. 75,000/- (Rupees Seventy-Five Thousand only) plus applicable taxes which is subject to ratification by the Members. The said remuneration as approved by the Board of Directors payable to CMA Chetan Gandhi, Cost Accountants requires to be ratified by the Members of the Company in accordance with the Provisions of the Section 148 of the Act.

None of the Directors or Key Managerial Personnel of the Company and their relatives are concerned or interested, financially or otherwise, in the said Resolution. Accordingly, the Board recommends the Ordinary resolution for approval by the Members.

**Item No. 5**

Pursuant to the provisions of Section 188 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014, the Related Party Transactions as mentioned in clause (a) to (g) of the said section requires a Company to obtain approval of the Board of Directors and subsequently the Shareholders of the Company by way of ordinary resolution in case the value of the Related Party Transactions exceed the stipulated thresholds prescribed in Rule 15 of the said Rules if such transactions are other than in ordinary course of business and on arm’s length basis.

Further, Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”) also stipulates that all material related party transactions shall require prior approval of the shareholders through ordinary resolution and related party shall not vote in the said resolution.

Accordingly, the related party transactions as recommended and prior approved by the Audit Committee and approved by the Board of Directors at their respective meetings held on 22<sup>nd</sup> May, 2024 are hereby placed before the shareholders for their approval by way of ordinary resolution to enable the Company / Subsidiary Company to enter into the following Related Party Transactions in one or more tranches. The transactions under consideration, are proposed to be entered into by the Company / Subsidiary



Company with the following related parties in the ordinary course of business and at arms' length basis.

Pursuant to Rule 15 of Companies (Meetings of Board and its Powers) Rules, 2014 and SEBI Circular SEBI/HO/CFD/CMD1/ CIR/P/2021/662, dated November 22, 2021, the particulars of transactions to be entered into by the Company with related parties are as under:

<b>Sr. No.</b>	<b>Name Of The Related Party</b>	<b>Name of the director or key managerial personnel who is related, if any</b>	<b>Nature of relationship (including nature of interest, financial or otherwise)</b>	<b>Aggregate maximum value of the contract/ arrangement/ transaction (Maximum Limits) (INR.)</b>	<b>Nature and material terms of contract/ arrangement/ transaction</b>
1	Mr. Bharat Desai		Managing Director	5 crores	Remuneration
2	Mr. Hemang J. Shah		Executive Director	5 crores	Remuneration
3	Mr. Bhahim B Desai		Relatives of Director	75 lakhs	Remuneration
4	Mrs. Nikita Desai		Relatives of Director	45 lakhs	Remuneration
5	Mrs. Himaben b. Desai		Relatives of Director	2 crores	Remuneration
6	Varenyam Healthcare Private Limited	Relative of Mr Bharat R Desai	Related Party	Sale - 80 Crores Purchase- 80 crores	Sale and Purchase Transaction
7	Varenyam Healthcare Private Limited		Related Party	55 – Crores	Unsecured Loan
8	Innoxel Lifesciences private limited		Subsidiary company	Unsecured or Secured Loan upto -75 crores Equity Investment - 80 crores	Unsecured Loan
9	Varenyam Biolifesciences private limited		Subsidiary Company	Loans - 55 crores Equity Investment - 60 crores	Unsecured Loan

**Brief about the Related Party Transactions-**





a) As mentioned above significant transaction involving related parties within the Bharat Parenterals Ltd, specifically concerning the sales and purchase of goods between our subsidiary companies. As outlined in the ordinary course of business, Bharat Parenterals Ltd and its subsidiary, Innoxel Lifesciences Pvt Ltd, along with our wholly-owned subsidiary company, Varenyam healthcare pvt ltd are set to engage in transactions involving the sales and purchase of goods. This transaction is in ordinary course of business aimed at facilitating the smooth functioning of our business operations and is conducted under fair market terms and conditions. The purpose of this transaction is to optimize operational efficiencies within our group of companies, enhance supply chain management and ultimately contribute to the overall growth and performance of Bharat Parenterals Ltd. The proposed contracts/arrangements/transactions relate to sale/purchase of goods/services or any other transaction(s), which shall be governed by the Company’s Related Party Transaction Policy and shall be reviewed by the Audit Committee within the overall limits approved by the members.

b)

Sr. No.	Particulars	For Unsecured Loan to Subsidiary and Wholly owned Subsidiary company		
	Name of the related party and its relationship with the listed entity or its subsidiary, including nature of its concern or interest (financial or otherwise)	Innoxel Lifesciences Pvt Ltd- Subsidiary	Varenyam Biolifesciences Pvt Ltd- subsidiary Company	Varenyam Healthcare Pvt Ltd- Related Party
	Name of Director(s) or key Managerial Personnel who is related, if any	Mr Bharat R. Desai being whole-time director at Innoxel lifesciences Pvt Ltd	Mr Bharat R. Desai being director at Varenyam Biolifesciences Pvt Ltd	Mr Bharat R. Desai relative (Spouse, Son and Daughter in liaw is director in this company) at Varenyam Healthcare Pvt Ltd
	Type, Tenure, Material terms and particulars	Type- a) Unsecured Loan b) Tenure- 9 years	Type- a) Unsecured Loan	Type- a) Unsecured Loan



		for unsecured Loan  Material Terms- At rate of Interest of 7% (The interest rate shall be revised based on revision in Rate interest Government Securities as per provision of Companies Act, 2013 with Approval of Audit Committee and Board)	b) Tenure- 9 years for unsecured Loan  Material Terms- At rate of Interest of 7% (The interest rate shall be revised based on revision in Rate interest Government Securities as per provision of Companies Act, 2013 with Approval of Audit Committee and Board)	b) Tenure- 9 years for unsecured Loan  Material Terms- At rate of Interest of 7% (The interest rate shall be revised based on revision in Rate interest Government Securities as per provision of Companies Act, 2013 with Approval of Audit Committee and Board)
	Value of the Transaction	75 crores	55 crores	55 crores
	The percentage of the listed entity's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction	28.20%	20.68%	Exceeding 20% on approximate basis as consolidation turnover including VHPL turnover will be calculated for current financial year
	Details of the transaction relating to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary	Unsecured Loan and advances	Unsecured Loan and advances	Unsecured Loan and advances
	Any valuation or other external party report			



	relied upon by the listed entity in relation to the transaction	-	-	-
	Any other information that may be relevant	Unsecured loans and advances are instrumental in meeting the dynamic financial requirements of corporate entities, specifically tailored to address the exigencies of working capital management and strategic business endeavors. These funds are deployed with a dual purpose: firstly, to ensure the seamless fulfilment of day-to-day operational needs; and secondly, to fuel strategic business planning and execution aimed at fostering development and expansion initiatives. l in meeting the dynamic financial requirements of corporate entities, specifically tailored to address the exigencies of working capital management and strategic business endeavors. These funds are deployed with a dual	Unsecured loans and advances are specifically allocated for the expansion and development of the manufacturing facility and for incur expenses before the company becomes operational.	Unsecured loan and advances will be utilize to drive growth through initiatives such as market expansion, product diversification, infrastructure enhancement, and strategic partnerships.



		<p>purpose: firstly, to ensure the seamless fulfilment of day-to-day operational needs; and secondly, to fuel strategic business planning and execution aimed at fostering development and expansion initiatives.</p> <p>These funds are strategically will be utilize to drive growth through initiatives such as market expansion, product diversification, infrastructure enhancement, and strategic partnerships.</p>		
--	--	---	--	--

c) Investment in Subsidiary Company

Sr. No.	Particulars	For Investment in Subsidiary Company		
1.	Name of the related party and its relationship with the listed entity or its subsidiary, including nature of its concern or interest (financial or otherwise)	Innoxel Lifesciences Pvt Ltd- Subsidiary	Varenyam Biolifesciences Pvt Ltd ('VBPL')- Wholly owned subsidiary	Varenyam Healthcare Pvt Ltd ('VHPL')- Wholly owned subsidiary
2.	Name of Director(s) or key Managerial Personnel who is related, if any	Mr Bharat R. Desai being whole-time director at Innoxel lifesciences Pvt	Mr Bharat R. Desai being director at Varenyam Biolifesciences	Mr Bharat R. Desai relative (Spouse, Son and Daughter in liaw is



		Ltd	Pvt Ltd	director in this company) at Varenyam Healthcare Pvt Ltd
3.	Type, Tenure, Material terms and particulars	Acquisition of additional Equity stake	Acquisition of 100% Equity stake	Acquisition of 100% Equity stake
4.	Value of the Transaction	INR. 64.90/- per share value (including INR 10/- Face value per share and Premium INR. 54.90/- per share) of Innoxel Lifesciences Pvt. Ltd. Aggregate amounting to INR. 64,80,57,457/- to invested for additional Equity stake acquisition	Swap of Equity shares of Bharat Parenterals Ltd of 16261 No. of shares allotted on Preferential basis for acquisition of remaining 40% Equity stake of VBPL	Swap of Equity shares of Bharat Parenterals Ltd of 351255 No. of shares allotted on Preferential basis for acquisition of 100% Equity stake of VHPL
5.	The percentage of the listed entity's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction	24.37%	0.68%	-
6.	Details of the transaction relating to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary	-	-	-
7.	Any valuation or other external party report relied upon by the listed	Based on Valuation report of Independent	Based on Valuation report of	Based on Valuation report of



	entity in relation to the transaction	Valuer CA Snehal Shah dated 04 <sup>th</sup> June, 2024	Independent Valuer CA Snehal Shah	Independent Valuer CA Snehal Shah
8.	Any other information that may be relevant	Post Acquisition Company will hold 55.89% of Equity Stake in Innoxel Lifesciences Pvt Ltd	After the completion of acquisition the company will be Wholly owned subsidiary of the company	After the completion of acquisition the company will be Wholly owned subsidiary of the company
9.	Any other information that may be relevant	-	-	-

The proposed contracts/arrangements/transactions relate to sale/purchase of goods/services or loan, investment or any other transaction(s), which shall be governed by the Company's Related Party Transaction Policy and shall be reviewed by the Audit Committee within the overall limits approved by the members. The Board of Directors or any Committee thereof would carefully evaluate the proposals providing and/or receiving of loans or guarantees or securities or making investments through deployment of funds out of internal resources/accruals and/or any other appropriate sources, from time to time, only for principal business activities of such entities.

The proposal outlined above will contribute to the principal business activities of your Company and is in the interest of the Company. Hence, the Audit Committee/Board recommends the resolution set out in the Item no. 5 of the notice for your approval as an ordinary resolution. None of the Related Parties shall vote in the resolution.

Except Mr. Bharat R. Desai being Managing Director of the Company none of the other Directors, Key Managerial Personnel or their respective relatives in any way, financially or otherwise, concerned or interested in the said resolution except to the extent of their shareholding in the Company, if any.

### **Item No.6**

In order to make optimum use of funds available with the Company and also to achieve long term strategic and business objectives, the Board of Directors of the Company proposes to make use of the same by making investment in other bodies corporate or





granting loans, giving guarantee or providing security to other persons or other bodies corporate as and when required.

Members may note that pursuant to Section 186 of the Companies Act, 2013 ("Act"), the Company can give loan or give guarantee or provide security in connection with a loan to any other body corporate or person and acquire securities of any other body corporate, in excess of 60% of its paid up share capital, free reserves and securities premium account or 100% of its free reserves and securities premium account, whichever is higher, with the approval of Members by special resolution passed at the general meeting.

In view of the aforesaid, it is proposed to take approval under Section 186 of the Companies Act, 2013, by way of special resolution, up to a limit of Rs. 150 Crores, as proposed in the Notice. The above proposal is in the interest of the Company and the Board recommends the Resolution as set out at Item No. 6 for approval by the members of the Company as Special Resolution.

Except Mr. Bharat R. Desai, None of the Directors or Key Managerial Personnel or their relatives are in any way concerned with or interested, financially or otherwise in the said resolution except to the extent of their shareholding in the Company, if any.

#### **Item No.7**

#### **1. TO APPROVE ISSUANCE OF EQUITY SHARES ON PREFERENTIAL BASIS FOR CONSIDERATION OTHER THAN CASH:**

In furtherance of the Company's expansion plans, the Board of Directors of the Company ("Board") at their meeting held on June 10th, 2024, have approved the acquisition of Varenym Healthcare Pvt Ltd ('VHPL') and Varenym Biolifesciences Pvt Ltd ('VBPL'). The Board had also approved the execution of a Share Purchase agreement ("SPA") between the Company and execution of other necessary documents with regard to the Proposed Transaction, whereby the Company would acquire 100% of the share capital of VBPL & VHPL.

Further, Subject to the approval of the shareholders of the Company and such other approvals as may be required, the Company proposes to issue 3,67,516 equity shares at a face value of Rs. 10 each and at issue price of INR 1,479.90 per equity share. This issuance is pursuant to the provisions of Regulation 164 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the "SEBI ICDR Regulations"), for consideration other than cash, specifically through the swap of equity shares. The Company will acquire 18,00,000 equity shares of Varenym Biolifesciences Pvt Ltd at a price of INR 13.37/- (Indian Rupees Thirteen point Thirty-Seven only) per share of VBPL and 2,50,000 equity shares of Varenym Healthcare



Pvt Ltd at a price of INR 2,079.30/- (Indian Rupees Two Thousand and Seventy-Nine point Thirty only) per share of VHPL. This acquisition will result in these companies becoming wholly owned subsidiaries of the Company.

Pursuant to such acquisition of shares, the company as will issue its own shares to the shareholders of such company as consideration.

**THE LIST OF PROPOSED ALLOTTEES ARE: -**

<b>SR. NO.</b>	<b>NAME OF ALLOTTEES</b>	<b>CATEGORY</b>	<b>CONSIDERATION OTHER THAN CASH (SWAP OF SHARES) NO OF BPL SHARES TO BE PROPOSED TO BE ALLOTTED</b>
1	Bharatkumar Rameshchandra Desai	Promoter	140
2	Himaben Bharatkumar Desai	Promoter	179069
3	Bhahim Bharatkumar Desai	Promoter	87779
4	Nikita Bhahim Desai	Non-promoter	84267
5	Varenyam Healthcare Private Limited	Non-Promoter	16261
	<b>TOTAL</b>		<b>3,67,516</b>

The Equity Shares, if any, allotted in the Offer shall rank pari-passu in all respects with the existing equity shares.

Accordingly, the approval of the Shareholders is required in accordance with Sections 42 and 62 and other applicable provisions of the Companies Act, 2013 and the rules made thereunder read with Chapter V - Preferential Issue of the SEBI ICDR Regulations as amended.

The consent of the members is being sought by way of a special resolution to issue Equity Shares to the Proposed Allottees in accordance with the provisions of the Act, SEBI ICDR Regulations, as amended, and any other applicable laws.

Necessary information / disclosures in respect of the proposed Preferential Issue in terms of Act and rules made thereunder and Chapter V of the SEBI ICDR Regulations and other applicable laws are as provided herein below:

**Further details of the proposed offer are disclosed below:**



The following disclosures for the issue of equity shares on preferential basis are made in accordance with the provisions of Section 42 and 62 of the Companies Act, 2013 and the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the Companies (Share Capital and Debenture) Rules, 2014:

**1. Particulars of the offer including date of passing of Board Resolution:**

The Board has pursuant to its resolution dated June 10th, 2024 accorded its approval for Consideration in kind for acquisition of 100% stake in VBPL & VHPL by issue, offer and allot up to up to approximately 3,67,516 (Three Lakhs Sixty-Seven Thousand Five hundred and Sixteen) fully paid-up Equity Shares of with a face value of Rs. 10 (Rupees Ten only) each ("Equity Shares") at a price of Rs. 1,479.90 (Rupees One Thousand Four hundred and Seventy-Nine Point Ninety) (including a premium of Rs. 1469.90/- (Rupees One Thousand Four hundred and Sixty-Nine Point Ninety) per Equity Share. The Equity Shares, if any, allotted in the Offer shall rank in all respects pari-passu with the existing equity shares.

**2. The objects of the issue:**

The object of issue of Equity Shares on a preferential basis are expansion of the business of the Company by acquiring 100 % stake of in the subsidiary companies namely VHPL and VBPL and convert them into Wholly owned Subsidiary of the Company.

**3. Maximum number of specified securities to be issued and offered and price or price band at/which the allotment is proposed/ kinds of securities offered and the price at which security is being offered;**

The Company proposes to offer, issue and allot in aggregate up to approximately 3,67,516 (Three Lakhs Sixty-Seven Thousand Five hundred and Sixteen) fully paid-up Equity Shares of Rs. 10/- (Rupees Ten only) each ("Equity Shares") at a price of Rs. 1,479.90 (Rupees One Thousand Four hundred and Seventy-Nine Point Ninety) (including a premium of Rs. 1469.90/- (Rupees One Thousand Four hundred and Sixty-Nine Point Ninety) per Equity Share.

**4. The total number of shares to be issued:**

3,67,516 (Three Lakhs Sixty-Seven Thousand Five hundred and Sixteen) fully paid-up Equity Shares of Rs. 10/- (Rupees Ten only) each.



**5. Basis or justification on which the price has been arrived at (including premium) at which the offer or invitation is being made, along with report of the registered valuer:**

Price arrived as per the valuation report issued by the registered valuer CA Snehal Shah including swap ration in compliance with Reg 164 of SEBI ICDR being frequently traded shares of the Company.

**6. Amount which the company intends to raise by way of such Securities:**

By this issue, the Company is not raising any fund but will increase its Assets by acquiring 100% Equity Stake of two subsidiary companies namely VHPL & VBPL

**7. Name and address of valuer who performed valuation:**

The Valuation is performed by the valuation of the Equity Shares has been carried out by CA Snehal Shah, Registered valuer having Reg. no IBBI/RV/06/2019/11772 a Registered Valuer having office at Vadodara.

**8. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees**

As mentioned in Annexure -A

**9. Relevant date with reference to which the price has been arrived at:**

Friday, May 31st 2024, being 30 days previous to the date of General Meeting. Wherever the reference of "Relevant Date".

**10. The percentage of post preferential issue capital that may be held by the allottee(s) and change in control, if any, in the issuer consequent to the preferential issue]**

<b>Category of Shareholding</b>	<b>No. of Shares</b>	<b>Nominal Value of Shares</b>	<b>Percentage</b>
Promoters	4615037	4,61,50,370	66.96%
Private Investor	7,04,781	70,47,810	10.23%
Public	15,72,145	1,57,21,450	22.81%



<b>Total</b>	<b>68,91,963</b>	<b>6,89,19,630</b>	<b>100.00%</b>
--------------	------------------	--------------------	----------------

Post issue, no change in control over the Company.

\*\* Please be informed that the number of shares allotted has been rounded down, and any excess amount received will be refunded. Total number of shares to be allotted has been changed due to rounding off.

### **11. Material terms of raising such securities:**

Issue and Allotment of 3,67,516 (Three Lakhs Sixty-Seven Thousand Five hundred and Sixteen) fully paid-up Equity Shares of with a face value of Rs. 10 (Rupees Ten only) each ("Equity Shares") at a price of Rs. Rs. 1,479.90 (Rupees One Thousand Four hundred and Seventy-Nine Point Ninety) (including a premium of Rs. 1469.90/- (Rupees One Thousand Four hundred and Sixty-Nine Point Ninety) per Equity Share, in lieu of acquiring the shares of 18,00,000 no of Equity shares of Varenyam Biolifesciences Pvt Ltd and 2,50,000 no of Equity shares of Varenyam Healthcare Pvt ltd companies and the said shares shall rank pari-passu with the existing Equity Shares are offered on preferential basis to be done in one or one tranche, as may be applicable.

### **12. Lock In Period**

The proposed allotment of equity shares shall be subject to lock-in as per the requirement of Chapter V of SEBI ICDR Regulations.

### **13. Undertaking**

The Company hereby undertakes that:

- (i) It would re-compute the price of the securities specified above in terms of the provisions of SEBI (ICDR) Regulations, where it is so required;
- (ii) If the amount payable, if any, on account of the re-computation of price is not paid within the time stipulated in SEBI (ICDR) Regulations the above shares shall continue to be locked-in till the time such amount is paid by the allottees.

### **14. Disclosures specified in Schedule VI, if the issuer or any of its promoters or directors is a wilful defaulter or a fraudulent borrower.**

Not Applicable as the Company or any of its promoters or directors are not wilful defaulter or a fraudulent borrower.

### **15. Proposed time schedule:**



Within 15 day (Fifteen) days from the date of passing of this special Resolution the company will issue and allot the shares to the proposed shareholders. .

**16. Contribution being made by the promoters or directors either as part of the offer or separately in furtherance of objects:**

No contribution is being made by the promoters or directors for issuance of the shares but the shares under reference are being issued in lieu of acquiring the shares of 18,00,000 no of Equity shares of Varenyam Biolifesciences Pvt Ltd and 2,50,000 no of Equity shares of Varenyam Healthcare Pvt Ltd.

**17. The current and proposed status of the allottee(s) post the preferential issues namely, promoter or non-promoter.**

The proposed allottees will be part of the promoter and promoter groups as mentioned below

<b>Name of Proposed Allottees</b>	<b>No of Shares (Pre-Preferential issue holding)</b>	<b>No of Shares (Post Preferential issue holding)</b>	<b>Current Class or Classes of persons</b>	<b>Proposed Class or classes of person</b>
Bharatkumar Rameshchandra Desai	741515	741655	Promoter	Promoter
Himaben Bharatkumar Desai	783430	962499	Promoter	Promoter
Bhahim Bharatkumar Desai	2502	90281	Promoter	Promoter
Nikita Bhahim Desai	0	84267	*Non-promoter	Promoter
Varenyam Healthcare Private Limited	0	16261	Non-Promoter	Non-Promoter
<b>Total</b>	<b>1527447</b>	<b>1894963</b>		

\*post allotment of shares shall be classified under promoter category of the company.

**18. The class or classes of persons to whom the allotment is proposed to be made:**

The List of proposed allottee and class and classes of persons as mentioned above at point no 13.

**19. Intention of promoters, directors or key managerial personnel or senior management to subscribe to the offer:**





The Equity Shares shall be offered to the Proposed Allottee who are Promoters and related part of the Company intends to subscribe to any of the Equity Shares proposed to be issued under the Preferential basis. The intention is to make the subsidiary Company as Wholly Owned Subsidiary Company.

**20. The proposed time within which the allotment shall be completed:**

Within 15 days from the date of passing of this special Resolution.

**21. The number of persons to whom allotment on preferential basis have already been made during the year, in terms of number of securities as well as price:**

The Company has allotted 704781 to Non-promoter and Non QIB 68 investors which is under process of listing. The Allotment was approved in Board meeting of 5<sup>th</sup> June, 2024 and Shareholders approved in EoGM held on 21<sup>st</sup> May, 2024

**22. The justification for the allotment proposed to be made for consideration other than cash together with valuation report of the registered valuer:**

The issue of shares under reference, is pursuant to the valuation report including swap ration as identified by the Registered Valuer CA Snehal Shah, copy of Valuation Report is available for inspection and placed on company's website at <https://www.bplindia.in/index.html> by acquiring the shares acquiring the shares of 18,00,000 no of Equity shares of Varenyam Biolifesciences Pvt Ltd and 2,50,000 no of Equity shares of Varenyam Healthcare Pvt ltd, they become wholly owned companies and will help the management of grow business in all respect including asking advantage of its good will, intellectual rights, business strategy etc.

**23. The pre-issue and post issue shareholding pattern of the company:**

**a) Pre-preferential Shareholding of Below mentioned Allottees: -**

Sr .No.	Name of the Proposed Allottee	Category (Promoter/ Non - Promoter)	Permanent Account Number (PAN)	If allottee is not a natural person, identity of the natural person who are the ultimate beneficial owner of the shares proposed to be issued, if	Permanent Account Number (PAN) of the beneficial owners of proposed allottee	Pre-preferential (i.e. current holding of shares)	Allottee is: *QIB/ Non QIB	Pre issue % of capital that allottee will hold



				applicable				
1	BHARATKUMAR RAMESHCHANDRA DESAI	Promoter	ABWPD8288Q	Individual	-	741515	Non- QIB	12.74
2	HIMABEN BHARATKUMAR DESAI	Promoter	ACUPD6891J	Individual	-	783430	Non- QIB	13.46
3	BHAHIM BHARATKUMAR DESAI	Promoter	BACPD4375E	Individual	-	2502	Non- QIB	0.04
4	NIKITA BHAHIM DESAI	Non-Promoter	FRWPS8149J	Individual	-	0	Non- QIB	0
5	VARENYAM HEALTHCARE PRIVATE LIMITED	Non-Promoter	AAFCV5417L	Shareholder of the company 1. BHARAT R. DESAI 2. HIMABEN B. DESAI 3. BHAHIM B. DESAI 4. NIKITA B. DESAI	As mentioned here 1. ABWPD8288Q 2. ACUPD6891J 3. BACPD4375E 4. FRWPS8149J	0	Non- QIB	0

**b) Post-preferential Shareholding of Below mentioned Allottees: -**

Sr .No.	Name of the Proposed Allottee	Category (Promoter/ Non - Promoter)	Permanent Account Number (PAN)	If allottee is not a natural person, identity of the natural person who are the ultimate beneficial owner of the shares proposed to be issued, if	Permanent Account Number (PAN) of the beneficial owners of proposed allottee	No. of securities post allotment (pre-preferential holding) + (Proposed shares to be	Allottee is: *QIB/ Non QIB	Post issue % of capital that allottee will hold
---------	-------------------------------	-------------------------------------	--------------------------------	---	--	--	----------------------------	---



				applicable		allotted)		
1	BHARATKUMAR RAMESHCHANDRA DESAI	Promoter	ABWPD8288Q	Individual	-	741655	Non- QIB	10.76%
2	HIMABEN BHARATKUMAR DESAI	Promoter	ACUPD6891J	Individual	-	962499	Non- QIB	13.97%
3	BHAHIM BHARATKUMAR DESAI	Promoter	BACPD4375E	Individual	-	90281	Non- QIB	1.31%
4	NIKITA BHAHIM DESAI	Non-Promoter	FRWPS8149J	Individual	-	84267	Non- QIB	1.22%
5	VARENYAM HEALTHCARE PRIVATE LIMITED	Non-Promoter	AAFCV5417L	Shareholder of the company 5. BHARAT R. DESAI 6. HIMABEN B. DESAI 7. BHAHIM B. DESAI 8. NIKITA B. DESAI	As mentioned here 1. ABWPD8288Q 2. ACUPD6891J 3. BACPD4375E 4. FRWPS8149J	16261	Non- QIB	0.24%

**24. Certificate from Practicing Company Secretary:**

The Certificate issued by M/s. TNT & Associates, Practicing Company Secretaries, certifying that the preferential issue is being made in accordance with the requirements contained in the SEBI ICDR Regulations and the same will be made available for inspection by the members during the Meeting and will also be made available on the Company's website and will be accessible at link: [www.bplindia.in](http://www.bplindia.in).

As required by Section 102(3) of the Companies Act, 2013, the documents with regard to the preferential issue shall be available for inspection at the Registered Office of the Company during business hours from 9:00 A.M. to 6:00 P.M. (IST)

**25. Principle terms of assets charged as securities:**

Not Applicable

The Board of Directors accordingly recommends the resolution for your approval as Special Resolution.

Except Mr. Bharat R. Desai, None of the Directors or Key Managerial Personnel or their relatives are in any way concerned with or interested, financially or otherwise in the said resolution except to the extent of their shareholding in the Company, if any.

**ANNEXURE-1 TO THE NOTICE**

**Details of Directors seeking variation in remuneration/appointment/re-appointment at the forthcoming thirty first Annual General Meeting {in pursuance of Regulation 36 (3) of the Listing Regulations, 2015 and Secretarial Standard on General Meeting.**

<b>Name of the Director</b>	<b>Hemang J. Shah</b>
DIN	03024324
Nationality	Indian
Date of Joining Board	08/07/2010
Brief Resume/Nature of Expertise and Experience	Mr. Hemang Shah is Bachelor of Commerce and also holds degree of MSW. He is associated with the Company from more than last ten years and has played a pivotal role in the growth and development of the Company.
Age	53 years
Qualifications	B. Com and MSW degree
Experience	30 years
Disclosure of Inter-se relationship between directors	None
Name of Listed entities in which person also holds directorship or membership of committee	None other than Bharat Parenterals Ltd
No. of Board Meeting attended during the year	11 Board Meeting in FY 2023-24
Remuneration last drawn	Rs. 22,54,000/- p.a.
Remuneration sought to be paid	Rs. 25,00,000/- p.a.
No. of shares held	18350 Equity Shares
Terms and Conditions of Appointment /Re-appointment.	Re-appointment in terms of Section 152(6) of the Companies Act,2013
Listed Entities from which he has resigned as Director in past 3 years	NA



Annexure -A

Sr .No.	Name of the Proposed Allottee	Category (Promoter/ Non - Promoter)	Permanent Account Number (PAN)	If allottee is not a natural person, identity of the natural person who are the ultimate beneficial owner of the shares proposed to be issued, if applicable	Permanent Account Number (PAN) of the beneficial owners of proposed allottee	No. of securities post allotment (pre-preferential holding) + (Proposed shares to be allotted)	Allottee is: *QIB/ Non QIB	Post issue % of capital that allottee will hold
1	BHARATKUMAR RAMESHCHANDRA DESAI	Promoter	ABWPD8288Q	Individual	-	741655	Non- QIB	10.76%
2	HIMABEN BHARATKUMAR DESAI	Promoter	ACUPD6891J	Individual	-	962499	Non- QIB	13.97%
3	BHAHIM BHARATKUMAR DESAI	Promoter	BACPD4375E	Individual	-	90281	Non- QIB	1.31%
4	NIKITA BHAHIM DESAI	Non-Promoter	FRWPS8149J	Individual	-	*84267	Non- QIB	1.22%
5	VARENYAM HEALTHCARE PRIVATE LIMITED	Non-Promoter	AAFCV5417L	Shareholder of the company 9. BHARAT R. DESAI 10. HIMA BEN B. DESAI 11. BHAHIM B. DESAI 12. NIKIT A B. DESAI	As mentioned here 1. ABWPD8288Q 2. ACUPD6891J 3. BACPD4375E 4. FRWPS8149J	16261	Non- QIB	0.24%

\*Please note on allotment of shares as mentioned above allottees shall be considered in promoters Shareholding





## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **BOARD'S REPORT**

TO,  
THE MEMBERS,  
**BHARAT PARENTERALS LIMITED,**  
**VADODARA**

Your Directors have pleasure in presenting the 31<sup>st</sup> Annual Report of the Company together with the Audited Annual Financial Statements (Standalone and Consolidated) showing the financial position of the Company prepared in compliance with Ind AS accounting standards, for the Financial year ended March 31, 2024.

#### **1. FINANCIAL PERFORMANCE:**

The Company's financial performance for the year under review along with previous year's figures is given here under:

(Rs.in lakhs)

<b>PARTICULARS</b>	<b>STANDALONE</b>		<b>CONSOLIDATED</b>	
	<b>FOR THE YEAR ENDED ON 31.03.2024</b>	<b>FOR THE YEAR ENDED ON 31.03.2023</b>	<b>FOR THE YEAR ENDED ON 31.03.2024</b>	<b>FOR THE YEAR ENDED ON 31.03.2023</b>
Net Income from Business Operations	25416	21798.15	25736	21798.15
Other Income	1196	1883.84	859	1173.91
<b>Total Income</b>	<b>26611</b>	<b>23681.98</b>	<b>26595</b>	<b>22972.06</b>
Profit / (loss) before Depreciation	3720	3801.73	2774	2942.95
Less Depreciation	640	584.80	902	588.24
Profit after depreciation	3080	3216.93	1872	2354.71
Less Tax Expenses:	821	783.24	821	792.24
Net Profit after Tax	<b>2259</b>	<b>2433.69</b>	<b>1051</b>	<b>1575.47</b>
Earning per equity shares (EPS)	<b>38.81</b>	<b>42.14</b>	<b>24.94</b>	<b>28.40</b>

#### **2. DIVIDEND:**

The Board has recommended payment of final dividend of Rs. 1.00 (Rupees One Only) per Equity Share of Rs. 10/- each (fully paid-up) for the financial year ended March 31, 2024. The Dividend amount is payable after declaration by the Shareholders at the ensuing Annual General Meeting (AGM).

#### **3. RESERVES**

There is no amount proposed to be transferred to the reserves in consideration of the implementation of expansion and strategic planning.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **4. CHANGES IN SHARE CAPITAL**

#### **SHARES:**

During the year under review, the Paid-up Equity Share capital of the company as on April 1<sup>st</sup>, 2023 was INR. 5,77,46,660. However, the Company has allotted 45,000 Equity shares under ESOP scheme which result into increase in paid up share capital as on March 31<sup>st</sup>, 2024 to INR. 5,81,96,660.

During the year under review, no changes occurred in the Authorized Share capital. The company has not issued shares with differential voting rights sweat equity during the year.

#### **a) BUY BACK OF SECURITIES**

The Company has not bought back any of its securities during the year under review.

#### **b) SWEAT EQUITY**

The Company has not issued any Sweat Equity Shares during the year under review.

#### **c) BONUS SHARES**

No Bonus Shares were issued during the year under review.

#### **d) EMPLOYEES STOCK OPTION PLAN**

The company during the year had granted Employee Stock Option of 45,000 Equity shares allotted to the employees of the company on 12th September, 2023.

### **5. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND:**

The provisions of Section 125(2) of the Companies Act, 2013 apply as a dividend was declared for the first-time last year by the company. The amount is currently held in the Unclaimed and Unpaid Dividend Account. Once the figure remains unclaimed for seven years, the said fund will be transferred to the Investor Education and Protection Fund (IEPF) account after completion of due procedure.

### **6. FINANCIAL PERFORMANCE AND OPERATION'S REVIEW:**

During the year under review, the company generated Gross Income of INR. 26,611 lakhs, earned Gross Profit of INR. 3,080 lakhs and Net Profit of INR. 2,259 lakhs as against Gross Income of Rs. 23,682 lakhs, earned Gross Profit of Rs. 3,217 lakhs and Net Profit of Rs. 2,434 lakhs of previous year.

### **7. STATE OF COMPANY'S AFFAIRS:**

During the Year under review, the turnover of the company has been increased by 15.20% and EBITDA to Revenue from operations percentage for Financial Year ended on 31<sup>st</sup> March, 2024 is 15.89%.

### **8. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED FROM THE END OF THE FINANCIAL YEAR TILL THE DATE OF THE REPORT:**



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

There are no Material changes and commitments, if any, affecting the financial position of the Company which have occurred from the end of the financial year till the date of the Report.

### **9. MANAGEMENT BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:**

The constitution of the Board of Directors of the Company is in compliance with the provisions of Companies Act, 2013 and Rules thereto and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In accordance with the Articles of Association of the Company and pursuant to the provisions of Section 152 of the Companies Act, 2013 and the applicable rules made thereof, Mr. Hemang J. Shah, Executive Director of the Company retire by rotation at the ensuing 31<sup>st</sup> Annual General Meeting and being eligible have offered himself for re-appointment.

Details of the proposal for re-appointment of Mr. Hemang J. Shah along with his brief resume is mentioned in the Explanatory Statement under Section 102 of the Act and disclosure under Regulation 36(3) of the Listing Regulations as annexed to the Notice of the 31<sup>st</sup> Annual General Meeting. The Board recommends re-appointment / appointment of the above Director.

#### **KEY MANAGERIAL PERSONNEL (“KMP”)**

As on 31 March 2024, the following persons are Key Managerial Personnel of the Company pursuant to Section 2(51) read with Section 203 of the Act, read with the Rules framed thereunder:-

<b>SR.NO</b>	<b>NAME OF DIRECTOR/KMP</b>	<b>DESIGNATION</b>	<b>DATE OF APPOINTMENT</b>
1	Bharatkumar Rameshchandra Desai	Managing Director	30/09/2014
2	Hemang Jayendrabhai Shah	Executive Director	08/07/2010
3	Jignesh Nitinchandra Shah	CFO	14/08/2018
4	Krutika Bhattbhatt	CS	02/10/2023

### **10. CHANGE IN DIRECTORS / KEY MANAGERIAL PERSONNEL DURING THE YEAR:**

During the year under review, the Company Secretary of the company has been changed as Mr. Shyam Singh Rajpurohit resigned from the post on 02/10/2023, and Ms. Krutika Bhattbhatt has been appointed in place of him as Company Secretary with effect from 02/10/2023.

### **11. ANNUAL RETURN:**

Pursuant to Section 92(3) read with Section 134(3)(a) of the Companies Act 2013 and rules made thereunder, the Annual Return of the Company as on March 31, 2023 in Form MGT-7 and for Financial Year ended on 31<sup>st</sup> March, 2024 is available on the Company’s website at [www.bplindia.in](http://www.bplindia.in)

### **12. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:**



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

The information pertaining to conservation of energy, technology absorption, Foreign exchange Earnings and outgo as required under Section 134 (3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 are applicable to the company and annexed as **Annexure – 1** which forms part of this Annual Report.

### **13. INTERNAL FINANCIAL CONTROL SYSTEM AND THEIR ADEQUACY:**

The Company has adequate internal financial control system including suitable monitoring procedures commensurate with the size and nature of business. The internal control system provides all documented policies, guidelines, and authorization and approval procedure. The company has internal auditors which carries out extensive audits throughout the year and across all functional areas and submits its report to the Audit Committee of the Board of Director. The statutory auditors while conducting the statutory audit reviewed and evaluated the internal controls and their observations are discussed by the audit committee of the board.

### **14. STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY:**

The Company is not required to constitute risk management committee as provided in the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

However, the Company has in place an internal Risk Management Policy to monitor the risk plans of the Company and ensure its effectiveness. The Audit Committee and the Board of Directors has additional oversight in the area of financial risks.

### **15. DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY (CSR) INITIATIVES:**

The CSR Committee constituted by the Board of Directors in terms of the provisions of Section 135(1) of the Companies Act, 2013 (the Act) reviews and restates the Company's CSR Policy in order to make it more comprehensive and aligned in line with the activities specified in Schedule VII of the Act. The Company constantly strive to positively impact the health of people throughout the country. In India, we have strived to serve our community by setting the standard for quality, safety and value in the discovery, development, manufacture and delivery of medicines. Your Company through its Corporate Social Responsibility ("CSR") Policy encourages stronger commitment from the organization and employees towards the society to address the healthcare challenges of the country. The Policy applies to all CSR programs/projects of the Company and has been prepared keeping own core competence and priorities in mind. The policy also aims to align your Company's CSR interventions with the healthcare priorities of the Government of India and other stakeholders working with similar mandates. In doing so, it would be the endeavor of your Company to synergize it's CSR initiatives undertaken by various functions/divisions within one unified strategic umbrella.

The CSR Committee acts in an advisory capacity to the Board and Management with respect to policies and strategies that affect your Company's role as a socially responsible organization. The CSR Committee ensures that the implementation, monitoring and impact assessment of the projects is in compliance with the CSR Objectives and Policy of your Company. The details of CSR expenditures made during the year are provided in **Annexure – 2** to this report.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

The Company as per Section 135(4) has adopted the CSR Policy and placed it on the Company's website: [www.bplindia.in](http://www.bplindia.in)

Composition of CSR Committee is given in the Corporate Governance Report hence not reproduced here for the sake of brevity.

### **16. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013:**

During the year under review, the company has provided loans, Guarantees or investments in compliance with the provision of section 186 of the Companies Act, 2013. The details relating to loans, Investments or Guarantees made by the company are disclosed by the auditor in the Notes to financial results of the Company.

### **17. COST AUDIT COMPLIANCE REPORT:**

For the year under review, specified operations of your Company were covered under the Companies (Cost Accounting Records) Rules, 2014 for maintenance of cost records. Accordingly, as per provisions of Section 148 of the Companies Act, 2013 such accounts and records are made and maintained.

The Board of Directors of the Company on the recommendation of made by the Audit Committee, has appointed CMA Chetan Gandhi, Cost Accountant, who are in whole Time Practice as Cost Accountant, having Registration No. 102341 as Cost Auditor of the Company to carry out cost audit of Cost record of the Company for the FY 2024-25 on a remuneration not exceeding of Rs.75,000/-.

A resolution seeking members' ratification of remuneration payable to M/s. CMA Chetan Gandhi, Cost Accountants, Cost Auditor is included at item No. 04 of the Notice convening the AGM and Board recommends the said Resolution.

### **18. COMPANY'S POLICY ON NOMINATION AND REMUNERATION OF DIRECTORS APPOINTMENT AND PAYMENT OF REMUNERATION:**

The Company has constituted nomination and remuneration committee and adopted revised Policy relating to appointment of Directors, payment of Managerial remuneration, KMP and other employees, Directors' qualifications, positive attributes, independence of Directors, and other related matters as provided under Section 178(3) of the Companies Act, 2013 as specified in Corporate Governance Report which forms part of this report.

A copy of the policy is uploaded on the Company's website at <https://www.bplindia.in/policies.html>

We confirm that the remuneration paid to Directors, Key Managerial Personnel, and Senior Management Personnel complies with the Company's policy. This policy has been revised and recommended by the board for shareholder approval to update it in accordance with market research.

The statement of Disclosure of Remuneration under Section 197 of Companies Act, 2013 and Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is mentioned in **Annexure 6**.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

None of the Executive Directors of the Company were in receipt of any commission from the Company or any remuneration from the subsidiaries of the Company.

### **19. NUMBER OF BOARD MEETINGS CONDUCTED DURING THE YEAR UNDER REVIEW:**

Total 11 (Eleven) Board Meetings were held during the financial year ended on 31st March, 2024.

The details of the Board and Committee Meetings held and attendance of each of the directors thereat have been set out in the report on corporate governance attached at **Annexure 6**.

### **20. DIRECTOR RESPONSIBILITY STATEMENT AS REQUIRED UNDER SECTION 134(3)(c) OF THE COMPANIES ACT, 2013:**

Pursuant to Section 134(3)(c) and 134(5) of the Companies Act, 2013, in relation to financial statements of the Company for the year ended 31st March 2024, the Board of Directors to the best of their knowledge and ability, confirm that:

- In the preparation of the annual accounts for the financial year ended March 31st, 2024 the applicable accounting standards have been followed along with proper explanation relating to material departures, if any.
- The directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period.
- The directors had taken proper and sufficient care towards the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities.
- The directors have prepared the annual accounts on a going concern basis.
- The directors have laid down internal financial controls, which are adequate and are operating effectively.
- The directors have devised proper system to ensure compliance with the provision of all applicable laws and such systems are adequate and operating effectively.

### **21. DECLARATION BY INDEPENDENT DIRECTOR(S):**

The Company has received necessary declaration from each Independent Directors under Section 149(7) of the Companies Act, 2013, that he meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 16(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. In accordance with the provisions of the Companies Act, 2013, none of the Independent Directors are liable to retire by rotation.

According to Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014, as amended, the names of all the Independent Directors of the Company have been included in the data bank maintained by the Indian Institute of Corporate Affairs. The Independent director on meeting was scheduled on 20<sup>th</sup> March, 2024 to undertake review and performance of all the directors of the company and





## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

Familiarization Programme was scheduled on 20<sup>th</sup> May, 2023 at being of the Financial year.

### **22. BOARD AND ITS COMMITTEE EVALUATION:**

The Board of Directors has carried out an annual performance evaluation of its own performance, Committees of the Board and Individual Directors pursuant to the provisions of the Companies Act, 2013 and as per the SEBI Listing (Obligations and Disclosure Requirements) Regulations, 2015.

The performance of Board was evaluated after seeking inputs from all Directors on basis such as Knowledge and Skills, Professional Conduct, Duties, Role & Function, Effectiveness, etc. The Nomination & Remuneration Committee further evaluated performance of individual directors on criteria such as preparedness on the agenda to be discussed, contribution to the discussion, etc. In a separate meeting of Independent Director, the performance of non-independent directors and the board as a whole was evaluated. Further Board opined that the Independent Directors of company appointed during the year has requisite integrity, expertise and experience (including the proficiency).

### **23. SUBSIDIARIES, ASSOCIATE COMPANY AND JOINT VENTURE:**

During the year under review, the company has following subsidiaries:

1. Innoxel Lifesciences Private Limited- Subsidiary incorporated on 16<sup>th</sup> October, 2020 which is also Material Subsidiary of the company
2. Varenayam Biolifesciences Private Limited incorporated on 28<sup>th</sup> June, 2022.

The information, pursuant to first proviso to Section 129(3) and rule 5 of Companies (Accounts) Rules, 2014, relating to the financial statement of subsidiary/associate company / joint ventures forms part of this report in the prescribed format **AOC-1** and is given by way of **“Annexure- 3”**.

Further, pursuant to provisions of Section 136 of the Act, the financial statements, including Consolidated Financial Statements of the Company along with relevant documents and separate audited accounts in respect of Subsidiaries and Associate, are available on the website of the Company at [www.bplindia.in](http://www.bplindia.in)

### **24. DEPOSIT:**

The Company has neither accepted nor renewed any deposits within the meaning of Section 73 and 74 of the Act read with the Companies (Acceptance of Deposits) Rules, 2014 during the year under review and hence there were no outstanding deposits and no amount remaining unclaimed with the Company as on March 31, 2024.

### **DETAILS OF LOANS AVAILED FROM DIRECTORS OR THEIR RELATIVES:**

As required under Clause (viii) of Rule 2 of Companies (Acceptance of Deposits) Rules, 2014, during the year under review, no loans have been availed by the Company from its Directors and/or from their relatives.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **25. PARTICULARS OF CONTRACTS OR RELATED ARRANGEMENTS MADE WITH RELATED PARTIES:**

All Related Party Transactions that were entered into during the financial year 2023-24 were on an arm's length basis and were in the ordinary course of business and in accordance with the provisions of the Companies Act, 2013 read with the Rules issued thereunder and as per Listing Regulations.

All Related Party Transactions with related parties were reviewed and approved by the Audit Committee and the Board. Policy on Transactions with Related Parties as approved by the Board is uploaded on the Company's website. **Further the approvals have been taken from the shareholders for material related party transactions.**

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, the disclosure of Related Party Transactions, in the format specified in the accounting standards for the half year ended 30<sup>th</sup> September, 2023 and 31<sup>st</sup> March, 2024 has been uploaded on the Exchange and the website of the company.

The Related Party Transactions, wherever necessary are carried out by company as per this policy. During the year the policy has not been changed and uploaded on the Company's website.

### **26. SECRETARIAL AUDITORS:**

The provisions of Secretarial Audit and appointment of Secretarial Auditor as required under section 204(1) of the Companies Act, 2013 read with rule 9(1) of Companies (Appointment and Remuneration) Rules, 2014 are applicable to the Company pursuant to which the Company has appointed M/s Jigar Trivedi & Co., Company Secretaries ICSI Membership No. 46488 and COP No. 18483 as the Secretarial Auditor of the Company to undertake the Secretarial Audit of the Company for the financial year 2023-24. The Secretarial Audit report of the company as on 31.03.2024 is annexed herewith as **Annexure-4**. The Secretarial Audit Report does not contain any qualification, reservation, disclaimer or adverse remarks.

### **27. STATUTORY AUDITORS:**

M/s. CNK & Associates LLP, Chartered Accountants (Firm Registration No. 101961W), Vadodara, were appointed as Statutory Auditors of the Company to hold office for Second term of 5 years starting w.e.f. 2021-22 so as to hold office up to the 34<sup>th</sup> Annual General Meeting of the Company, in terms of the provisions of Section 139 of the Companies Act, 2013

The Auditor's Report for Financial Year 2023-24 is enclosed with the Financial Statements in this Annual Report and there are no qualifications, reservations, adverse remarks, or disclaimers made by the statutory auditor in their Audit Report.

### **28. MAINTENANCE OF COST RECORDS**

The Company is maintaining cost records as specified by Central Government under Section 148(1) of the Companies Act, 2013.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

**29. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND THE PRACTICING COMPANY SECRETARY IN THEIR REPORTS:**

No qualifications, reservations or adverse remarks were made by the Statutory Auditor and the Secretarial Auditor in their respective reports.

**30. CHANGE IN NATURE OF BUSINESS IF ANY:**

There was no change in the nature of business of the company or in the nature of business carried by the Company during the year under review.

**31. WHISTLE BLOWER / VIGIL MECHANISM:**

Your Company has established a Whistle Blower/ Vigil Mechanism through which its Directors, Employees and Stakeholders can report their genuine concerns about unethical behavior, actual or suspected fraud or violation of the Company's code of conduct or ethics policy. It is affirmed that no employee has been denied access to the Audit Committee of the Company pursuant to this policy.

The details of the whistle blower policy are provided in the report on Corporate Governance forming part of this report as well as its weblink are contained in the Corporate Governance Report and website of the Company [www.bplindia.in](http://www.bplindia.in).

**32. AUDIT COMMITTEE:**

The Company has an Audit Committee pursuant to the requirements of the Act read with the rules framed thereunder and Listing Regulations.

The details pertaining to composition of Audit Committee are included in the Corporate Governance Report, which forms part of this report.

During the year under review, the Board has accepted all recommendations of the Audit Committee and accordingly, no disclosure is required to be made in respect of non-acceptance of any recommendation of the Audit Committee by the Board.

**33. DISCLOSURE FOR OBSERVATION OF SECRETARIAL STANDARDS:**

During the year under review, the Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India and approved by the Central Government under section 118 (10) of the Companies Act, 2013.

**34. ANNUAL SECRETARIAL COMPLIANCE REPORT:**

The Company has undertaken an audit for the financial year 2023-24 for all applicable compliances as per SEBI Regulations and Circulars/Guidelines issued thereunder. The Annual Secretarial Compliance Report has been submitted to the stock exchanges within 60 days from the end of the financial year under review.

**35. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:**

During the year no significant material order has been passed by the Regulators or Tribunals or Courts which would impact the going concern status of the Company and its future operations.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **36. PARTICULARS OF EMPLOYEES AND REMUNERATION:**

The information required pursuant to Section 197(12) read with Rule 5(1) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees of the Company, forms part of this report as **Annexure-5**.

### **37. POLICY ON PREVENTION, PROHIBITION AND REDRESSAL OF SEXUAL HARASSMENT AT WORK PLACE:**

The Company has zero tolerance for sexual harassment at work place and has adopted a policy on prevention, prohibition and redressal of sexual harassment at the work place in line with the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules thereunder. The Company has complied with the provisions relating to constitution of Internal Complaints Committee under the said Act. The policy aims to provide protection to the employees at the work place and prevent and redress complaints of sexual harassment.

The following is a summary of sexual harassment complaints received and disposed of during the year:

- No. of complaints received: Nil
- No. of complaints disposed of: Nil
- No. of complaints received: Nil

### **38. CODE OF CONDUCT**

Your Company has laid down a Code of Conduct ("Code") for all the Board Members and Senior Management Personnel of the Company. The Code is available on the website of the Company i.e., <https://www.bplindia.in/policies.html>. All Directors and Senior Management Personnel of the Company have affirmed compliance with the Company's Code of Conduct for the financial year ended March 31, 2024.

### **39. CORPORATE GOVERNANCE:**

Your Company continue to imbibe and emulate the best corporate governance practices aimed at building trust among all stakeholders - shareholders, employees, customers, suppliers and others. Your Company believes that fairness, transparency, responsibility and accountability are the four key elements of corporate governance. In compliance with Regulations 17 to 22 and Regulation 34 of the Listing Regulations, a separate report on Corporate Governance presented in a separate section forms an integral part of this Annual Report as **Annexure-6**.

### **40. PREVENTION OF INSIDER TRADING AND CODE OF CONDUCT FOR FAIR DISCLOSURE:**

The Company has adopted a code of conduct for Regulating, Monitoring and Reporting trading by Insiders in securities of the company. The code requires pre-clearance for dealing in the company's securities and prohibits the purchase or sale of securities of the company by the directors and the Directors while in possession of unpublished price sensitive information in relation to the company and during the period when the trading window is closed. The company has also adopted a Code of Practices and Procedures for Fair Disclosure and Conduct of Unpublished price Sensitive information to formulate a stated framework and policy for prompt and fair disclosure of events and occurrences



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

that could impact price discovery in the market for securities of the company. The policy is available on website of the Company.

#### **41. BUSINESS RESPONSIBILITY REPORT:**

The Business Responsibility Report under regulation 34 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 is not applicable to Company for the year under review ended 31st March, 2024. Therefore, there is no requirement to submit a separate report by the company.

#### **42. DETAILS OF FRAUDS: -**

The Auditors have not reported any instances of frauds committed in your Company by its officers or employees, to the Audit Committee under Section 143(12) of the Act details of which needs to be mentioned in this Report.

#### **43. PROCEEDINGS PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE:**

No application is made and no such proceedings or appeals pending under Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year and at the end of the financial year.

#### **44. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF: -**

No such instance of One-time settlement or valuation was done while taking or discharging loan from the Banks/ Financial institutions occurred during the year.

#### **45. LISTING: -**

The Equity shares of the Company continue to remain listed on BSE Limited and. The annual listing fees for the F.Y. 2024-25 has been paid to the Stock Exchange.

#### **46. ACKNOWLEDGMENT BY THE BOARD OF DIRECTORS:**

We thank our customers, vendors, dealers, investors, business partners and bankers for their continued support during the year which made the Company grow successfully. We also place on record our appreciation of the contribution made by our employees at all levels. Our consistent growth was made possible by their hard work, solidarity, cooperation and support.

**FOR AND ON BEHALF OF DIRECTORS**

Date: 10/06/2024  
Place: Vadodara

Sd/-  
Mr. Bharat Desai  
Chairman



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **ANNEXURE - 1**

**CONSERVATION OF ENERGY, RESEARCH AND DEVELOPMENT, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:** (Particulars pursuant to the Companies (Accounts) Rules, 2014)

**CONSERVATION OF ENERGY:**

We continue to strengthen our energy conservation efforts. Inter alia the following steps have been taken to reduce energy consumption:

- Use of energy efficient devices/motors for running of machineries.
- Standardization of utility pipelines leading to optimum utilization.
- Efforts have been initiated to improve overall equipment efficiency.

The process is ongoing and the Engineering team is working on various measures to conserve this scarce resource.

**RESEARCH & DEVELOPMENT:**

The Company has on-going basis takes steps to enhance its technical expertise for pharmaceutical formulations. The Company puts emphasis on innovation in its operations.

The Company's R & D department is making constant efforts in absorbing and updating themselves with the technological advancements in the product portfolio of the Company.

We continue to focus on product and process improvement and collaborate with product vendors to co-create business solutions on customer specific themes.

**TECHNOLOGY ABSORPTION:**

Your Company has not taken new technology for absorption and hence it has neither imported any technology. The company did not incur any costs for gaining access to this expertise and this has resulted in availability of an entirely new product/market for the company to explore.

The Company continued its initiatives during the year, to upgrade technology and quality at its plants. As pioneers in the country, your Company invests in best in class technology and has lined up an accelerated investment plan to retain its technology leadership position. Our Research and Development capabilities, including test equipment's and design software are being improved in line with modern practices.

**FOREIGN EXCHANGE EARNING AND OUTGO:** **[Figures in Rs. Lakhs]**

<b>FOREIGN EXCHANGE EARNINGS AND OUTGO</b>	<b>2023-24</b>	<b>2022-23</b>
Foreign Exchange earnings (USD)	190.79	5265.14
Foreign Exchange earnings (EURO)	9767.50	-
Foreign Exchange outgo (USD)	16.87	177.18
Foreign Exchange outgo (EURO)	-	-

**FOR AND ON BEHALF OF DIRECTORS**

Date: 10/06/2024  
Place: Vadodara

Sd/-  
Mr. Bharat Desai  
Chairman





## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **ANNEXURE – 2 CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES**

**1. A brief outline of the company's CSR policy of the company:**

At Bharat Parenterals Limited, we constantly strive to positively impact the health of people throughout the country. From past several years, we have strived to serve our community by setting the standard for quality, safety and value in the discovery, development, manufacture and delivery of medicines. Your Company through its Corporate Social Responsibility ("CSR") Policy encourages stronger commitment from the organization and employees towards the society to address the healthcare challenges of the country. The Policy applies to all CSR programs/projects of the Company and has been prepared keeping Company's own core competence and priorities in mind. The CSR Committee acts in an advisory capacity to the Board and Management with respect to policies and strategies that affect your Company's role as a socially responsible organization. The CSR Committee ensures that the implementation, monitoring and impact assessment of the projects is in compliance with the CSR Objectives and Policy of your Company.

**2. The Composition of the CSR Committee:**

<b>Name of Member</b>	<b>Category</b>	<b>No. of meeting held</b>	<b>No. of Meeting Attended</b>
Mr. Bharat Desai	Chairman- Managing Director	2	2
Mr. Hemang Shah	Member- Executive Director	2	2
Mr. Shailesh Gabhawala	Member- Independent Director	2	2
Mrs. Zankhana Sheth	Member- Independent Director	2	2

**1. Provide the web-link(s) where Composition of CSR Committee, CSR Policy and CSR Projects approved by the board are disclosed on the website of the company.**

- a. CSR Committee Composition: <https://www.bplindia.in/composition.html>
- b. CSR Projects details: <https://www.bplindia.in/csr.html>

**BHARAT PARENTERALS LIMITED****ANNUAL REPORT 2023-24**

2. Provide the executive summary along with web-link(s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable. :- Not Applicable

3.

(a) Average net profit of the company as per sub-section (5) of section 135.

YEAR	2022-23	2021-22	2020-21
NET PROFIT	26,21,26,831	27,98,34,357	26,57,40,999

Average net profit of the company for last three financial years is: INR. 26,92,34,062/-

(b) Two percent of average net profit of the company as per sub-section (5) of section 135. :- INR 53,84,681/-

(c) Surplus arising out of the CSR Projects or programmes or activities of the previous financial years. :- NA

(d) Amount required to be set-off for the financial year, if any. :- Nil

(e) Total CSR obligation for the financial year [(b)+(c)-(d)]. :- 53,84,681/-

4.

(a) Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project). :-INR. 56,60,069/-

(b) Amount spent in Administrative Overheads. :- Nil

(c) Amount spent on Impact Assessment, if applicable. :- Nil

(d) Total amount spent for the Financial Year [(a)+(b)+(c)]. :- INR. 56,60,069/-

(e) CSR amount spent or unspent for the Financial Year:

Total Amount Spent for the Financial Year. (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per subsection (6) of section 135.		Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135.		
	Amount.	Date of Transfer.	Name of the Fund	Amount.	Date of Transfer.
56,60,069	-	-	-	-	-

(f) Excess amount for set-off, if any:

Sl. No.	Particular	Amount (in Rs.)
(1)	(2)	(3)



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

(i)	Two percent of average net profit of the company as per sub-section (5) of section 135	53,84,681
(ii)	Total amount spent for the Financial Year	56,60,069
(iii)	Excess amount spent for the Financial Year [(ii)-(i)]	2,75,388
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	Nil
(v)	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	2,75,388

**5. Details of Unspent Corporate Social Responsibility amount for the preceding three Financial Years:**

1 Sl. No.	2 Preceding Financial Year(s)	3 Amount transferred to Unspent CSR Account under subsection (6) of section 135 (in Rs.)	4 Balance Amount in Unspent CSR Account under subsection (6) of section 135 (in Rs.)	5 Amount Spent in the Financial Year (in Rs)	6 Amount transferred to a Fund as specified under Schedule VII as per second proviso to subsection (5) of section 135, if any		7 Amount remaining to be spent in succeeding Financial Years (in Rs)	8 Deficiency, if any
					Amount (in Rs)	Date of Transfer		
1	FY-1							
2	FY-2							
3	FY-3							

**6. Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:**

Yes       No

If Yes, enter the number of Capital assets created/ acquired

Furnish the details relating to such asset(s) so created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

Sl. No.	Short particulars of the property or asset(s)	Pincode of the property or asset(s)	Date of creation	Amount of CSR amount spent	Details of entity/ Authority/ beneficiary of the registered owner



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

	[including complete address and location of the property]					
(1)	(2)	(3)	(4)	(5)	(6)	
					<b>CSR Registration Number, if applicable</b>	<b>Name Registered address</b>
	NA	NA	NA	NA	NA	NA

**7. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per subsection (5) of section 135. :- NA**

**8. Brief detail about the CSR Expenses-**

SR NO	CSR PROJECT/ ACTIVITIES	BRIEFING OF CSR ACTIVITIES	SECTOR	LOCATION	AMOUNT OUTLAY (BUDGET) PROJECT OR PROGRAM WISE	AMOUNT SPENT ON THE PROJECT OR PROGRAMS SUB - HEADS: 1. DIRECT EXPENDITURE 2. OVERHEADS *	CUMULATIVE EXPENDITURE UPTO REPORTING PERIOD	AMOUNT SPENT: DIRECT OR THROUGH IMPLEMENTATION AGENCY
1	<b>HEALTH</b>	The company directly donated medicines and medical aids to a hospital directly to treat patients from	Health	Vadodara	15,00,000/-	Direct Expenditure	Rs. 15,23,431/-	Direct Expenditure



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

		economical ly weaker sections free of cost.						
2	<b>EDUCATION</b>	The company directly supported a few residents living near rural areas close to the company who were unable to pursue their studies due to financial constraints and lack of basic necessities, as they come from economically weaker sections.	Educational	Vadodara	10,00,000/-	Direct Expenditure	Rs. 60,510/-	Direct Expenditure
3	<b>RURAL DEVELOPMENT</b>	Related to School Infrastructure in rural area near company	Rural Development	Vadodara	10,00,000/-	Direct Expenditure	Rs. 5,58,128/-	Direct Expenditure
4	<b>EMPOWERING YOUTH THROUGH EDUCATION</b>	The Project was conducted by United Way of Baroda Foundation on behalf of Company under	Educational	Vadodara	10,00,000/-	Direct Expenditure	Rs. 5,00,000/-	Implementation Agency



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

		“Education Project’ the funds were utilized before 11 <sup>th</sup> March, 2024 by these funds supported Few students from Economical ly weaker section to complete their education and achieve their Dream in Medical field							
5	<b>SOCIAL WELFARE</b>	The Project was conducted by Implementing Agencies	Rural Development	Vadodara	10,00,000/-	Direct Expenditure	Rs. 27,50,000/-	Implementation Agency	
6	<b>SOCIAL WELFARE</b>	The Company directly contributed towards social welfare requirement in rural area near company	Rural Development	Vadodara	10,00,000/-	Direct Expenditure	Rs. 2,68,000/-	Implementation Agency	
			<b><u>TOTAL</u></b>					<b><u>INR. 56,60,069</u></b>	



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

9. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report): Not Applicable
10. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any: NIL
11. In case the Company has failed to spend two percent of average net profit of last three financial years or any part thereof, the Company shall provide reason for not spending the Amount: Not Applicable, as the company has spent the whole amount towards its obligation.
12. A responsibility statement of the CSR Committee that the implementation and monitoring of CSR Policy is in compliance with CSR objective and Policy of the company:

CSR projects were designed, implemented and periodically monitored based on need assessment reports and CSR Policy of the Company, which in turn is based on and implemented with statutory requirements.

**FOR AND ON BEHALF OF DIRECTORS**

Date: 10/06/2024  
Place: Vadodara

Sd/-  
Mr. Bharat Desai  
Chairman





## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **ANNEXURE – 3**

#### **FORM AOC-1**

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries or associate companies or joint ventures:

#### **Part A Subsidiaries**

(Information in respect of each subsidiary to be presented with amounts in Rs.)

##### **1. SI. NO. -1**

2. Name of the subsidiary: Innoxel Lifesciences Private Limited
3. The date since when subsidiary was acquired: 16/10/2020
4. Reporting period for the subsidiary concerned, if different from the holding company's reporting period: Not Applicable
5. Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries: Not Applicable
6. Authorized Share Capital: INR. 100,00,00,000
7. Paid up Share Capital: INR. 90,01,45,230
8. Reserves and surplus : NIL
9. Total assets : INR. 2,26,37,31,209
10. Total Liabilities : INR. 1,46,30,15,381
11. Investments : Nil
12. Turnover: INR. 3,74,00,645
13. Profit before taxation: INR. (7,98,40,666)
14. Provision for taxation : NIL
15. Profit after taxation : INR. (7,98,40,666)
16. Proposed Dividend : Not Applicable
17. Extent of shareholding (in percentage): 51%

**\* Innoxel Lifesciences Private Limited became the subsidiary of the company w.e.f. 16<sup>th</sup> October, 2020.**

##### **1. SI. NO. -2**

2. Name of the subsidiary: Varenyam Biolifesciences Private Limited
3. The date since when subsidiary was acquired: 28/06/2022
4. Reporting period for the subsidiary concerned, if different from the holding company's reporting period: Not Applicable
5. Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries: Not Applicable
6. Authorized Share Capital: INR. 10,00,00,000
7. Paid up Share Capital: INR. 4,50,00,000
8. Reserves and surplus: NIL
9. Total assets: INR. 26,11,23,932
10. Total Liabilities: INR. 21,93,23,091
11. Investments: NIL
12. Turnover: (Not yet commenced operations)
13. Profit before taxation: INR. (22,61,498)
14. Provision for taxation: NIL
15. Profit after taxation: INR. (22,61,498)
16. Proposed Dividend: Not Applicable
17. Extent of shareholding (in percentage): 60%



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

**Varenyam Biolifesciences Private Limited became the subsidiary of the company  
w.e.f. 28<sup>th</sup> June, 2022.**

**FOR AND ON BEHALF OF DIRECTORS**

Date: 10/06/2024  
Place: Vadodara

Sd/-  
Mr. Bharat Desai  
Chairman



**Form No. MR-3**  
**SECRETARIAL AUDIT REPORT**

For the Financial Year ended March 31, 2024

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

**To,**  
**The Members,**  
**Bharat Parenterals Limited,**  
**Vadodara, Gujarat**

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Bharat Parenterals Limited** (herein after called "the Company"). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on March 31, 2024 complied with the statutory provisions listed hereunder as applicable to the company and also that the Company has proper board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter and **Annexure- "A"** attached hereto.

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the company for the financial year ended on March 31, 2024 according to the provisions of:

1. The Companies Act, 2013 (the Act) and the rules made thereunder;
2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
3. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

4. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
5. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
  - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
  - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 and The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
  - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 **(Not Applicable to the company during the audit period)**;
  - (d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014
  - (e) The Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015
  - (f) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 **(Not Applicable to the company during the audit period)**;
  - (g) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
  - (h) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 **(Not Applicable to the company during the audit period)**; and
  - (i) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 **(Not Applicable to the company during the audit period)**;
6. We have relied on the representations made by the company and its officers for systems and mechanism formed by the Company for compliances of other specific applicable Acts, Laws, Rules and Regulations to the Company including but not limited to the acts mentioned hereunder:
  - (a) The Payment of Wages Act, 1936;
  - (b) The Minimum Wages Act, 1948;
  - (c) The Employee Provident Fund and Miscellaneous Provisions Act, 1952;

- (d) Employees' State Insurance Act, 1948 and the Employees' State Insurance (General) Regulations, 1950;
- (e) The Payment of Bonus Act, 1965;
- (f) The Payment of Gratuity Act, 1972;
- (g) The Contract Labour (Regulation and Abolition) Act, 1970;
- (h) The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013
- (i) Drugs (Control) Act, 1950
- (j) The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 and other rules made thereunder
- (k) The Food Safety and Standards Act, 2006
- (l) The Narcotic Drugs and Psychotropic Substances Act, 1985
- (m) The Narcotic Drugs and Psychotropic Substances Act, 1985
- (n) The Water (Prevention and control of pollution) Act, 1974
- (o) The Air (Prevention and control of pollution) Act, 1981

We have also examined compliance with the applicable clauses of

- i. Secretarial Standards issued by The Institute of Company Secretaries of India and
- ii. the Listing Agreement entered into by the Company with BSE Limited and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**We further report that,** During the period under review, the company has reasonably complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above except the qualification remarks made herein below.

**We further report that,** The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors except as stated herein below. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

As informed, adequate notice was given to all Directors to schedule the Board Meetings. Agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decisions at Board meetings and Committee meetings were carried out by requisite majority as recorded in the minutes of meetings of the Board of Directors or Committees of the Board, as the case may be and Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

**We further report that** there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**We further report that** the compliance by the Company of the applicable financial laws like direct and indirect tax laws and maintenance of financial records and books of accounts has not been reviewed by me since the same have been subject to review by statutory auditors and other professionals.

**We further report that,**

**1) the BSE Ltd. (Stock exchange) has imposed a fine of Rs. 5900/- on the company for 1 day delay in filing of submission of Related Party Transaction pursuant to Reg. 23(9) of SEBI (LODR) 2015.**

**We further report that,** apart from above there was no specific events / actions having a major bearing on the Company's affairs in pursuance of the above referred laws, regulations, guidelines, standards, etc.

Place: Ahmedabad

Date: 10/06/2024

**For, Jigar Trivedi & Co.**  
Company Secretaries

JIGAR  
KANAKCHANDRA  
TRIVEDI

Digitally signed by JIGAR KANAKCHANDRA TRIVEDI  
DN: cn=JIGAR KANAKCHANDRA TRIVEDI, o=JIGAR & CO., ou=JIGAR & CO., email=jigar@jigartrivedi.com, c=IN  
Date: 2024.06.10 14:51:45 +05'30'

Jigar Trivedi

M. No.:46488

C.P. No.:18483

P.R. No.:2278/2022

UDIN: A046488F000551718

Note: This report is to be read with my letter of even date which is annexed as Annexure herewith and forms an integral part of this report



**'ANNEXURE A'**

**(To the Secretarial Audit Report for the Financial Year ended March 31, 2024)**

**To,  
The Members  
Bharat Parenterals Limited  
Vadodara, Gujarat**

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

Place: Ahmedabad

Date: 10/06/2024

**For, Jigar Trivedi & Co.**  
Company Secretaries

JIGAR  
KANAKCHANDRA  
TRIVEDI

Digitally signed by JIGAR KANAKCHANDRA TRIVEDI  
DN: c=IN, postalCode=380014, o=CSJIGAR TRIVEDI & CO., ou=Practicing Company Secretaries, email=jigar@csjigartrivedi.com, cn=JIGAR KANAKCHANDRA TRIVEDI  
Date: 2024.06.10 14:40:12 +05'30'

Jigar Trivedi

M. No.:46488

C.P. No.:18483

P.R. No.:2278/2022

UDIN: A046488F000551718





**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

**ANNEXURE - 5**

**PARTICULARS OF EMPLOYEES**

Particulars of employees pursuant to section 197(12) of the companies act, 2013 read with rule 5(1) of the companies (appointment and remuneration of managerial personnel) rules, 2014:

<b>SR. NO.</b>	<b>REQUIREMENT UNDER RULE -5(1)</b>	<b>DETAILS</b>	
1.	The ratio of the remuneration of each Director to the median remuneration of the Employees of the Company for the financial year:	<ul style="list-style-type: none"> <li>• Mr. Bharat Desai, Managing Director – 50:1</li> <li>• Mr. Hemang Shah, Executive Director – 10:1</li> </ul>	
2.	The percentage increase in remuneration of each Director, Chief Executive Officer, Chief Financial Officer, Company Secretary in the financial year:	<ul style="list-style-type: none"> <li>• Mr. Bharat Desai, Managing Director – 0%</li> <li>• Mr. Hemang Shah, Executive Director – 5.77%</li> <li>• Mr. Jignesh Shah, CFO- 6.40%</li> <li>• Ms. Krutika Bhattbhatt, Company Secretary-Appointed on 2<sup>nd</sup> October, 2023.</li> </ul>	
3.	The names of the top ten employees in terms of remuneration drawn and the name of every employee	<b>1. Mr. Bharat R Desai</b>	<b>2. Mrs. Hima B. Desai</b>
	(i) designation of the employee;	Managing Director	President Commercial
	(ii) remuneration received; (Rs. In Lakhs)	143.11	171.84
	(iii) nature of employment, whether contractual or otherwise;	Permanent	Permanent
	(iv) qualifications and experience of the employee;	B.SC IC	B. Com
	(v) date of commencement of employment;	03-09-1992	01.05.2006
	(vi) the age of such employee;	62yrs	56yrs
	(vii) the last employment held by such employee before joining the company;	NA	NA
	(viii) the percentage of equity shares held by the employee in the company within the meaning of clause (iii) of sub-rule (2) above; and	12.74%	13.46%
	(ix) whether any such employee is a relative of any director or manager of the	NA	NA



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

	company and if so, name of such director or manager:		
4.	The percentage increase in the median remuneration of employees in the financial year	13%	
4.	The number of permanent employees on the rolls of Company	363	
5.	Average percentile increase / decrease made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration	<ul style="list-style-type: none"><li>• Managerial Remuneration- 9%</li><li>• Others- 13%</li></ul>	
6.	Affirmation that the remuneration is as per the remuneration policy of the company.	Remuneration is as per the Nomination and Remuneration Policy of the Company.	



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **CORPORATE GOVERNANCE REPORT**

Report on Corporate Governance pursuant to Regulation 34 (3) read with the Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations, 2015) for the financial year 2023-24.

#### **Company's Philosophy on Code of Corporate Governance**

The Company continued to stay true to its purpose of promoting access to quality healthcare in the country by nurturing innovation, encouraging community involvement of our colleagues and synergizing efforts with government and other stakeholders for collective impact. The Company believes that Corporate Governance envisages attainment of high level of transparency, accountability, fair and equal treatment of all shareholders, compliance with regulations and sustainable value creation for all shareholders, ethical practices and integrity thereby assisting the top management of the Company in efficient conduct of its business. The Company believes that its systems and actions must be integrated for enhancement of corporate performance resulting in maximization of shareholders' value in the long run, protection of the interest of its shareholders and employees and maintenance of cordial relationship with its customers and bankers. The Company gives due emphasis on regulatory compliances.

#### **1. Board of Directors:**

##### **A) Composition of Board:**

The present Board of Directors of the Company comprises of Six directors of which one is Managing Director, one is Executive Director, One is non-Executive Director and Three are Independent Directors. The board comprises of 50% Non-Executive Independent Directors.

##### **B) No. of Board Meetings during the year:**

The Board of Directors met 6 times during the year under review. Detailed agenda notes and the information required to be given in terms of Business on the agenda were circulated in advance to all the Directors of the Company. The Directors including Non-Executive Directors and Independent Directors actively participated in the Board Meetings.

Attendance of Directors at the Board and Shareholders' Meeting during the financial year 2023-24:

<b>Name of Director</b>	<b>Category</b>	<b>No. of BM attended</b>	<b>No. of Committee Meeting attended</b>	<b>Attendance at Last Annual General Meeting</b>
Bharat R. Desai	Promoter- Executive Director	11	14	Yes
Hemang Shah	Executive Director	11	14	Yes
Shailesh Gabhawala	Non-Executive Independent Director	11	14	Yes



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

Zankhana Sheth	Non-Executive Independent Director	11	14	No
Mukesh Patel*	Non-Executive Independent Director	11	12	Yes
Sanjay Shah**	Non-Executive Director	11	NA	Yes

The Above mentioned directors concerned are not holding position as directorship, membership or chairmanship of any other committee in any other listed entity and hence, the same is not separately disclosed.

C) **Board Meetings:**

During the year under review regular meetings of the Board are held to review performance of the Company and to discuss and decide on various business strategies, policies and other issues. Following meetings were held and the details of directors present at the meeting:

<b>SR. NO.</b>	<b>DATE OF BOARD MEETING</b>	<b>BOARD STRENGTH</b>	<b>NO. OF DIRECTORS PRESENT</b>
1	20.05.2023	6	6
2	09.08.2023	6	6
3	31.08.2023	6	6
4	12.09.2023	6	6
5	01.10.2023	6	6
6	09.11.2023	6	6
7	05.12.2023	6	6
8	17.01.2024	6	6
9	02.02.2024	6	6
10	13.02.2024	6	6
11	20.03.2024	6	6

D) The Board of directors confirm that in the opinion of the Board of Directors the Independent Directors fulfill the conditions specified under SEBI (Listing Obligations and Disclosures Requirement) regulation, 2015 and are independent of the management.

**2. No. of Shares and Convertible Instruments held by Non-Executive Directors:**

None of the Non-executive directors held any equity shares and Convertible Instruments of the company except Mr. Shailesh Gabhawala, non-executive Independent director, who hold 9000 equity shares of the company and Mr. Mukesh Patel, Non-executive Independent Director who holds 100 shares of the company.

**3. Familiarization Programme for Independent Directors**

The Company has a familiarization Program for Independent Directors to familiarize them with regard to their roles, rights, responsibilities in the Company, along with industry, business operations, business model, code of conduct and



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

policies of the Company etc. The company's policy on familiarization programme is available on the website on the company: <https://www.bplindia.in>.

#### **4. Details of Skill / expertise / competence of the Board of Directors:**

The Board of directors of the company looking to the business model of the company have short listed the few core skills/ expertise / competence as expected for the board members. The chart / matrix with respect to area of focus or expertise of individual Board members is as under:

Name of Director	Area of Skills / Expertise				
	Business Leadership	Financial Expertise	Risk Management	Corporate Governance	Technology & Innovation
Shri Bharat Shah	✓	✓	✓	✓	✓
Shri Hemang Shah	✓	✓	✓	✓	✓
Shri Shailesh Gabhawala	✓	✓	✓	✓	-
Smt. Zankhana Sheth	✓	-	✓	✓	✓
Shri Mukesh Patel	✓	-	✓	✓	✓
Shri Sanjay Shah	✓	✗	✓	✓	✓

5. Detailed reasons for the resignation of an independent director who resigns before the expiry of his /her tenure along with a confirmation by such director that there are no other material reasons other than those provided- NA

#### **6. Audit Committee:**

The Audit Committee, inter-alia, covers all the matters, specified under Section 177 of the Companies Act, 2013 and also to comply with Regulation 18 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 and as Part C of Schedule II of SEBI Listing Regulation, 2015 and Companies Act, 2013 such as overseeing the Company's financial reporting process and disclosure of financial information to ensure presentation is correct, sufficient and credible financial statements, recommending the appointment, remuneration and terms of appointment of Auditors of the Company. The Audit Committee has powers, inter-alia, to investigate any activity within its terms of reference and to seek information from any employee of the Company as well as seek outside legal and professional advice. During the FY 2023-24 Four meeting were held of Audit Committee – 20.05.2023, 09.08.2023, 09.11.2023 and 13.02.2024.

The Audit Committee of the Company comprises of the following persons and the details of attendance of meeting of audit committee is as under:



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

<b>NAME OF MEMBER</b>	<b>CATEGORY</b>	<b>NO. OF MEETING HELD</b>	<b>NO. OF MEETING ATTENDED</b>
Mr. Shailesh Gabhawala	Non-Executive Independent Director, Chairperson	- 4	4
Mrs. Zankhana Sheth	Non-Executive Independent Director, Member	- 4	4
Mr. Hemang J. Shah	Executive Director, Member	4	4

Company Secretary of the Company by default acts as a Secretary of the Committee.

### **7. Nomination and Remuneration Committee:**

In terms of the provisions Section 178 of the Companies Act, 2013 and as per Regulation 19 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 and other regulations as may be applicable, the Board has constituted a Nomination and Remuneration Committee. Terms of reference of the Committee are as follows:

- a) Identify persons who are qualified to become directors and may be appointed in senior management in accordance with the criteria laid down, recommend to the Board their appointment and removal and shall carry out evaluation of every director's performance;
- b) Formulation of the criteria for determining qualifications, positive attributes and independence of a Director;
- c) Formulation of criteria for evaluation of performance of independent directors and the Board of Directors;
- d) Devising a policy on diversity of board of directors;
- e) Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;
- f) Determine our Company's policy on specific remuneration package for the Managing Director / Executive Director including pension rights;
- g) Decide the salary, allowances, perquisites, bonuses, notice period, severance fees and increment of Executive Directors;
- h) Define and implement the Performance Linked Incentive Scheme (including ESOP of the Company) and evaluate the performance and determine the amount of incentive of the Executive Directors for that purpose.
- i) Decide the amount of Commission payable to the Whole time Directors;
- j) Review and suggest revision of the total remuneration package of the Executive Directors keeping in view the performance of the Company, standards prevailing in the industry, statutory guidelines etc; and
- k) Recommend to the board, all remuneration, in whatever form, payable to senior management.
- l) Recommend to the Board a policy, relating to the remuneration of the Directors, Key Managerial Personnel and Senior Management;
- m) Formulation of criteria for evaluation of Independent Directors and the Board;
- n) Devising a policy on Board diversity;



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

The Nomination and Remuneration Committee has formulated the Nomination and Remuneration Policy. The Nomination and Remuneration Policy is designed to attract, motivate and retain manpower in a competitive market. The policy reflects the Company's objectives for good Corporate Governance and compliance of Section 178 and other applicable provisions of the Companies Act, 2013 and SEBI LODR. During the FY four meeting of Nomination and Remuneration Committee was held on 20.05.2023, 09.08.2023, 09.11.2023 and 13.02.2024.

The Nomination and Remuneration of the Company comprises of the following persons and the details of attendance of committee meeting is as under:

Name of Member	Category	No. of meeting held	No. of Meeting Attended
Mr. Shailesh Gabhawala	Non-Executive Independent Director, Chairperson	- 4	4
Mrs. Zankhana Sheth	Non-Executive Independent Director, Member	- 4	4
Mr. Mukesh Patel	Non-Executive Independent Director, Member	- 4	4

Company Secretary of the Company by default acts as a Secretary of the Committee.

### **8. PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:**

The Nomination and Remuneration Committee has formulated the performance evaluation criteria in the Nomination and Remuneration Policy of the Company. The Nomination and Remuneration Policy is available on the website of the company [www.bplindia.in](http://www.bplindia.in). Pursuant to the provisions of the Companies Act, 2013 and with the applicable Rules thereto and applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, the performance of the Board, its Committees, individual Directors, Chairman and Independent Directors was evaluated on the basis of a structured questionnaire as it was prepared after taking into consideration inputs received from the Directors, covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, Board culture, execution and performance of specific duties, obligations and governance. The performance evaluation of the Independent Directors was carried out by the entire Board except the Independent Director being evaluated.

The Directors were asked to rate the performance on various parameters including a high degree of commitment to his responsibilities as an Independent Director, appears to be familiar with the business model of the Company and the industry it belongs to, he is aware of his role, rights and responsibilities as an Independent Director, he has been actively participating in the Board/Committee discussions and contributing to the decision-making process, he has been known to take initiative on matters of common interest of the Company and to exhibit sensitivity to the interest of all the stakeholders, he comes across as a person with expertise and experience, he keeps himself informed on the latest developments in corporate governance.





## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **9. CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:**

In compliance with the provisions of Section 135 and Schedule VII of the Companies Act, 2013, the Board has constituted the Corporate Social Responsibility Committee. This Committee consists of:

- a) Mr. Bharat R. Desai
- b) Mr. Hemang Shah
- c) Mr. Shailesh Gabhawala
- d) Mr. Zankhana Sheth

Terms of Reference:

Your Company has been contributing in the upliftment and development of the surrounding areas. Pursuant to the requirement of Section 135 of the Companies Act, 2013, Schedule VII, and Rules made there under a duly constituted Corporate Social Responsibility Committee is in place. The CSR policy has been placed on the website of the Company. The CSR Committee is empowered, pursuant to its terms of reference, inter alia, to:

- Formulate and recommend to the Board, a Corporate Social Responsibility policy indicating the activities to be undertaken by the Company.
- Recommend the amount of expenditure to be incurred.
- Monitor the Corporate Social Responsibility policy.
- Such other roles and functions as may be prescribed in the Companies Act, 2013 and rules made there under.

Further, as required under the Companies Act, 2013 and rules made there under, the information on the CSR activities undertaken by the Company during the year ended March 31, 2024 is annexed to the Board's Report.

### **10. REMUNERATION OF DIRECTORS**

There are no pecuniary transactions or relationships exist with the Non- Executive Directors of the Company. The Non-executive Directors and Independent Directors of the Company are entitled to sitting fees as determined by Board from time to time for attending Board / Committee meetings thereof in accordance with the provisions of Act. The details related to remuneration paid to the Executive Directors are specified below:

<b>Name</b>	<b>Salary</b>	<b>Stock options</b>	<b>Bonus &amp; Performance Linked Incentive</b>	<b>Total</b>
Bharat R. Desai	1,43,11,250	0	0	1,43,11,250
Hemang Shah	40,24,104	0	0	40,24,104

- a. **Service Contracts, Severance Fees and Notice Period**  
The appointment of the Managing Director and Whole-time Director(s) is governed by the Articles of Association of the Company, Board Resolutions, Members Resolutions and service/employment contracts. The Board Resolutions and Members Resolutions cover the terms and conditions of such appointment read with the service rules of the Company. There is no separate provision for payment of severance fee under the resolutions/contracts governing the appointment of



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

Managing Director and Whole- time Director(s). The service/ employment contracts are terminable by either party by serving notice of three months.

### **11. STAKEHOLDER RELATIONSHIP COMMITTEE:**

The Company has constituted the Stakeholders Relationship Committee in compliance of provisions of the Section 178 of the Companies Act, 2013 and as per Regulation 20 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. The terms of reference of the Stakeholders Relationship Committee are as under:

- Resolving the grievances of the security holders of the listed entity including complaints related to transfer / transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new / duplicate certificates, general meetings etc.
- Review of measures taken for effective exercise of voting rights by shareholders.
- Review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent. Review of the various measures and initiatives taken by the listed entity for ensuring timely receipt of dividend warrants / annual reports / statutory notices by the shareholders of the Company. During the FY 2022-2023 three meeting were held of Stakeholder and Relationship Committee – 20.05.2023, 09.08.2023, 09.11.2023 and 13.02.2024.

The Stakeholder relationship committee of the Company comprises of the following persons:

Name of Member	Category	No. of meeting held	No. of Meeting Attended
Mr. Shailesh Gabhawala	Non-Executive Independent Director, Chairperson	- 4	4
Mrs. Zankhana Sheth	Non-Executive Independent Director, Member	- 4	4
Hemang J. Shah	Executive Director, Member	4	4

Mr. Shyam Rajpurohit, Company Secretary and Compliance Officer of the Company by will acts as a Secretary of the Committee till 02.10.2023 and thereafter Ms. Krutika Bhattbhatt acts as a Secretary of the Committee w.e.f. 02.10.2023.

No. of investor complaints received during the year: 13

No. of complaints not resolved to the satisfaction of shareholders: 1

No. of complaints pending: 0

### **12. Risk Management Committee :- Not Applicable**

**13. Senior Management:** There is no change in Senior Management since the compared to previous financial year



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **14. General body meetings:**

a. The details of the last three Annual General Meetings held are as follows:

Financial Year	Venue	Date & Time
2020-2021	Annual General Meeting conducted through Video Conferencing / Other Audio Visual Means. Deemed  Venue is the registered office of the company.	30 <sup>th</sup> September, 2021 at 01:00 PM
2021-2022	Annual General Meeting conducted through Video Conferencing / Other Audio Visual Means. Deemed  Venue is the registered office of the company.	27 <sup>th</sup> September, 2022 at 10.30 AM
2022-2023	Annual General Meeting conducted through Video Conferencing / Other Audio Visual Means. Deemed  Venue is the registered office of the company.	30 <sup>th</sup> September, 2023 at 10.30 AM

- b. Two Special Resolutions was passed at the 28<sup>th</sup> Annual General Meeting held on 30<sup>th</sup> September, 2021 which are as follows:
- RE-APPOINTMENT OF MR. SHAILESH GABHAWAL AS INDEPENDENT DIRECTOR OF THE COMPANY
  - APPROVAL OF LOANS, INVESTMENTS, GUARANTEE OR SECURITY UNDER SECTION 185 OF COMPANIES ACT, 2013
- c. Two Special Resolutions was passed at the 29<sup>th</sup> Annual General Meeting held on 27<sup>th</sup> September, 2022 which are as follows:
- RE-APPOINTMENT OF MRS. ZANKHANA BIMALKUMAR SHETH (DIN: 08200311) AS INDEPENDENT DIRECTOR OF THE COMPANY
  - APPROVAL OF LOANS, INVESTMENTS, GUARANTEE OR SECURITY UNDER SECTION 185 OF COMPANIES ACT, 2013
- d. Ordinary resolutions were passed at the 30<sup>th</sup> Annual General Meeting held on 30<sup>th</sup> September, 2023
- e. No resolutions were passed through postal ballot during the last year
- f. Person who conducted the postal ballot exercise – Not applicable



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **15. INDEPENDENT DIRECTOR'S MEETING DURING THE YEAR:**

In accordance with the provisions of SEBI(LODR) and provisions of companies act, 2013, meeting of the Independent Directors of the Company was held on 20<sup>th</sup> March, 2023.

Further, Confirmation In the opinion of the Board, all the Independent Directors, fulfill the criteria of independence as laid down in Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the Listing Regulations and such is based on the declaration received from all the Independent Directors.

During the year under review, the Independent Directors met inter alia, to discuss and review:

- Evaluation of the performance of Non-Independent Directors and the Board of Directors as a whole.
- Evaluation of the performance of the chairperson of the Company, taking into account the views of the Executive and Non-Executive Directors.
- Evaluation of the quality, content and timelines of flow of information between the Management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

### **16. MEANS OF COMMUNICATION**

The Company's quarterly and half yearly un-audited results and audited annual results were published in the leading print media, both in Loksatta Jansatta (regional language) and Business Standard (English language) having nation-wide circulation and also through various information notices sent to Stock Exchanges about the latest developments in the Company. Our Company's web site i.e. <https://www.bplindia.in> is regularly updated regarding disclosures of financial results and the corporate actions undertaken by the Company. Further, the related information is uploaded / submitted to Stock Exchanges on time to time basis .

### **17. General shareholder information:**

- a) Annual General Meeting:  
Date: 30<sup>th</sup> September, 2023 | Time: 10.30 AM IST | Venue: This meeting will be held through VC / OAVM
- b) Financial Year:  
The Company follows Accounting financial year which starts from the 1st April and ends on 31st March.
- c) Listing on Stock Exchange: BSE Limited and the annual listing fees has been paid by the company.
- d) Stock Code: 541096
- e) ISIN: INE365Y01019
- f) Monthly High and Low Market Price Data during FY 2023-24:

<b>PERIOD</b>	<b>High Price (in Rs.)</b>	<b>Low Price (In Rs.)</b>
April, 2023	351.00	321.05
May, 2023	390.00	321.20
June, 2023	397.00	339.50
July, 2023	457.90	365.00
August, 2023	648.40	421.00



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

September, 2023	638.00	531.65
October, 2023	640.00	523.10
November, 2023	635.00	513.15
December, 2023	874.40	553.70
January, 2024	876.90	743.00
February, 2024	1350.00	774.25
March, 2024	1464.90	1040.00

**g) Registrar and Share Transfer Agent:**

**M/s. Adroit Corporate Services Pvt. Ltd**

19/20, 1<sup>st</sup> Floor, Plot No. 639, Makwana Road, Marol, Andheri East, Mumbai - 400059

**h) Company Secretary and Compliance Officer:**

**Name:** Ms. Krutika Bhattbhatt  
**Contact at:** [cs@bplindia.in](mailto:cs@bplindia.in) , +91-9909928332  
**Website:** [www.bplindia.in](http://www.bplindia.in)  
**Address for correspondence:** Survey No. 144A,  
Jarod Samlaya Road,  
Vill. Haripura, Tal. Savli,  
Dist. Vadodara – 391520

**i) Share Transfer System:**

Share transfers, dividend payments and all other investor related activities are attended to and processed at the Office of our Registrars and Transfer Agents. For lodgment of transfer deeds and any other documents for any grievances / complaints kindly contact at the following address. The powers to approve share transfers and dematerialization requests have also been delegated to some of the executives of the company in order to avoid delays that may arise due to non-availability of the Members of the Stakeholders Relationship Committee.

**j) DISTRIBUTION OF SHAREHOLDING AS ON 31<sup>st</sup> MARCH 2024**

<b>PARTICULARS</b>	<b>NUMBER OF SHARES</b>	<b>% OF TOTAL SHARES</b>
Promoter and Promote Group	4263780	73.27
Public	1555886	26.73
Individuals	1034326	17.77
Bank	500	0.01
Clearing Members	0	0
HUF	30231	0.52
Bodies Corporate	490829	8.43
Non-Resident Indian	237416	4.11



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **k) Dematerialization of Shares and Liquidity:**

The Company's shares are under compulsory dematerialization list and can be transferred only through depository system. The Company entered into tripartite agreement with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) to facilitate the dematerialization of shares. As on 31.03.2024, 89.93% shares of the Company were in electronic form.

Dematerialization of shares details as on 31/03/2024:

<b>No. of equity Shareholding</b>	<b>No. of Shares</b>	<b>% to total capital issued</b>
Held in dematerialized mode in NSDL	4700399	80.77
Held in dematerialized mode in CDSL	532932	09.16
Sub-Total (dematerialized mode)	5233331	89.93
Physical mode	586335	10.08
<b>Total</b>	<b>5819666</b>	<b>100.00%</b>

### **l) Plant Location:**

Survey No. 144-A, Jarod Samlaya Road, Vill. Haripura, Tal. Savli, Dist. Vadodara – 391520, Gujarat, India.

### **m) Address of Correspondence:**

Survey No. 144-A, Jarod Samlaya Road, Vill. Haripura, Tal. Savli, Dist. Vadodara – 391520, Gujarat, India.

**n)** List of all credit ratings obtained by the entity along with any revisions thereto during the relevant financial year, for all debt instruments of such entity or any fixed deposit programme or any scheme or proposal of the listed entity involving mobilization of funds, whether in India or abroad- NA

**o)** Outstanding global depository receipts or american depository receipts or warrants or any convertible instruments, conversion date and likely impact on equity-NA

**p)** Dividend payment date-30.09.2023

## **18. OTHER DISCLOSURES:**

### **a) Related Party Transactions:**

All contracts/ transactions/ arrangements entered into during the year with related parties were in the ordinary course of business and on arm's length basis. The company had not entered into any contract/ arrangement/ transaction with related parties which could be considered material in accordance with policy of the company.

The disclosure relating to related party transactions entered into by the company in the ordinary course of business and on arm's length basis is disclosed in notes to financial statements.

### **b) Details of Non-compliance and penalty:**

The Company has complied with all the mandatory and non-mandatory requirements of the Listing Regulations relating to Corporate Governance and not done any non-compliance of any applicable laws, regulations and rules. Further no penalty has been levied on the company.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

**c) Vigil Mechanism/Whistle Blower Policy:**

As required by the provisions of Companies Act 2013 and Listing Agreement with BSE Limited, the Company has established Vigil Mechanism and adopted Whistle Blower Policy to provide for adequate safeguards against victimization of employees and directors who avail of the vigil mechanism and also provide for direct access to the Chairman of the Audit Committee or the director nominated to play the role of Audit Committee. No employee has been denied access to the Chairman of the Audit Committee.

**d) Details of Compliance With Mandatory Requirements And Adoption Of The Non-Mandatory Requirements;**

The company has complied with all mandatory requirements SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended from time to time. The Company has also adopted all the non-mandatory requirements as specified in the Schedule II Part E of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

**e) Web link where policy for determining 'material' subsidiaries is disclosed:**

The Audit Committee reviews the consolidated financial statements of the company and the investments made in the unlisted subsidiary company. The company does not have any material unlisted subsidiary company. The company has policy determining "material" subsidiaries is disclosed on website of the company at: <https://www.bplindia.in/for%20investors/policies%20and%20code%20of%20conduct/Material%20Subsidiary%20policies.pdf>

**f) Web link where policy on dealing with related party transactions:**

The URL of the policy on dealing with related party transaction is [https://www.bplindia.in/for%20investors/policies%20and%20code%20of%20conduct/RPT\\_Policy.pdf](https://www.bplindia.in/for%20investors/policies%20and%20code%20of%20conduct/RPT_Policy.pdf)

**g) Disclosure of commodity price risks and commodity hedging activities.**

There is no exposure of the Company involving any commodity price risk or foreign exchange risk and therefore there is no hedging activities undertaken.

Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A)-NA

**h) Certificate from Practicing company Secretary**

The company has obtained the certificate from practicing company secretary M/s. Jigar Trivedi & Co., Ahmedabad that none of the directors of the board of the company have been debarred or disqualified from being appointed or continuing as a director of the companies by the Board / Ministry of Corporate Affairs or any other statutory authority. The said certificate forms part of the annual report.

**i) Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor for the financial year 2023-2024**

Sr. No.	Particulars	Consolidated Amount (In Rs.)
1	CNK & Associates LLP	4,94,500/-





## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

- j) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:**
- Number of complaints filed during the financial year: NIL
  - Number of complaints disposed of during the financial year: NIL
  - Number of complaints pending as on end of the financial year: NIL
- k) Non-compliance of any requirement of corporate governance report of paras (2) to (10) of Para C of Schedule V of LODR, with reasons thereof.**  
Not Applicable
- l) Disclosure of the compliance with corporate governance requirements**  
The company has complied with all the mandatory requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 of the SEBI (Listing obligation disclosure requirement) Regulation 2015.
- m) Code of Conduct**  
Declaration by the Managing Director under Reg. 26 of the SEBI (Listing obligation disclosure requirement), 2015 regarding compliance with Code of Conduct in accordance with Reg. 26 of the SEBI (Listing obligation disclosure requirement), 2015 with the Stock Exchanges.
- n) Transfer of shares to Unclaimed Suspense Account**  
No shares has been transferred to unclaimed Suspense account of the company.
- o) Recommendation of Committees**  
The Board has accepted all the recommendation of all committees which are required to mandatory during the Financial Year.
- p) Details of Loans and Advances in the nature of loan to firms/companies in which Directors are interested- Mentioned in Audited Financial Statement**

### **FOR AND ON BEHALF OF DIRECTORS**

Date: 10/06/2024  
Place: Vadodara

Sd/-  
Mr. Bharat Desai  
Chairman



**CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS**

*(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015)*

To,  
The Members of,  
Bharat Parenterals Limited,  
Vill-Haripura, Savli,  
Baroda Gujarat-389330

I/We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Bharat Parenterals Limited having CIN: L24231GJ1992PLC018237 and having registered office at Vill-Haripura, Savli, Baroda Gujarat-389330 (hereinafter referred to as 'the Company'), produced before me/us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal [www.mca.gov.in](http://www.mca.gov.in)) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31<sup>st</sup> March, 2024 have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

<b>Sr. No.</b>	<b>Name Of Director</b>	<b>DIN</b>	<b>Date Of Appointment in company</b>
1.	Mukeshbhai Jivrajbhai Patel	00410134	26/09/2020
2.	Bharatkumar Rameshchandra Desai	00552596	03/09/1992
3.	Hemang Jayendrabhai Shah	03024324	08/07/2010
4.	Shaileshkumar Gabhawala	07884641	03/08/2017
5.	Zankhana Bimalkumar Sheth	08200311	14/08/2018
6.	Sanjay Parasmal Shah	08899131	02/10/2020



**AUDITOR'S CERTIFICATE ON CORPORATE GOVERNANCE**

To,  
The Members,  
M/s. Bharat Parenterals Ltd  
Vadodara

We have examined the compliance of conditions of Corporate Governance by Bharat Parenterals Limited ("the Company") for the year ended on 31<sup>st</sup> March 2024, as per regulations 17 to 27, clauses (b) to (i) of regulation 46(2) and Paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") with amendments as applicable

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination has been limited to a review of the procedures and implementation thereof, adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion, and to the best of our information and according to the explanations given to us, and the representations made by the Directors and Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in Reg. 27 of the SEBI (Listing obligation disclosure requirement) 2015 except the appointment of Independent Director in terms of Regulation 24 of the SEBI (Listing obligation disclosure requirement) 2015 in material subsidiary of the company.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the company

Place: Ahmedabad  
Date: 10/06/2024

**For, Jigar Trivedi & Co.**  
Company Secretaries

JIGAR  
KANAKCHANDRA  
TRIVEDI



Jigar Trivedi  
M. No.:46488  
C.P. No.:18483  
P.R. Certificate No.:2278/2022  
UDIN: A046488F000551696



**AUDITOR'S CERTIFICATE ON CORPORATE GOVERNANCE**

To,  
The Members,  
M/s. Bharat Parenterals Ltd  
Vadodara

We have examined the compliance of conditions of Corporate Governance by Bharat Parenterals Limited ("the Company") for the year ended on 31<sup>st</sup> March 2024, as per regulations 17 to 27, clauses (b) to (i) of regulation 46(2) and Paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") with amendments as applicable

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination has been limited to a review of the procedures and implementation thereof, adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion, and to the best of our information and according to the explanations given to us, and the representations made by the Directors and Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in Reg. 27 of the SEBI (Listing obligation disclosure requirement) 2015 except the appointment of Independent Director in terms of Regulation 24 of the SEBI (Listing obligation disclosure requirement) 2015 in material subsidiary of the company.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the company

Place: Ahmedabad  
Date: 10/06/2024

**For, Jigar Trivedi & Co.**  
Company Secretaries

JIGAR  
KANAKCHANDRA  
TRIVEDI

Digitally signed by JIGAR KANAKCHANDRA TRIVEDI  
DN: cn=JIGAR KANAKCHANDRA TRIVEDI, o=JIGAR TRIVEDI & CO., ou=Practicing Company Secretaries, email=jigar@jigartrivedi.com, c=IN  
Date: 2024.06.10 14:39:22 +0530

Jigar Trivedi  
M. No.:46488  
C.P. No.:18483  
P.R. Certificate No.:2278/2022  
UDIN: A046488F000551696



## **CERTIFICATE**

**To,  
The Board of Directors,  
M/s. Bharat Parenterals Ltd  
Vadodara**

I Jigar Trivedi Company Secretary in practice, have been appointed as the Secretarial Auditor vide a resolution passed at its meeting held on 31<sup>st</sup> August, 2023 by the Board of Directors of Bharat Parenterals Limited (hereinafter referred to as 'the Company'), having CIN L24231GJ1992PLC018237 and having its registered office at Survey No.144A, Jarod Samlaya Road, Haripura, Savli, Vadodara, Gujarat, 391520. This Certificate is issued under Regulation 13 of the Securities and Exchange Board of India [Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (hereinafter referred to as "the Regulations"].

### **Management Responsibility:**

It is the responsibility of the Management of the Company to implement the Scheme(s) including designing, maintaining records and devising proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

### **Verification:**

The Company has implemented the following plans:

- I. Employees Stock Option Plan, 2020 [formulated under the SEBI (Share Based Employee Benefits) Regulations, 2014], approved by the members at the General Meeting of the Company held on 30<sup>th</sup> September, 2020 (hereinafter referred to ESOP, 2020).

For the purpose of verifying the compliance of the Regulations, I have examined the Schemes, Resolutions passed at General Meeting and the meeting of the Board of Directors / Nomination and Remuneration Committee, Disclosure by the Board of Directors and other relevant documents made available to me and the explanations provided by the Company.

### **Certification:**

In my opinion and to the best of my knowledge and according to the verifications as considered necessary and explanations furnished to me by the Company and its Officers, I Certify that the Company has implemented the ESOP, 2020 in accordance with the applicable provisions of the Regulations and Resolution passed in the General Meeting by the members of the Company.



Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: Ahmedabad  
Date: 10/06/2024

For, Jigar Trivedi & Co.  
Company Secretaries

JIGAR  
KANAKCHAND  
RA TRIVEDI

Digitally signed by JIGAR KANAKCHAND TRIVEDI  
DN: cn=JIGAR KANAKCHAND TRIVEDI, o=JIGAR TRIVEDI & CO., ou=JIGAR TRIVEDI & CO., email=jigar@jigartrivedi.com, c=IN  
Date: 2024.06.10 10:06:00 +05'30'



---

Jigar Trivedi  
M. No.:46488  
C.P. No.:18483  
P.R. No.:2278/2022  
UDIN: A046488F000551685





**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

**CERTIFICATION BY CFO AND MANAGING DIRECTOR**

- a. We have reviewed financial statements and the cash flow statement for the year ended March 31, 2024 and that to the best of our knowledge and belief:
  - i. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  - ii. these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- b. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violate the Company's Code of Conduct.
- c. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting. We have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

There have been no

- i. Significant changes in internal control over financial reporting during the year;
- ii. Significant changes in accounting policies during the year;
- iii. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having significant role in the Company's internal control system over financial reporting.

**For and on behalf of Board of Directors**

**Sd/-**

**Mr. Bharat Desai  
Managing Director**

**Sd/-**

**Mr. Jignesh Shah  
Chief Financial Officer**

**Date: 10.06.2024**

**Place: Vadodara**



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **CERTIFICATE**

**To,  
The Board of Directors,  
M/s. Bharat Parenterals Ltd  
Vadodara**

I Jigar Trivedi Company Secretary in practice, have been appointed as the Secretarial Auditor vide a resolution passed at its meeting held on 31<sup>st</sup> August, 2023 by the Board of Directors of Bharat Parenterals Limited (hereinafter referred to as 'the Company'), having CIN L24231GJ1992PLC018237 and having its registered office at Survey No.144A, Jarod Samlaya Road, Haripura, Savli, Vadodara, Gujarat, 391520. This Certificate is issued under Regulation 13 of the Securities and Exchange Board of India [Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (hereinafter referred to as "the Regulations"].

#### **Management Responsibility:**

It is the responsibility of the Management of the Company to implement the Scheme(s) including designing, maintaining records and devising proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

#### **Verification:**

The Company has implemented the following plans:

- I. Employees Stock Option Plan, 2020 [formulated under the SEBI (Share Based Employee Benefits) Regulations, 2014], approved by the members at the General Meeting of the Company held on 30<sup>th</sup> September, 2020 (hereinafter referred to as ESOP, 2020).

For the purpose of verifying the compliance of the Regulations, I have examined the Schemes, Resolutions passed at General Meeting and the meeting of the Board of Directors / Nomination and Remuneration Committee, Disclosure by the Board of Directors and other relevant documents made available to me and the explanations provided by the Company.

#### **Certification:**

In my opinion and to the best of my knowledge and according to the verifications as considered necessary and explanations furnished to me by the Company and its Officers, I Certify that the Company has implemented the ESOP, 2020 in accordance with the applicable provisions of the Regulations and Resolution passed in the General Meeting by the members of the Company.

#### **Assumption & Limitation of Scope and Review:**

1. Ensuring the authenticity of documents and information furnished is the responsibility of the Board of Directors of the Company.



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

2. My responsibility is to give certificate based upon examination of relevant documents and information. It is neither an audit nor an investigation.
3. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company

Date: 10/06/2024

Place: Ahmedabad

**For, Jigar Trivedi & Co.**

Company Secretaries

---

Jigar Trivedi  
M. No.:46488  
C.P. No.:18483  
P.R. Certificate No.:2278/2022  
UDIN:



**BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

**DECLARATION**

**DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH COMPANY'S CODE OF CONDUCT**

This is to inform that the company has adopted a code of conduct for its employees, non-executive directors and executive directors which is also available on the Company's website.

I confirm that the Company has in respect of the financial year ended March 31, 2024, received from the Senior Management Team of the Company and Members of the Board, a declaration of compliance with the code of conduct as applicable to them.

For the purpose of this declaration, Senior Management Team includes the Chief Financial Officer, Company Secretary and other employees in the executive cadre as on March 31, 2024.

**For and on behalf of Board of Directors**

**Date: 10.06.2024**

**Place: Vadodara**

**Sd/-  
Bharat R. Desai  
Managing Director**



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

### **MANAGEMENT DISCUSSION AND ANALYSIS REPORT**

#### **1. *Economic Overview and Indian Pharmaceutical market:***

Market size of India pharmaceuticals industry is expected to reach US\$ 65 billion by 2024, and ~US\$ 130 billion by 2030. According to the government data, the Indian pharmaceutical industry is worth approximately US\$ 50 billion with over US\$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India.

India is among the top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in Asia Pacific. In 2022, India's Biotechnology industry has crossed US\$ 80.12 billion, growing 14% from the previous year.

The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation.

According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. India's domestic pharmaceutical market stood at US\$ 42 billion in 2021 and is likely to reach US\$ 65 billion by 2024 and further expand to reach US\$ 120-130 billion by 2030. India's biotechnology industry comprises biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics. The Indian biotechnology industry was valued at US\$ 70.2 billion in 2020 and is expected to reach US\$ 150 billion by 2025. India's medical devices market stood at US\$ 10.36 billion in FY20. The market is expected to increase at a CAGR of 37% from 2020 to 2025 to reach US\$ 50 billion. As of August 2021, CARE Ratings expect India's pharmaceutical business to develop at an annual rate of ~11% over the next two years to reach more than US\$ 60 billion in value.

#### **2. *Industry Structure and Development:***

With more than 500 formulations to choose, a strong formulation development base and coveted WHO-cGMP certificate to its credit, Bharat Parenterals Limited has already made an export presence across the globe. The large scale modern production facility at Haripura, Savli is WHO-cGMP certified and abides by its stringent norms. Its processes are ISO 9001:2000 certified as well over years, Bharat Parenterals Limited has sharpened its production expertise, built modern production lines and consolidated manufacturing processes, which conform to international standards.

#### **3. *Opportunities and Threats:***

The Indian pharmaceutical environment is evolving rapidly with government involvement which may impact the development of the Indian Pharmaceutical Market. Factors like government mandated price controls, patent scenario, weakening of rupee, stringent quality standards, etc. are some of the major issues that need consideration in the current scenario. Bharat Parenterals Limited will be able to place itself in a strong position by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization. With the state of the art and regulatory compliant manufacturing facilities Bharat Parenterals Limited is geared up to encash the business opportunities available.



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

#### **4. Risk and Concerns:**

Dynamic business environment of modern times throws several challenges from time to time. Threats include:

- Growing competition both from domestic and global players
- Preference of some customers towards MNC suppliers over Indian suppliers
- High dependence on imported raw material.
- Volatility in raw and packing material prices and fluctuations in Foreign Exchange
- Rising cost of utilities.
- Cyclic demand changes in some market sectors.

Your company focuses on continual expansion of its products and customer base, while systematically strengthening its quality, innovation and cost competence in order to mitigate the potential impact of some of the above threats.

#### **5. Segment-Wise Performance**

a) The Company is only in one line of business- Pharmaceuticals.

b) The Segment Revenue in the Geographical Segment considered for disclosures are as follow:

- Revenue in India includes sales to customers located within India -10886.38 (Rs. In lakhs)
- Revenue outside India includes sales to customers located outside India – 10863.75 (Rs. In lakhs)

#### **6. Outlook:**

The Company is focusing on its core business of manufacturing and marketing of formulations. Research and development has been put on fast track for cost competitiveness and to comply with the regulatory market. Cost rationalization and management control at all levels are practiced to ensure operational efficiency in the sphere of manufacturing and marketing. Armed with strong resources base and a vision to be a leading manufacturer of formulations, the company is poised to unleash its true potentials to meet the challenges and exploit growth opportunities ahead.

World economic overview:

In the global pharmaceuticals sector, India is a significant and rising player. India is the world's largest supplier of generic medications, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand. The Indian pharmaceutical sector is worth US\$ 42 billion worldwide. In August 2021, the Indian pharmaceutical market increased at 17.7% annually, up from 13.7% in July 2020. According to India Ratings & Research, the Indian pharmaceutical market revenue is expected to be over 12% Y-o-Y in FY22

#### **7. Internal Control System and their adequacy:**

The Company has in place adequate internal control mechanism to ensure proper and stringent compliance of all policies, procedures and statutes, applicable to the company, nationally as well internationally. The company undergoes periodical review and a report thereon is provided to the management for taking further actions.

#### **8. Human Resource:**

Your company knows and believes that the success in establishment of Bharat Parenterals Limited as an international player with core strengths of R&D and Quality has been achieved due to the hard work and commitment of the human resource. A happy organization is made by happy human resource and thus, the company ensures continuous development, work-life balance and high morale of its employees at all times. Recognizing that people are important part of the organization, a major exercise in development and training of employees is undertaken at all levels of the



## **BHARAT PARENTERALS LIMITED**

**ANNUAL REPORT 2023-24**

company. The industrial relations in all the units of the Company during the financial year 2022-23 were peaceful and harmonious. Experienced and motivated employees have been the backbone of the Company. There were 363 peoples employed in the Company as on 31.03.2023. Your Company puts special emphasis on team building and positive work culture. We train employees to understand and absorb the latest technological trends which in turn, prepare them to achieve higher efficiency levels in production, quality besides leading to higher customer satisfaction. There is a systematic identification of training needs. Training and development inputs are provided to all employees – in the areas of skill development and behavioral improvement so that individual development keeps pace with organizational development.

### **9. *Formulation and Developments:***

Company always considering Formulation and Development as crucial for sustain growth of the Company. Company always try to introduce newer and newer drugs delivery system for ensuring products available as regard to time and enhancing therapeutic value. To achieve this objective we have experienced and qualified pharmacists whose activity is to maintain and find out newer and newer delivery system as well as re-engineering innovative process. This will held the Company to maintain material consumption ration.

### **10. *Financial performance with respect to operational performance:***

A detailed financial overview is given in the Board's Report of the Company.

### **11. *Cautionary Statement:***

Certain statement made in this report, are forward looking statements and actual results may differ from such expectations or projections about the future, as several factors would make significant difference to the Company's operations such as economic conditions affecting demand and supply, government's regulations, level of competitions prevailing at the relevant time, etc. The Company assumes no responsibility publicly to amend, modify or revise any such statements on the basis of subsequent developments, information or events.

**FOR AND ON BEHALF OF DIRECTORS**

Date: 10/06/2024  
Place: Vadodara

Sd/-  
Mr. Bharat Desai  
Chairman



## **INDEPENDENT AUDITOR'S REPORT**

### **TO THE MEMBERS OF BHARAT PARENTERALS LIMITED Report on the Audit of the Standalone Financial Statements**

#### **Opinion**

We have audited the accompanying Standalone Financial Statements of Bharat Parenterals Limited ("the Company"), which comprise the Balance Sheet as at 31<sup>st</sup> March, 2024, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended and notes to the Standalone Financial Statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31<sup>st</sup> March, 2024, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the independence requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Standalone Financial Statements.

#### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

## **Information other than the Standalone Financial Statement and Auditor's Report thereon**

The Company's management and Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in Board's Report including Annexure to that Board's Report, Corporate Governance and Shareholder's Information, but does not include the Standalone Financial Statements and our auditor's report thereon.

Our opinion on the Standalone Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Standalone Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Standalone Financial Statements or our knowledge obtained in audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## **Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements**

The Company's management and the Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India, including the accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error;

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so;

The Board of Directors are also responsible for overseeing the company's financial reporting process.

## **Auditor's Responsibilities for the Audit of Standalone Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation;

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative

factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit;

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards;

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A", a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
  - (c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account;
  - (d) In our opinion, the aforesaid Standalone Financial Statements comply with the Accounting Standards specified under Section 133 of the Act;
  - (e) On the basis of the written representations received from the directors as on 31<sup>st</sup> March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2024 from being appointed as a director in terms of Section 164(2) of the Act;
  - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B";

(g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act; and

(h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements – Refer Note 38 to the Standalone Financial Statements;
- ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses;
- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
- iv.
  - i. The Management has represented that, to the best of its knowledge and belief that no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
  - ii. The Management has represented that, to the best of its knowledge and belief that no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
  - iii. Based on such audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material mis-statement.
- v. The final dividend paid by the company during the year in respect of the same declared for the previous year is in accordance with section 123 of the Companies Act 2013 to the extent it applies to payment of dividend.

As stated in note 56 to the financial statements, the Board of Directors of the Company have proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act, to the extent it applies to declaration of dividend.

- vi. Based on our examination, which includes test checks, the company has used accounting software for maintaining its books of accounts for the financial year ended 31st March, 2024 which has a feature of recording audit trails (edit log) facility and the same has been operated throughout the year for all the relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with.

**For CNK & Associates LLP**  
Chartered Accountants  
Firm Registration No. 101961W/W-100036

**Rachit Sheth**  
Partner  
Membership No. 158289  
Place: Vadodara  
Date: 22<sup>nd</sup> May 2024  
UDIN: 24158289BKAQIC4647

## **ANNEXURE “A” TO THE INDEPENDENT AUDITOR’S REPORT**

**Referred to in Para 1 ‘Report on Other Legal and Regulatory Requirements’ in our Independent Auditor’s Report to the members of the Company on the Standalone Financial Statements for the year ended 31<sup>st</sup>March,2024.**

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

- I. (a) In respect of the Company’s Property, Plant and Equipment’s and Intangible Assets:
    - (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;
    - (B) The Company has maintained proper records showing full particulars of Intangible Assets;
  - (b) The company has a phased programme of physical verification of its Property, Plant and Equipment so as to cover all assets once in three years. In accordance with this programme, certain Property, Plant and Equipment were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets;
  - (c) Based on our verification of the documents provided to us and according to the information and explanations given by the Management, the title deeds of all the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) as disclosed in the financial statements, are held in the name of the Company as at the Balance Sheet date;
  - (d) The company has not revalued any of its Property, Plant and Equipment (including Right of Use assets) and intangible assets during the year;
  - (e) No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder;
- II. (A) The inventory have been physically verified by the Management at reasonable intervals. Considering the size of the Company, the frequency of verification is reasonable and the procedures are adequate. No discrepancies have been noticed on such verification;
    - (B) Based on our examination of the records, the company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets and quarterly returns or statements filed by the company with such banks are in agreement with the books of account of the company;
- III. The Company has made investments in, companies, firms, Limited Liability Partnerships and granted unsecured loans to other parties, during the year, in respect of which:



- a) The Company has provided unsecured loan to two subsidiaries with aggregate amount granted/provided during the year is Rs. 2,205.56 lakhs during the year and where balance outstanding as at Balance Sheet date is Rs. 7590.68 lakhs.

Further company has provided Corporate Guarantee for its one of its subsidiary with aggregate amount granted/provided during the year Rs. 6,686.06 lakhs whose balance outstanding as at Balance Sheet date is Rs.6,686.06 lakhs.

- b) In our opinion, the investments made and the terms and conditions of the grant of loans, during the year are, prima facie, not prejudicial to the Company's interest;
- c) In our opinion, schedule of repayment of principal and payment of interest has been stipulated and receipts of principal and interest are as per the terms of agreement.
- d) In our opinion, there is no overdue amount of principal and interest for more than 90 days;
- e) In our opinion, there is no loan or advance in the nature of loan granted which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to the same parties;
- f) In our opinion, there company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment and accordingly reporting under this clause is not applicable.
- IV. The Company has complied with the provisions of sections 185 and 186 of the Companies Act 2013 in respect of loans granted, investment made, and guarantee and securities provided, as applicable;
- V. The Company has not accepted any deposits or amounts which are deemed to be deposits within the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed there under, therefore, the provisions of paragraph 3(v) of the Order are not applicable to the Company;
- VI. We have broadly reviewed the cost records maintained by the Company as prescribed by the Central Government under sub section (1) of Section 148 of the Companies Act and are of the opinion that prima facie the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete;
- VII. According to the information and explanations given to us, in respect of statutory dues:
- (a) In our opinion, the company is generally regular in depositing undisputed statutory dues including Goods and Service tax, provident fund, employee state insurance, income-tax, sales tax, service tax, duty of custom, duty of excise, value added tax, cess and other statutory dues as applicable to the appropriate authorities. There were no undisputed amounts payable with respect to above statutory dues in arrears as at March 31, 2024 for a period of six months from the date they became payable;
- (b) According to the information and explanations given to us and the records examined by us, the particulars of statutory dues as at March 31, 2024 which have not been deposited on account of a dispute, are as follows:

<b>Name of the statute</b>	<b>Nature of dues</b>	<b>Amounts (Rs. In lakhs)</b>	<b>Period to which the amounts relates</b>	<b>Forum where dispute is pending</b>
Income Tax Act, 1961	Income Tax	52.69	2014-15	CIT Appeal
Finance Act, 1994	Service Tax	9.70	April 2012 to March 2015	CESTAT, Ahmedabad

- VIII. There were no transactions which were not recorded in the books of account, have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961;
- IX. (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender;
- (b) The company is not declared as wilful defaulter by any bank or financial institution or other lender;
- (c) The company has applied the term loan for the purpose for which the loans were obtained;
- (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company;
- (e) The company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;
- (f) We report that the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies
- X. (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable;
- (b) The Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Therefore, the provisions of paragraph 3(x)(b) of the Order are not applicable;
- XI. (a) No fraud by the Company and no material fraud on the company has been noticed or reported during the year;
- (b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report;
- (c) As represented to us by the management, there are no whistle blower complaints received by the company during the year;

- XII. The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable;
- XIII. In our opinion, all the transactions with the related parties are in compliance with section 177 and 188 of the Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements as required by the applicable accounting standards;
- XIV. (a) In our opinion and the records examined by us, the company has an internal audit system commensurate with the size and nature of its business of the company;
- (b) We have considered report of the internal auditors for the period under audit;
- XV. According to the information and explanation given to us and based on our examination of the records, the Company has not entered into non-cash transactions with the directors or persons connected with them. Hence, the provisions of Section 192 of the Act are not applicable;
- XVI. (a) In our opinion, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi) (a), (b) and (c) of the order is not applicable;
- (b) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable
- XVII. The company has not incurred cash losses in the financial year and in the immediately preceding financial year;
- XVIII. There has been no resignation of the statutory auditors during the year;
- XIX. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due;
- XX. (a) The company is not required to transfer unspent amount to a fund specified in Schedule VII to the Companies Act for other than ongoing projects. Accordingly, reporting under clause 3(xx)(a) of the Order is not applicable for the year;

(b) The company has not spent amount towards Corporate Social Responsibility (CSR) on ongoing project. Accordingly, reporting under clause 3(xx)(b) of the Order is not applicable for the year.

For **CNK & Associates LLP**  
Chartered Accountants  
Firm Registration No. 101961W/W-100036

**Rachit Sheth**  
Partner  
Membership No.158289  
Place: Vadodara  
Date: 22<sup>nd</sup> May 2024  
UDIN: 24158289BKAQIC4647

## **ANNEXURE “B” TO THE INDEPENDENT AUDITOR’S REPORT**

### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **BHARAT PARENTERALS LIMITED** (“the Company”) as of 31<sup>st</sup> March, 2024 in conjunction with our audit of the Standalone Financial Statements of the Company for the year ended on that date.

#### **Management’s Responsibility for Internal Financial Controls**

The company’s management and Board of Directors of the company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls with reference to financial statements of the Company that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the “Guidance Note”) and the Standards on Auditing prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements of the company were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the internal financial controls with reference to financial statements of the company and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

## **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

## **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

## **Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an internal financial controls with reference to financial statements of the Company and such internal financial controls over financial reporting were operating effectively as at 31<sup>st</sup> March, 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **CNK & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036

**Rachit Sheth**

Partner

Membership No.158289

Place: Vadodara

Date: 22<sup>nd</sup> May 2024

UDIN: 24158289BKAQIC4647

**BHARAT PARENTERALS LIMITED**  
**CIN:L24231GJ1992PLC018237**  
**STANDALONE BALANCE SHEET AS AT 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

Sr. No.	Particulars	Note No	As at 31st March, 2024	As at 31st March, 2023
	<b>ASSETS</b>			
<b>(1)</b>	<b>Non current Assets</b>			
	(a) Property, Plant and Equipment	3	3,846.54	3,527.69
	(b) Investment Properties	4	89.46	98.52
	(c) <u>Financial Assets</u>			
	(i) Investment in subsidiaries	5	4,860.74	3,840.00
	(ii) Loans	6	7,590.68	5,385.13
	(iii) Other Financial assets	7	309.22	321.26
	(d) Deferred tax assets (net)	8	11.67	-
	(e) Other Non Current Assets	9	190.85	178.89
<b>(2)</b>	<b>Current assets</b>			
	(a) Inventories	10	5,443.16	3,784.22
	(b) <u>Financial Assets</u>			
	(i) Trade receivables	11	13,977.60	11,239.88
	(ii) Cash and cash equivalents	12	142.99	635.46
	(iii) Bank Balances other than Cash and cash equivalents	13	123.36	107.49
	(iv) Loans	14	10.73	6.57
	(v) Other financial assets	15	354.50	376.79
	(c) Other current assets	16	1,736.29	1,300.99
	(d) Current tax Assets		27.50	-
	<b>Total Assets</b>		<b>38,715.31</b>	<b>30,802.87</b>
	<b>EQUITY AND LIABILITIES</b>			
<b>(1)</b>	<b>Equity</b>			
	(a) Equity Share capital	17	581.97	577.47
	(b) Other Equity	18	20,779.00	18,528.79
	<b>Total equity attributable to equity holders of the Company</b>		<b>21,360.97</b>	<b>19,106.25</b>
<b>(2)</b>	<b>LIABILITIES</b>			
	<b>Non-Current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings	19	365.82	688.96
	(b) Provisions	20	210.29	132.66
	(c) Deferred tax liabilities (Net)	8	-	39.88
<b>(3)</b>	<b>Current liabilities</b>			
	(a) <u>Financial Liabilities</u>			
	(i) Borrowings	21	7,936.42	3,882.43
	(ii) Trade payables	22		
	a) total outstanding dues of Micro Enterprises and Small Enterprises		92.56	401.79
	b) total outstanding dues of creditors other than Micro Enterprises and Small Enterprises		5,225.31	4,390.53
	(iii) Other financial liabilities	23	1,479.24	1,000.77
	(b) Other current liabilities	24	1,899.60	998.46
	(c) Provisions	25	145.10	107.15
	(d) Current Tax Liability (Net)		-	54.00
	<b>Total Liabilities</b>		<b>17,354.34</b>	<b>11,696.62</b>
	<b>Total Equity and Liabilities</b>		<b>38,715.31</b>	<b>30,802.87</b>

The accompanying notes are an integral part of the financial statements.

As per our Report of even date

**For CN K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May, 2024

Place: Vadodara  
Date: 22nd May, 2024



**BHARAT PARENTERALS LIMITED**

CIN:L24231GJ1992PLC018237

**STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2024**

**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

Sr. No.	Particulars	Note No.	Year ended 31st March, 2024	Year ended 31st March, 2023
I	Revenue From Operations	26	25,415.74	21,798.15
II	Other Income	27	1,195.66	1,883.84
III	<b>Total Income (I+II)</b>		<b>26,611.40</b>	<b>23,681.98</b>
IV	<b>EXPENSES</b>			
	Cost of materials consumed	28	17,316.50	14,606.93
	Purchase of Stock-in-Trade	29	40.88	116.48
	Changes in Inventories of Finished goods, Stock-in-Trade and work-in-progress	30	(1,518.97)	(975.33)
	Employee benefits expense	31	1,961.12	1,693.32
	Finance costs	32	318.83	218.59
	Depreciation and amortization expense	3 & 4	639.80	584.80
	Other expenses	33	4,773.14	4,220.28
	<b>Total expenses (IV)</b>		<b>23,531.31</b>	<b>20,465.05</b>
V	<b>Profit/(loss) before tax (III-IV)</b>		<b>3,080.09</b>	<b>3,216.93</b>
VI	<b>Tax expense:</b>	34		
	(1) Current tax		868.89	840.32
	(2) Deferred tax		(44.87)	(57.08)
	(3) Short / (Excess) provision of tax in respect of earlier years		(3.29)	-
VII	<b>Profit (Loss) for the period (V-VI)</b>		<b>2,259.36</b>	<b>2,433.69</b>
VIII	<b>Other Comprehensive Income</b>			
	(i) Items that will not be reclassified to profit or loss			
	- Remeasurement of Defined benefit plans		(26.54)	5.75
	- Income tax relating to Remeasurement of Defined benefit plans		6.68	(1.45)
	<b>Total other comprehensive income (VIII)</b>		<b>(19.86)</b>	<b>4.30</b>
IX	<b>Total comprehensive income for the period (VII+VIII)</b>		<b>2,239.51</b>	<b>2,438.00</b>
X	<b>Earnings per equity share:</b>	35		
	(1) Basic		38.81	42.14
	(2) Diluted		38.81	42.14

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

**For C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhattbhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May, 2024

Place: Vadodara  
Date: 22nd May, 2024

**BHARAT PARENTERALS LIMITED**  
**CIN:L24231GJ1992PLC018237**  
**STANDALONE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

	Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
<b>A</b>	<b>Cash flow from operating activities :</b>		
	Profit before income tax	3,080.09	3,216.93
	<b>Adjustments for :</b>		
	Depreciation and amortisation expense	639.80	584.80
	(Gain)/Loss on Sales of Property, Plant and Equipments (Net)	4.44	(563.02)
	Fair valuation of Investments through FVTPL	-	20.50
	Amount no longer payable written back	12.11	-
	(Gain)/Loss on Sales of Investment (Net)	-	(53.15)
	Share Based Payment	13.96	53.09
	Finance Cost	318.83	218.59
	Unrealised Foreign exchange fluctuation	(84.37)	11.21
	Interest Income	(417.22)	(182.73)
	<b>Operating profit before working capital changes</b>	<b>3,567.65</b>	<b>3,306.23</b>
	<b>Movements in working capital:</b>		
	<b>Assets</b>		
	(Increase) / Decrease in trade receivables	(2,640.30)	(3,914.98)
	(Increase) / Decrease in inventories	(1,658.95)	(1,708.18)
	(Increase) / Decrease in other financial assets	36.35	2,028.26
	(Increase) / Decrease in Loans	(2,209.72)	(3,161.27)
	(Increase) / Decrease in other current assets	(435.30)	(429.31)
	(Increase) / Decrease in other non current assets	(11.96)	58.61
	<b>Liabilities</b>		
	Increase / (Decrease) in trade payables	519.45	2,541.70
	Increase / (Decrease) in provisions	115.57	45.15
	Increase / (Decrease) in other current liabilities	901.15	574.90
	Increase / (Decrease) in other financial liabilities	474.65	381.21
	<b>Cash generated from operations :</b>	<b>(1,341.41)</b>	<b>(277.66)</b>
	Direct taxes paid (net)	950.39	878.36
	<b>Net cash from operating activities (A)</b>	<b>(2,291.80)</b>	<b>(1,156.04)</b>
<b>B</b>	<b>Cash flows from investing activities :</b>		
	Purchase of Property, plant and equipments (Including Capital work in progress Including capital Advance)	(1,036.08)	(506.50)
	Proceeds of sale of Property, plant and equipments	70.09	989.69
	Purchase of investments in subsidiaries	(1,020.74)	(2,177.25)
	(Increase) / Decrease Bank Balances other than Cash and cash equivalents	(15.88)	20.62
	Interest Received	392.90	278.58
	<b>Net cash (used) in Investing activities (B)</b>	<b>(1,609.70)</b>	<b>(1,394.86)</b>
<b>C</b>	<b>Cash flow from financing activities :</b>		
	Proceeds from issue of shares	44.55	-
	Dividend Paid	(39.47)	-
	Proceeds/(Repayment) of long term Borrowings	(323.15)	(253.32)
	Proceeds/(Repayment) of short term Borrowings	4,054.00	3,324.27
	Finance Cost	(318.83)	(218.59)
	<b>Net cash (used) in financing activities (C)</b>	<b>3,417.10</b>	<b>2,852.36</b>
	<b>NET INCREASE IN CASH AND CASH EQUIVALENTS [(A) + (B) + (C)]</b>	<b>(484.41)</b>	<b>301.46</b>
	<b>CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR</b>	<b>634.34</b>	<b>332.88</b>
	<b>Balances with banks</b>		
	(a) In current accounts	140.61	567.23
	(b) In Cash Credit Account	-	65.76
		<b>140.61</b>	<b>632.99</b>
	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	6.95	(1.12)
		<b>147.56</b>	<b>631.87</b>
	Cash on Hand	2.38	2.47
	<b>CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR</b>	<b>149.94</b>	<b>634.34</b>

**NOTES:**

- (i) The above cash flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standards - 7, "Statement of Cash Flow".  
(ii) Figures in bracket indicate Cash Outflow.

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

For **C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May, 2024

Place: Vadodara  
Date: 22nd May, 2024

**BHARAT PARENTERALS LIMITED**  
**STANDALONE STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31st MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**a. Equity Share Capital:**

Particular	As at 31st March, 2024		As at 31st March, 2023	
	Nos.	Rs. In Lakhs	Nos.	Rs. In Lakhs
<b>Balance at the 01st April, 2023</b>	5,774,666	577.47	5,774,666	577.47
Changes in Equity Share Capital due to prior period errors	-	-	-	-
<b>Restated balance at the 01st April, 2023</b>	-	-	-	-
Changes in equity share capital during the current year	45,000	4.50	-	-
<b>Balance at the 31st March, 2024</b>	<b>5,819,666</b>	<b>581.97</b>	<b>5,774,666</b>	<b>577.47</b>

**b. Other Equity:**

**(1) Current reporting period**

Particular	Reserves and Surplus				Total
	General Reserve	Security Premium reserve	Employee Stock Option Reserve	Retained Earnings	
<b>Balance at the 01st April, 2023</b>	3.99	152.37	53.09	18,319.33	<b>18,528.78</b>
Changes in accounting policy or prior period errors	-	-	-	-	-
<b>Restated balance at the 01st April, 2023</b>	-	-	-	-	-
Total Comprehensive Income for the current year	-	-	-	2,259.36	<b>2,259.36</b>
Addition during the year	-	-	59.28	-	<b>59.28</b>
Transfer during the year	-	107.10	(112.37)	(43.31)	<b>(48.58)</b>
Remeasurement of the Net Defined benefit liability/asset, net of tax effect	-	-	-	(19.86)	<b>(19.86)</b>
<b>Balance at the 31st March, 2024</b>	<b>3.99</b>	<b>259.47</b>	<b>0.00</b>	<b>20,515.53</b>	<b>20,779.00</b>

**(2) Previous reporting period**

Particular	Reserves and Surplus				Total
	General Reserve	Security Premium reserve	Employee Stock Option Reserve	Retained Earnings	
<b>Balance at the 01st April, 2022</b>	3.99	152.37	-	15,881.33	<b>16,037.70</b>
Changes in accounting policy or prior period errors	-	-	-	-	-
<b>Restated balance at the 01st April, 2022</b>	-	-	-	-	-
Total Comprehensive Income for the current year	-	-	-	2,433.69	<b>2,433.69</b>
Addition during the year	-	-	53.09	-	<b>53.09</b>
Transfer during the year	-	-	-	-	-
Remeasurement of the Net Defined benefit liability/asset, net of tax effect	-	-	-	4.30	<b>4.30</b>
<b>Balance at the 31st March, 2023</b>	<b>3.99</b>	<b>152.37</b>	<b>53.09</b>	<b>18,319.33</b>	<b>18,528.79</b>

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**For C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhattbhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May, 2024

Place: Vadodara  
Date: 22nd May, 2024

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**3 Property, Plant and Equipment**

Particulars	Land - Freehold	Windmill	Electrical Installation	Factory Building	Building - Others	Plant and Equipment	Furniture and Fixtures	Vehicles	Computers	Capital work-in-progress	Total
<b>Gross carrying amount As at 31st March, 2023</b>	34.08	234.63	331.57	1,120.20	496.33	4,039.28	550.14	504.90	100.66	-	7,411.78
Additions	-	-	-	139.27	-	811.02	58.81	-	15.03	-	1,024.13
Disposals	-	81.06	-	-	-	107.70	-	56.66	-	-	245.43
<b>Gross carrying amount As at 31st March, 2024</b>	34.08	153.57	331.57	1,259.47	496.33	4,742.59	608.94	448.24	115.69	-	8,190.48
<b>Accumulated depreciation as at 31st March, 2023</b>	-	136.68	217.60	309.06	237.71	2,197.61	345.82	354.97	84.64	-	3,884.09
Charge for the year	-	9.42	29.53	84.26	16.81	381.58	54.19	42.96	12.00	-	630.74
Disposals	-	29.95	-	-	-	100.67	-	40.28	-	-	170.90
<b>Accumulated depreciation as at 31st March, 2024</b>	-	116.15	247.13	393.32	254.52	2,478.53	400.01	357.65	96.63	-	4,343.93
<b>Net carrying amount:</b>											
As at 31st March, 2024	34.08	37.42	84.44	866.15	241.81	2,264.07	208.93	90.59	19.06	-	3,846.54
As at 31st March, 2023	34.08	97.95	113.97	811.14	258.62	1,841.66	204.31	149.93	16.03	-	3,527.69

Particulars	Land - Freehold	Windmill	Electrical Installation	Factory Building	Building - Others	Plant and Equipment	Furniture and Fixtures	Vehicles	Computers	Capital work-in-progress	Total
<b>Gross carrying amount As at 31st March, 2022</b>	415.34	234.63	327.80	970.98	496.33	3,796.16	510.47	457.61	88.33	62.10	7,359.75
Additions	-	-	7.08	149.22	-	298.28	39.67	47.29	12.33	-	553.86
Disposals	(381.26)	-	(3.30)	-	-	(55.16)	-	-	-	(62.10)	(501.83)
<b>Gross carrying amount As at 31st March, 2023</b>	34.08	234.63	331.57	1,120.20	496.33	4,039.28	550.14	504.90	100.66	-	7,411.78
<b>Accumulated depreciation as at 31st March, 2022</b>	-	124.05	188.66	240.04	211.84	1,876.60	303.30	303.41	74.32	-	3,322.21
Charge for the year	-	12.63	32.12	69.02	25.87	330.90	42.52	51.56	10.31	-	574.94
Disposals	-	-	(3.18)	-	-	(9.88)	-	-	-	-	(13.06)
<b>Accumulated depreciation as at 31st March, 2023</b>	-	136.68	217.60	309.06	237.71	2,197.61	345.82	354.97	84.64	-	3,884.09
<b>Net carrying amount:</b>											
As at 31st March, 2023	34.08	97.95	113.97	811.14	258.62	1,841.66	204.31	149.93	16.03	-	3,527.69
As at 31st March, 2022	415.34	110.59	139.14	730.94	284.49	1,919.56	207.17	154.20	14.01	62.10	4,037.54

**Notes:**

- Assets pledged as security :  
The free hold Land and Buildings , all movable Plant and Machineries and other assets are pledged as security on pari passu basis to the bankers under a mortgage. The Company is not allowed to sell these assets to other entity.

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**4 Investment Properties**

<b>Particulars</b>	<b>As at 31st March, 2024</b>	<b>As at 31st March, 2023</b>
<b>INVESTMENT PROPERTY (at cost less accumulated depreciation)</b>		
<b>Building given on Operating Lease</b>		
Opening Gross Block	149.93	149.93
Additions	-	-
Closing Gross Block	<b>149.93</b>	<b>149.93</b>
<b>Less :</b>		
Opening Accumulated Depreciation	51.41	41.55
Add : Depreciation for the year	9.06	9.86
Closing Accumulated Depreciation	<b>60.47</b>	<b>51.41</b>
<b>Total</b>	<b>89.46</b>	<b>98.52</b>

Note : Refer note (46) for other disclosure.

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**5 Investments**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Investment valued at Cost</b>		
<b>a) Investment in subsidiary (Cost)</b>		
Investment in Shares of Innoxel Lifesciences Private Limited (CY 4,59,07,407 & PY 3,56,99,998 Nos. Equity Shares)	4,590.74	3,570.00
Investment in Shares of Varenyam Biolifesciences Private Limited (CY 27,00,000 & PY 27,00,000 Nos. Equity Shares)	270.00	270.00
<b>Total</b>	<b>4,860.74</b>	<b>3,840.00</b>
<b>Aggregate amount of quoted investments</b>		

During the year company has acquired additional 1,02,07,409 Nos. of equity shares in Innoxel Lifesciences Private Limited ("ILPL").

**6 Loans**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Unsecured, considered good</b>		
- Loans and Advances to Subsidiaries (Refer note no. 43)	7,590.68	5,385.13
<b>Total</b>	<b>7,590.68</b>	<b>5,385.13</b>

**7 Other Financial Assets**

Particulars	As at 31st March, 2024	As at 31st March, 2023
(i) Bank deposits with more than 12 months of original maturity	242.31	254.35
(ii) Deposits	66.91	66.91
<b>Total</b>	<b>309.22</b>	<b>321.26</b>

**8 Deferred tax assets (net)**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Deferred Tax Assets</b>		
<b>The balance comprises temporary differences attributable to:</b>		
Provision For Employee Benefit	92.76	56.99
Remeasurements of the defined benefit plans	-	3.36
Others	52.45	42.38
<b>Total DTA</b>	<b>145.21</b>	<b>102.74</b>
<b>Deferred Tax Liability</b>		
<b>The balance comprises temporary differences attributable to:</b>		
Property, Plant & Equipment's	130.22	142.61
Remeasurements of the defined benefit plans	3.31	-
<b>Total DTL</b>	<b>133.54</b>	<b>142.61</b>
<b>Net Deferred Tax (Asset)/Liability</b>	<b>(11.67)</b>	<b>39.88</b>

**9 Other Non - Current Assets**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Unsecured, considered good</b>		
(a) Capital Advances	91.09	79.13
(b) Balance with Government Authorities	99.76	99.76
<b>Total</b>	<b>190.85</b>	<b>178.89</b>

BHARAT PARENTERALS LIMITED  
NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024  
ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED

10 Inventories

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Inventories (lower of cost and net realised value)</b>		
Raw Materials	2,107.23	2,225.20
Raw Material (F&D)	34.34	34.78
Work-in-Progress	436.90	422.44
Finished goods	2,488.86	984.36
Goods in Transit (Raw materials)	375.83	117.44
<b>Total</b>	<b>5,443.16</b>	<b>3,784.22</b>

11 Trade Receivables

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Trade Receivables considered Good-Secured</b>		
<b>Trade Receivables considered Good-Unsecured</b>		
- Receivable from Related Parties (Refer Note 37(d))	1,292.42	1,138.46
- Others	12,855.50	10,247.46
	<b>14,147.92</b>	<b>11,385.92</b>
<b>Trade Receivable which have significant increase in credit risk</b>	38.04	22.33
<b>Trade Receivables credit impaired</b>	-	-
<b>Total</b>	<b>14,185.96</b>	<b>11,408.25</b>
Less : Expected Credit Loss Allowance	(208.37)	(168.37)
<b>Total</b>	<b>13,977.60</b>	<b>11,239.88</b>

Note: Refer Note 47 for Aging of Trade Receivable.

12 Cash and cash equivalents

Particulars	As at 31st March, 2024	As at 31st March, 2023
Balances with banks		
(a) In current accounts	140.61	567.23
(b) In cash credit accounts (Refer note 21 (i))	-	65.76
Cash on Hand	2.38	2.47
<b>Total</b>	<b>142.99</b>	<b>635.46</b>

13 Bank Balances

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Other Bank Balances</b>		
(a) Term deposits with original maturity for more than 3 months but less than 12 months	1.64	1.64
(b) Balances held as Margin Money	117.88	105.85
(c) In earmarked accounts		
- Balances held in unpaid dividend accounts	3.84	-
<b>Total</b>	<b>123.36</b>	<b>107.49</b>

14 Loans

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Loans to Employees	10.73	6.57
<b>Total</b>	<b>10.73</b>	<b>6.57</b>

15 Other Financial Assets

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Interest accrued on deposits	98.33	74.01
(b) Security and other deposits	255.67	302.28
(c) Term deposits	0.50	0.50
<b>Total</b>	<b>354.50</b>	<b>376.79</b>

16 Other Current Assets

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Advance to Suppliers	279.78	324.05
(b) Advance to employees	0.06	0.12
(c) Expenses paid in advance	146.20	127.04
(d) Balances with government authorities	1,310.25	849.78
<b>Total</b>	<b>1,736.28</b>	<b>1,300.99</b>

17 Share Capital

Authorised Equity Share Capital

Particulars	As at	As at
	31st March, 2024	31st March, 2023
<b>a) Authorised</b> 63,00,000 - Equity shares of Rs. 10/- each	630.00	630.00
	<b>630.00</b>	<b>630.00</b>
<b>b) Shares issued, subscribed and fully paid</b> C.Y. 58,19,666 (P.Y. 57,74,666) - Equity shares of Rs. 10/- each	581.97	577.47
	<b>581.97</b>	<b>577.47</b>
<b>c) Shares fully paid</b> C.Y. 58,19,666 (P.Y. 57,74,666) - Equity shares of Rs. 10/- each	581.97	577.47
	<b>581.97</b>	<b>577.47</b>

d) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period.

Particulars	As at 31st March, 2024		As at 31st March, 2023	
	Numbers	Rs. in Lakhs	Numbers	Rs. in Lakhs
At the beginning of the period	5,774,666	577.47	5,774,666	577.47
Add / (Less) : Changes during the year (refer note No. 53)	45,000	4.50	-	-
At the end of the period	<b>5,819,666</b>	<b>581.97</b>	<b>5,774,666</b>	<b>577.47</b>

e) Terms & Rights attached to each class of shares;

The Company has only one class of equity shares having par value of Rs. 10 per share. Each holder of equity shares is entitled to one vote per share. In the event of the liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company. The distribution will be in proportion to the number of equity shares held by the shareholders.

f) Shares reserved for issue under options

Pursuant to approved employee stock option scheme "Bharat Parenterals Employee Stock Option Plan 2020", the Company has granted 2,00,000 nos of employees stock options of which 45,000 (31 March 2023: NIL) of the options have been exercised (also refer note 53).

g) Shareholding of promoters;

Promoter Name	As at 31st March, 2024			As at 31st March, 2023		
	No of shares	% of total shares	% change during the year	No of shares	% of total shares	% change during the year
Bharat R. Desai	741,515	12.74%	-0.10%	741,515	12.84%	0.00%
Hima B. Desai	783,430	13.46%	-0.10%	783,430	13.57%	0.00%
Pooja P. Shah	500	0.01%	0.00%	500	0.01%	0.00%
Shailesh G. Desai	2,600	0.04%	0.00%	2,500	0.04%	0.00%
Bhahim B. Desai	1,699	0.03%	-0.01%	2,500	0.04%	0.00%
Lataben S. Parikh	2,000	0.03%	0.00%	2,000	0.03%	0.00%
Desai shares and stock Private Limited	2,731,536	46.94%	-0.37%	2,731,536	47.30%	0.00%

h) Shares held by shareholders each holding more than 5% of the shares

Shareholders	As at 31st March, 2024		As at 31st March, 2023	
	No. of shares	Percentage	No. of shares	Percentage
<b>Equity shares with voting rights</b>				
Bharat R. Desai	741,515	12.74%	741,515	12.84%
Hima B. Desai	783,430	13.46%	783,430	13.57%
Desai shares and stock Private Limited	2,731,536	46.94%	2,731,536	47.30%
Asoj Soft Caps Private Limited (Anchor)	340,130	5.84%	340,130	5.89%
<b>Total</b>	<b>4,596,611</b>	<b>78.98%</b>	<b>4,596,611</b>	<b>79.60%</b>

18 Other Equity

Particulars	As at	As at
	31st March, 2024	31st March, 2023
General Reserve	3.99	3.99
Employee Stock Option Reserve	0.00	53.09
Security Premium reserve	259.47	152.37
Retained Earnings	20,515.53	18,319.33
<b>Total</b>	<b>20,779.00</b>	<b>18,528.79</b>

Particulars	As at	As at
	31st March, 2024	31st March, 2023
<b>General Reserve</b>		
As per last Balance Sheet	3.99	3.99
	<b>3.99</b>	<b>3.99</b>
<b>Employee Stock Option Reserve</b>		
Balance as per the last financial statements	53.09	-
Add: Reserve Created during the year	59.28	53.09
Less: Reserve Utilised during the year	112.37	-
<b>Total</b>	<b>0.00</b>	<b>53.09</b>
<b>Security Premium reserve</b>		
Balance as per the last financial statements	152.37	152.37
Add: Increased during the year	107.10	-
<b>Total</b>	<b>259.47</b>	<b>152.37</b>
<b>Retained Earnings</b>		
Balance as per the last financial statements	18,319.33	15,881.34
Add: Profit for the year as per Statement of Profit and Loss	2,259.36	2,433.69
Less: Equity Dividend	(43.31)	-
<b>Items of Other Comprehensive Income</b>		
Remeasurement of the Net Defined benefit liability/asset, net of tax effect	(19.86)	4.30
<b>Total</b>	<b>20,515.53</b>	<b>18,319.33</b>

18.1 The General Reserve is used from time to time to transfer profits from retained earnings for appropriation purposes. As the General Reserve is created by a transfer from one component of equity to another and is not an item of other comprehensive income, items included in the general reserve is not reclassified subsequently to the Statement of Profit and Loss.

18.2 Employee Stock Option Reserve is used to recognise the fair value of equity settled share based payment transactions.

18.3 Security premium reserve is used to record the premium on issue of equity share under ESOP scheme. The reserve is utilised in accordance with the provision of the Companies Act, 2013.



**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**19 Borrowings**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Secured - at amortized cost</b>		
(a) Term Loans		
- from Banks (Refer below note (i) and (ii))	339.17	685.83
-Vehicle Loans (Refer below note (iii))	26.65	3.12
<b>Total</b>	<b>365.82</b>	<b>688.96</b>

(i) The above Term loans are secured by first charge by way of hypothecation of all the movable machinery financed or to be financed under the said term loans by the respective banks. The above Term Loan also includes hypothecation of entire Plant & Machinery (excluding Plant & Machinery covered under Primary Security) of the Company Situated at Survey No. 144 & 146, Jarod Samlaya Road, Haripura Village, Savli, Vadodara (Both Present & Future).

Interest rate on term loan is 1 Y MCLR (Presently 1 Y MCLR is 8.60%) + 0.60% p.a. i.e. 9.20% p.a. The Loan is repayable in 60 Equated monthly installment of Rs. 18.75 lakhs.

Interest rate on ECLGS loan is Repo + 2.4% presently 8.9% p.a. The Loan is repayable in 36 Equated monthly installment after the end of 24 months of moratorium.

**(ii) Maturity profile of Secured Term loans are set out below:**

Particulars	Amount
0-1 year	351.98
1-2 years	263.26
2-3 years	102.56

(iii) The above Vehicle Loans are secured by way of Hypothecation of respective Vehicles.

**20 Provisions**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>a) Provision for employee benefits</b>		
Provision for Compensated absences	91.68	70.55
Provision for Gratuity (Refer Note 36)	118.60	62.10
<b>Total</b>	<b>210.29</b>	<b>132.66</b>

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**21 Borrowings**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Secured</b>		
a) Current Maturities On Long Term Debt (Refer note 19 (i) & (ii))	351.98	280.26
b) Loans repayable on demand (Refer below note) - Working capital loan and Packing Credit	7,584.44	3,602.17
<b>Total</b>	<b>7,936.42</b>	<b>3,882.43</b>

Note: (i) The above loan exclusively hypothecated against the entire current asset and entire movable fixed assets including plant and machinery (Present & Future) of the company, Further, the above loan is guaranteed by Mr. Bharat Desai & Mr. Hima Desai. Rate of interest on the above cash credit facility ranges from 8% to 8.74 % P.a.

Note: (ii) The company has borrowings from banks secured against the current asset and quarterly returns filled for the same with the banks are in agreement with the books of accounts of the company.

**22 Trade Payables**

Particulars	As at 31st March, 2024	As at 31st March, 2023
Total outstanding due to Micro and Small Enterprises (Refer Note 40)	92.56	401.79
Total outstanding due to other than Micro and Small Enterprises	5,225.31	4,390.53
<b>Total</b>	<b>5,317.87</b>	<b>4,792.32</b>

Note: Refer Note 48 for Aging of Trade Payable.

**BHARAT PARENTERALS LIMITED**

NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024

ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED

**23 Other Financial Liabilities**

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Security Deposits	20.08	21.50
(b) Other payable*	1,455.32	979.27
(c) Unpaid Dividend	3.84	-
<b>Total</b>	<b>1,479.24</b>	<b>1,000.77</b>

\*Include Commission payable pertains to Sales.

**24 Other Current Liabilities**

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Advances from Customers	1,431.77	746.13
(b) Statutory Dues	48.06	39.00
(c) Salary and Wages Payable	126.05	114.01
(d) Other payable	293.73	99.31
<b>Total</b>	<b>1,899.60</b>	<b>998.46</b>

**25 Provisions**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Provision for employee benefits</b>		
(a) Provision for compensated absences	4.65	2.66
(b) Provision for Gratuity (Refer Note 36)	16.51	7.08
(c) Provision for Bonus	123.93	97.41
<b>Total</b>	<b>145.10</b>	<b>107.15</b>

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**26 Revenue from Operations**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Sale of Products	25,375.62	21,750.13
Other Operating Revenue	40.12	48.02
<b>Total</b>	<b>25,415.74</b>	<b>21,798.15</b>

**26.1 Sales including GST**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Gross sales of Product (including GST)	28,283.51	25,224.68
Less:- Goods & Service Tax	2,907.89	3,474.55
<b>Net Sales of product</b>	<b>25,375.62</b>	<b>21,750.13</b>

**26.2 Sale of Products comprises of :**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Domestic Sales	7,707.85	8,148.19
Export Sales	15,742.92	10,863.75
Deemed Export	1,924.86	2,738.19
<b>Total</b>	<b>25,375.62</b>	<b>21,750.13</b>

**26.3 Other operating revenue comprises of :**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Sale of Scrap	31.40	41.88
Services Income - Job work	8.72	6.14
<b>Total</b>	<b>40.12</b>	<b>48.02</b>

**27 Other Income**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Interest Income	417.22	182.73
Fair Value change of investment held for trading	-	(20.50)
Gain / (Loss) on sale of investments (Net)	-	53.15
Export Incentives	204.82	132.21
Gain/(loss) on sale of Property, Plant and Equipments (Net)	-	563.02
Net gain on foreign currency transactions/translations	298.93	469.85
Bad Debts Recovered	66.00	18.00
Amount no longer payable written back	12.11	-
Recovery of freight and other charges	123.89	433.71
Non operating income	72.69	51.67
<b>Total</b>	<b>1,195.66</b>	<b>1,883.84</b>

**28 Cost of Raw Material and Components**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Cost of Raw Material Consumed	17,316.50	14,606.93
<b>Total</b>	<b>17,316.50</b>	<b>14,606.93</b>

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**29 Purchase of Traded goods**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Purchase of Traded goods	40.88	116.48
<b>Total</b>	<b>40.88</b>	<b>116.48</b>

**30 Changes in inventories of finished goods, work-in-progress and stock-in-trade**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Inventories at the end of the year:		
Finished Goods	2,488.86	984.36
Work-in-Progress	436.90	422.44
	<b>2,925.77</b>	<b>1,406.80</b>
Inventories at the beginning of the year:		
Finished Goods	984.36	249.94
Work-in-Progress	422.44	181.53
	<b>1,406.80</b>	<b>431.47</b>
<b>Net (increase) / decrease</b>	<b>(1,518.97)</b>	<b>(975.33)</b>

**31 Employee benefits expense**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Salaries, Wages and Bonus	1,786.95	1,522.78
Share Based Payment (Refer note 53)	13.96	53.09
Contributions to Provident Fund and Other Funds	145.18	105.50
Staff Welfare Expenses	15.03	11.95
<b>Total</b>	<b>1,961.12</b>	<b>1,693.32</b>

**32 Finance costs**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Interest expense on borrowings	313.85	213.77
Interest due to MSME Vendors	4.99	4.82
<b>Total</b>	<b>318.83</b>	<b>218.59</b>

**BHARAT PARENTERALS LIMITED**

**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**

**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**33 Other Expenses**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Power and Fuel	423.59	372.72
Consumption of Stores and spares	275.24	282.15
Manufacturing Processing cost	633.99	527.48
Carting, Freight, Octroi Inwards	8.57	12.51
<b>Repairs &amp; Maintenance</b>		
-Machinery	105.64	78.24
-Building	86.90	89.88
-Others	18.28	16.17
Sales promotion and advertisement Expenses	143.04	74.77
Legal and Professional Fees	225.20	236.66
Freight / Clearing and Forwarding Charges on Sales	729.62	740.47
Payments to Auditors (Refer note 41)	4.95	3.96
Corporate Social Responsibility Expenses (Refer Note 42)	56.75	65.59
Travelling Expense	81.40	126.34
Research and development expenses	103.32	104.91
Commission on sales	868.26	816.74
Provision for Expected Credit Loss	40.00	42.25
Bank charges	74.31	37.99
Bad debts	85.20	-
Loss on discard of Property, Plant & equipments (Net)	4.44	-
Rates and Taxes	54.76	1.72
Donation	0.69	0.67
Insurance Expense	226.23	240.41
Deduction and Damages Expenses	163.01	7.52
Miscellaneous Expenses	359.77	341.14
<b>Total</b>	<b>4,773.14</b>	<b>4,220.28</b>

**BHARAT PARENTERALS LIMITED**
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**
**34 TAX EXPENSE**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>(a) Income tax expense</b>		
<i>Current tax</i>	868.89	840.32
Short/ (Excess) provision of earlier year	(3.29)	-
(i) <i>Total Current tax expenses</i>	865.60	840.32
(ii) <i>Total Deferred tax expenses (Benefits)</i>	(44.87)	(57.08)
	(44.87)	(57.08)
Total Income tax expenses (i + ii)	820.72	783.24
<b>(b) Reconciliation of tax expense and the accounting profit multiplied by India's tax rate</b>		
Profit before income tax expense	3,080.09	3,216.93
<b>Tax at the Indian tax rate of 25.17% (2022-2023 - 25.17%)</b>	775.20	809.64
Tax effect of amounts which are not deductible / (taxable) in calculating taxable income:		
Depreciation	32.50	28.74
Income considered separately	-	114.63
Non-deductible tax expenses (Disallowances u/s 43B etc)	31.78	9.92
deductible tax expenses (allowances u/s 35)	-	(1.95)
Short/(Excess) provision of earlier year	(3.29)	-
Others (including Deferred tax)	(15.46)	(177.73)
<b>Income Tax Expense</b>	<b>820.72</b>	<b>783.24</b>

**BHARAT PARENTERALS LIMITED****NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024****ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED****35 Earnings per share (EPS)**

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the Company by the weighted average number of Equity shares outstanding during the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of Equity shares outstanding during the year.

**i. Profit attributable to Equity holders of Company**

<b>Particulars</b>	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Profit attributable to equity holders of the Company for basic and diluted earnings per share	2,259.36	2,433.69

**ii. Weighted average number of ordinary shares**

<b>Particulars</b>	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Issued ordinary shares(in Nos)	5,819,666	5,774,666
Weighted average number of shares at March 31 for basic and diluted earnings per shares	5,821,633	5,774,666
<b>Basic earnings per share</b>	<b>38.81</b>	<b>42.14</b>



**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**36 Disclosure as required under Ind AS 19 - Employee Benefits**

**[A] Defined contribution plans:**

The Company makes contributions towards provident fund to defined contribution retirement benefit plan for qualifying employees. The provident fund contributions are made to Government administered Employees Provident Fund. Both the employees and the Company make monthly contributions to the Provident Fund Plan equal to a specified percentage of the covered employee's salary.

The company recognised Rs. 82.03 lakhs (P.Y : Rs. 75.21 lakhs ) for provident fund contributions in the Statement of Profit and Loss.

**[B] Defined benefit plan:**

The Company makes contributions to Gratuity Fund managed by ICICI Prudential life insurance, a funded defined benefit plan for qualifying employees. The scheme provides for payment to vested employees as under:

- i) On normal retirement / early retirement / withdrawal / resignation: As per the provisions of Payment of Gratuity Act, 1972 with vesting period of 5 years of service.
- ii) On death in service: As per the provisions of Payment of Gratuity Act, 1972 without any vesting period.

The following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at 31st March, 2023.

**Defined benefit plans- As per actuarial valuation**

<b>a) Reconciliation in present value of obligations (PVO) - Defined Benefit Obligation:</b>	<b>Gratuity Funded</b>	
	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Present value of Benefit Obligations at the beginning of the period	215.63	204.27
Current Service Cost	34.31	26.22
Interest Cost	15.31	15.12
Benefits paid	(4.71)	(16.94)
Actuarial (Gains) / Losses due to change in assumptions	39.75	(13.04)
<b>Present value of Benefit Obligations at the end of the period</b>	<b>300.29</b>	<b>215.63</b>

<b>b) Change in fair value of plan assets:</b>	<b>Gratuity Funded</b>	
	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Fair value of Plan assets at the beginning of the year	146.45	159.50
Expected Return on plan assets	10.23	11.18
Benefits paid	(4.71)	(16.94)
Actuarial Gains and (Losses)	13.21	(7.29)
<b>Fair value of Plan assets at the end of the year</b>	<b>165.19</b>	<b>146.45</b>

<b>c) Reconciliation of PVO and fair value of plan assets:</b>	<b>Gratuity Funded</b>	
	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Present value of Benefit Obligations at the end of the period	300.29	215.63
Fair value of Plan assets at the end of the year	165.19	146.45
<b>Net (Asset) / Liability recognised in Balance sheet</b>	<b>135.11</b>	<b>69.18</b>

<b>d) Net Expenses recognised in the statement of Profit and Loss accounts</b>	<b>Gratuity Funded</b>	
	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Net Interest Cost	5.08	3.94
Current Service Cost	34.31	26.22
<b>Total</b>	<b>39.39</b>	<b>30.16</b>

<b>e) Amount recognised in Other comprehensive income Remeasurements:</b>	<b>Gratuity Funded</b>	
	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Actuarial (Gains) / Losses	26.54	(5.75)

<b>f) Assumptions used in the accounting for the gratuity plan:</b>	<b>Gratuity Funded</b>	
	<b>31st March, 2024</b>	<b>31st March, 2023</b>
Discount Rate (%)	7.10%	7.40%
Salary escalation rate (%)	7.00%	7.00%
Mortality* :		
* Indian Assured Lives Mortality (2012-14) Ult.		

37 Related Party Disclosures

a) Name of the related party and nature of relationship: -

Sr No	Particulars	Relationship
<b>I</b>	<b>Subsidiary:</b> Innoxel Lifesciences Private Limited Varenyam Biolifesciences Private Limited	Subsidiary Company Subsidiary Company
<b>II</b>	<b>Key Managerial Personnel / Directors:</b> Mr. Bharat Desai Mr. Hemang J. Shah Mr. Shaileshkumar Ghabhawala Mrs. Zankhana Sheth Mr. Mukeshbhai Jivrajbhai Patel Mr. Sanjay Parasmal Shah Mr. Jignesh Shah Mr. Shyam Rajpurohit Krutika Bhatt	Managing Director Executive Director Independent Director Independent Director Independent Director Non Executive Director Chief Financial Officer Company secretary (Upto 02.10.2023) Company secretary (w.e.f 02.10.2023)
<b>III</b>	<b>Relatives of Key Managerial Personnel / Directors:</b> Mrs. Shital H. Shah Mr. Bhahim B Desai Mrs. Nikita Shah Mrs. Himaben b. Desai	Relatives of Director Relatives of Director Relatives of Director Relatives of Director
<b>IV</b>	<b>Enterprise in which is director or his relatives are interested or director</b> Varenyam Healthcare Private Limited	Enterprise in which is director or his relatives are interested or director

b) Key Managerial Personnel Compensation

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Short-term employee benefits	204.87	183.82
Terminal Benefits	2.59	1.30
<b>Total Compensation</b>	<b>207.46</b>	<b>185.12</b>

c) Transactions with Related Parties:

During the year, the following transactions were carried out with related parties and relative of Key Managerial Personnel in the ordinary course of the business.

Sr No	Particular	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>a)</b>	<b>Transactions with subsidiary</b>		
<b>1</b>	<b>Innoxel Lifesciences Private Limited</b>		
i)	Loans and advance Given	3,989.40	4,696.30
ii)	Loans and advance Repaid	2,521.56	3,388.14
iii)	Investment in Equity Shares	1,020.74	3,088.05
iv)	Interest On Loan and advances	264.37	119.15
v)	Sale of Property Plant and Equipment's	-	900.90
vi)	Trading Sales	3.24	-
<b>2</b>	<b>Varenyam Biolifesciences Private Limited</b>		
i)	Advance Given	389.50	1,629.73
ii)	Interest On Advance	122.54	29.78
iii)	Investment in Equity Shares	-	270.00
iv)	Reimbursement of Expense	-	744.86
<b>b)</b>	<b>Enterprise in which is director or his relatives are interested or director</b>		
<b>1</b>	<b>Varenyam Healthcare Private Limited</b>		
i)	Sale of Goods	2,405.34	1,250.79
ii)	Purchase of Goods	18.13	82.29

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

Sr No	Key Managerial Personnel and their relatives	Name of Parties	Year ended 31st March, 2024	Year ended 31st March, 2023
1	<b>Key Managerial Personnel</b> Remuneration	Mr. Bharat Desai	143.11	143.17
		Mr. Hemang J. Shah	40.24	25.71
		Mr. Jignesh Shah	15.22	10.33
		Mr. Shyam Rajpurohit	4.17	3.07
		Ms. Krutika Bhatt	4.72	-
2	Sitting Fees to Directors	Mr. Shaileshkumar Ghabhawala	0.10	0.20
		Mrs. Zankhana Sheth	0.10	0.20
		Mr. Bharat Desai	0.10	0.20
		Mr. Hemang J. Shah	0.10	0.20
		Mr. Mukeshbhai J. Patel	0.10	0.20
		Mr. Sanjay P. Shah	0.10	0.20
3	Sale of Property Plant and Equipment's	Mr. Bharat Desai	-	32.61
4	<b>Relatives of Key Managerial Personnel</b> Remuneration/Perquisite	Mr. Bhahim B Desai	74.73	67.88
		Mrs. Nikita Shah	39.96	36.01
		Mrs. Himaben b. Desai	171.84	173.65
5	Consultancy Expenses	Mrs. Shital H. Shah	11.00	9.00

**d) Outstanding Balances**

Sr No	Particulars	As at 31st March, 2024	As at 31st March, 2023
1	<b>Subsidiary Company</b>		
	Innoxel Lifesciences Private Limited (Loans and Advances)	5,434.37	3,728.59
	Innoxel Lifesciences Private Limited (Receivable)	3.82	-
	Guarantee given by the company on behalf of subsidiary (Innoxel Lifesciences Private Limited)	6,686.06	-
	Varenyam Biolifesciences Private Limited (Loans and Advances)	2,156.32	1,656.53
2	<b>Key Managerial Personnel and relatives</b>		
	Mr. Bharat Desai	11.50	11.50
	Mrs. Himaben b. Desai	9.44	9.44
	Mr. Hemang J. Shah	2.24	2.09
	Mr. Jignesh Shah	1.03	0.82
	Mr. Bhahim B Desai	1.56	0.92
	Mrs. Nikita Shah	0.83	0.52
	Mr. Shyam Rajpurohit	-	0.5
Ms. Krutika Bhatt	0.84		
3	<b>Enterprise in which is director or his relatives are interested or director</b> Varenyam Healthcare Private Limited	1,288.60	1,138.46

**38 Contingent Liabilities**

Sr No	Particulars	As at 31 March, 2024	As at 31 March, 2023
(i)	<b>Contingent liabilities</b>		
	a) Liabilities Disputed in appeals		
	- Income Tax	86.14	86.14
	- Service Tax	10.75	10.75
	b) Letter of Credit and Bank Guarantees	2,136.91	2,571.84
	<b>Total</b>	<b>2,233.81</b>	<b>2,668.73</b>
(ii)	<b>Commitments</b>		
	Estimated amount of contracts remaining to be executed on capital account & not provided for:		
	-Tangible Assets	333.92	81.71

**39 Disclosure pursuant to leases**

**As Lessee:**

**Short term Leases:**

The Company has obtained premises for its business operations under operating lease or leave and license agreements. These are not non-cancellable and are renewable by mutual consent on mutually agreeable terms.

Lease payments are recognised in statement of Profit and Loss under the head "Rent Expense" in note no 33.

**40 Disclosure related to Micro and Small Enterprises**

On the basis of confirmation obtained from the supplier who have registered themselves under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006) and based on the information available with the company, the following are the details:

Particulars	As at 31 March, 2024	As at 31 March, 2023
(a) the principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year (Refer below notes)	92.56	401.79
(b)the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	4.99	-
(c) the amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;	-	4.82
(d) the amount of interest accrued and remaining unpaid at the end of each accounting year; and	-	12.11
(e) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises	-	-

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**41 Auditor's Remuneration**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>Statutory Auditors</b>		
Audit Fees (including for quarterly limited review)	3.75	3.75
For certification	1.20	0.21
For other matters	-	-
<b>Total</b>	<b>4.95</b>	<b>3.96</b>

**42 Corporate Social Responsibility (CSR)**

As per section 135 of the Companies Act, 2013, a CSR committee has been formed by the company. The areas for CSR activities are promoting education, art and culture, healthcare, destitute care and rehabilitation and rural development projects as specified in Schedule VII of the Companies Act, 2013. The details of amount required to be spent and actual expenses spent during the year is as under:

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
(a) Gross amount required to be spent by the company during the year	53.85	59.51
<b>(b) Amount spent during the year on</b>		
<b>1. Construction / Acquisition of Assets</b>		
- In cash	-	-
- Yet to be paid in cash	-	-
<b>2. On purpose other than (i) above</b>		
- In cash	56.75	65.59
- Yet to be paid	-	-
(c) Shortfall at the end of the year	-	-
(d) Total of previous years shortfall	-	-
(e) Reason for shortfall		
	Rural Development, Health & Education promotion etc..	Rural Development, Health & Education promotion etc..
(f) Nature of CSR activities		
(g) Details of related party transactions		
<b>(h) Movements in the provision of CSR during the year</b>		
Balance at the beginning of the year	-	-
Provision made during the year	-	-
Provision utilised during the year	-	-
Balance at the end of the year	-	-

**43 Disclosure as per section 186(4) of the Companies Act, 2013**

(i) The company has given advances & loan to following parties and the outstanding balances are as under:

Name of party	As on 31st March, 2024	As on 31st March, 2023
<b>Advances and Loan given to subsidiaries</b>		
Innoxel Lifesciences Private Limited	5,434.37	3,728.59
Varenyam Biolifesciences Private Limited	2,156.32	1,656.53

The above loan has been given to above entities for meeting their business requirements.

(ii) The company has given Guarantees to following party and the outstanding balances are as under:

Name of party	As on 31st March, 2024	As on 31st March, 2023
<b>Guarantees</b>		
Innoxel Lifesciences Private Limited	6,686.06	-

The above Guarantees has been given for subsidiary's debt.

(iii) The company has made Investment to following party and the outstanding balances are as under:

Name of party	As on 31st March, 2024	As on 31st March, 2023
<b>Investment</b>		
Innoxel Lifesciences Private Limited	4,590.74	3,570.00
Varenyam Biolifesciences Private Limited	270.00	270.00

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

<b>Aggregate amount granted/ provided during the year</b>			
i)Subsidiaries	2,205.56	100%	2,205.56
ii)Joint Venture	-	-	-
iii)Associates	-	-	-
iv) Related Parties	-	-	-
iv) Others	-	-	-
<b>Balance outstanding as at balance sheet date in respect of above cases</b>			
i)Subsidiary	7,590.68	100%	7,590.68
ii)Joint Venture	-	-	-
iii)Associates	-	-	-
iv) Related Parties	-	-	-
iv) Others	-	-	-

(iii) The company has charged the Interest of Rs. 264.37 lakhs (P.Y. 119.15 lakhs) from Innoxel Lifesciences Private Limited & Rs. 122.54 lakhs (P.Y. 29.78) from Varenyam Biolifesciences Private Limited, The rate of interest range from 6% - 7 % P.a. The above loan given for a tenure of upto 9 years from the commencement of loan.

**44 Operating Segments**

The activities of the Company relate to only one segment i.e. Manufacturing of Pharmaceuticals Formulations

**Geographical Information**

The analysis of geographical information is based on the geographical location of the customers. The geographical information considered for disclosure are as follows:

**Revenue by Geography**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Within India	9,632.71	10,886.38
Outside India	15,742.92	10,863.75

**Carrying value of segment assets**

Particulars	As at 31st March, 2024	As at 31st March, 2023
Within India	28,526.39	24,910.85
Outside India	10,188.91	5,892.03

**Property, Plant & Equipment by Geographical Locations**

The Company has common PPE for producing goods for domestic as well as overseas market. There are no PPE situated outside India. Hence, additional segment-wise information for PPE / additions to PPE has not been furnished.

**45 Expenditure on Formulation and Development (R&D)**

The Company's F&D center as certified by Department of Scientific and Industrial Research function at survey No. 144/146 Jarod - Samlaya road, Village Haripura, Vadodara

Expenditure incurred in the F&D center during the financial year 2023-24 & 2022-23 are given below

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Capital Expenditure	-	1.95
Recurring Expenditure	106.07	137.78
<b>Total Expenditure</b>	<b>106.07</b>	<b>139.73</b>

**46 Investment Property:**

(i) Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Amount recognised in Statement of Profit or Loss for investment properties Rental Income	-	-
Direct operating expenses from property that generated rental income	-	-
Depreciation	(9.06)	(9.86)
<b>Profit from Investment Property</b>	<b>(9.06)</b>	<b>(9.86)</b>

(ii) Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>Fair Value</b>		
Investment Properties	193.54	193.54
<b>Total</b>	<b>193.54</b>	<b>193.54</b>

Estimation of fair value: Method of Estimation

In the absence of valuation reports, the Company has used the government registration rates for the purpose of determining the fair value of Land and Buildings.

**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**47 Trade receivables aging**

Particulars	Outstanding for following periods from due date of Payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
<b>As at 31st March, 2024</b>						
(i) Undisputed Trade receivables – considered good	10,754.7	1,915.14	905.16	358.52	214.45	14,147.92
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	38.04	38.04
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
Less : Expected Credit Loss Allowance	(65.08)	(11.68)	(45.26)	(35.85)	(50.50)	(208.37)
% Expected Credit Loss Allowance to Trade Receivable	-0.61%	-0.61%	-5.00%	-10.00%	-20.00%	
<b>Total</b>	<b>10,689.58</b>	<b>1,903.46</b>	<b>859.90</b>	<b>322.66</b>	<b>201.99</b>	<b>13,977.60</b>
<b>As at 31st March, 2023</b>						
(i) Undisputed Trade receivables – considered good	9,282.48	1,073.06	671.40	112.47	246.50	11,385.92
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	22.33	22.33
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
Less : Expected Credit Loss Allowance	(62.59)	(7.19)	(33.57)	(11.25)	(53.77)	(168.37)
% Expected Credit Loss Allowance to Trade Receivable	-0.67%	-0.67%	-5.00%	-10.00%	-20.00%	
<b>Total</b>	<b>9,219.89</b>	<b>1,065.87</b>	<b>637.83</b>	<b>101.22</b>	<b>215.07</b>	<b>11,239.88</b>

**48 Trade Payable Aging**

Particulars	Outstanding for following periods from due date of Payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at 31st March, 2024</b>					
(i) MSME	77.55	8.05	6.96	-	92.56
(ii) Others	5,127.99	26.28	7.08	63.96	5,225.30
(iii) Disputed dues – MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
<b>Total</b>	<b>5,205.54</b>	<b>34.32</b>	<b>14.04</b>	<b>63.96</b>	<b>5,317.86</b>
<b>As at 31st March, 2023</b>					
(i) MSME	394.53	7.26	-	-	401.79
(ii) Others	4,192.64	21.57	9.05	167.27	4,390.53
(iii) Disputed dues – MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
<b>Total</b>	<b>4,587.17</b>	<b>28.83</b>	<b>9.05</b>	<b>167.27</b>	<b>4,792.32</b>



**BHARAT PARENTERALS LIMITED**  
**NOTES TO STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**49 Accounting Ratios**

SN	Particulars	Numerator	Denominator	2023-24	2022-23	% Variance	Reasons for variance (if +/- 25%)
1	Current Ratio (in times)	Current Asset	Current Liabilities	1.30	1.61	-54.82%	Increase in Borrowings during the year.
2	Debt-Equity Ratio (in times)	Total Debt	Shareholder's Equity	0.39	0.24	164.95%	Increase in Borrowings during the year.
3	Debt Service Coverage Ratio (in times)	Earnings available for debt service	Debt Service	5.66	5.67	-32.06%	Increase in Borrowings during the year.
4	Return on Equity Ratio (in %)	Net Profits after taxes	Average Shareholder's Equity	11.17%	13.63%	-0.83%	
5	Inventory Turnover Ratio (in times)	Revenue From Operations	Average Value of Inventory	5.51	7.44	-24.22%	
6	Trade Receivables turnover ratio (in times)	Revenue From Operations	Average Trade Receivable	2.02	2.35	-21.85%	
7	Trade Payable turnover ratio (in times)	Cost of sales+Other expenses	Average Trade Payable	4.08	5.10	-26.31%	Higher procurement at year end resulting in to increasing in trade payable
8	Net capital turnover ratio (in times)	Revenue From Operations	Working Capital	5.04	3.29	60.29%	Increase in Borrowings during the year.
9	Net profit ratio (in %)	Net profit After Tax	Revenue From Operations	0.09	0.11	11.11%	
10	Return on Capital employed (in %)	EBIT	Capital Employed	0.11	0.14	-10.11%	
11	Return on Investment (in %)	Income from Investment	Average Investment	NA	NA	NA	

50 Fair Value Measurements

Financial instruments by category

Particulars	As at 31st March, 2024			As at 31st March, 2023		
	FVTPL	FVOCI	Amortized Cost	FVTPL	FVOCI	Amortized Cost
<b>Financial Assets</b>						
Investments in Subsidiary			4,860.74			3,840.00
Trade Receivables	-	-	13,977.60	-	-	11,239.88
Cash and Cash Equivalents	-	-	142.99	-	-	635.46
Bank balances other than above	-	-	123.36	-	-	107.49
Loans	-	-	7,601.42	-	-	5,391.69
Other Financial Assets	-	-	663.72	-	-	698.04
<b>Total Financial Assets</b>	-	-	<b>27,369.82</b>	-	-	<b>21,912.57</b>
<b>Financial Liabilities</b>						
Borrowings	-	-	8,302.24	-	-	4,571.39
Other current financial Liabilities	-	-	1,479.24	-	-	1,000.77
Trade payables	-	-	5,317.87	-	-	4,792.32
<b>Total Financial Liabilities</b>	-	-	<b>15,099.35</b>	-	-	<b>10,364.48</b>

(i) Fair value hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are (a) recognized and measured at fair value. To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

**Level 1:** Level 1 hierarchy includes financial instruments measured using quoted prices.

**Level 2:** The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

**Level 3:** If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

There are no transfers between levels 1 and 2 during the year.

The Company's policy is to recognise transfers into and transfers out of fair value hierarchy levels at the end of the reporting period.

(ii) Valuation technique used to determine fair value

Specific valuation techniques used to value financial instruments include:

- the use of quoted market prices or dealer quotes for similar instruments
- the fair value of the remaining financial instruments is determined using discounted analysis(if any).

## 51 Financial Risk Management

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

### (A) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers, loans and investments. Credit risk is managed through continuous monitoring of receivables and follow up for overdues.

#### (i) Investments

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter parties, and does not have any significant concentration of exposures to specific industry sector or specific country risks.

#### (ii) Trade Receivables

The Company has used Expected Credit Loss (ECL) model for assessing the impairment loss. For the purpose, the Company uses a provision matrix to compute the expected credit loss amount. The provision matrix takes into account external and internal risk factors and historical data to credit losses from various customers.

Reconciliation of loss allowance provision – Trade receivables

Particulars	(Rs. In Lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
Balance at the beginning of the year	168.37	126.12
Changes in loss allowance	40.00	42.25
Balance at the end of the year	208.37	168.37

Other than trade and other receivables, the Company has no other financial assets that are past due but not impaired.

### (B) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The responsibility for liquidity risk management rests with the board of directors, which has established an appropriate liquidity risk management framework for the management of the Company's short-term, medium-term and long-term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities.

#### (i) Maturities of financial liabilities

The tables herewith analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for:

The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

#### Contractual maturities of financial liabilities

Particulars	Less than 1 year	More than 1 year	Total
<b>As at 31st March, 2024</b>			
<b>Non-derivatives</b>			
Borrowings	7,936.42	365.82	8,302.24
Trade payables	5,317.87	-	5,317.87
Other financial liabilities	1,479.24	-	1,479.24
<b>Total Non-derivative liabilities</b>	<b>14,733.53</b>	<b>365.82</b>	<b>15,099.35</b>
<b>As at 31st March, 2023</b>			
<b>Non-derivatives</b>			
Borrowings	3,882.43	688.96	4,571.39
Trade payables	4,792.32	-	4,792.32
Other financial liabilities	1,000.77	-	1,000.77
<b>Total Non-derivative liabilities</b>	<b>9,675.52</b>	<b>688.96</b>	<b>10,364.48</b>

(C) Market risk

(i) Price Risk

The company is mainly exposed to the price risk due to its investments in mutual funds. The price risk arises due to uncertainties about the future market values of these investments. The above instruments risk are arises due to uncertainties about the future market values of these investments.

**Management Policy**

The company maintains its portfolio in accordance with the framework set by the Risk management Policies.

(ii) Foreign Currency Risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

The risk is measured through a forecast of foreign currency for the Company's operations.

The Company's exposure to foreign currency risk at the end of the reporting period expressed in Indian Rupee, are as follows:

(i) Trade receivable and other Receivable

Currency	As at 31st March, 2024		
	Trade receivable and other Receivable	Hedges available	Net exposure to foreign currency risk
USD	190.79	-	190.79
EURO	9,767.50	-	9,767.50

Currency	As at 31st March, 2023		
	Trade receivable and other Receivable	Hedges available	Net exposure to foreign currency risk
USD	5,265.14	-	5,265.14
EURO	-	-	-

(ii) Trade payable and other payable

Currency	As at 31st March, 2024		
	Trade payable and other payable	Hedges available	Net exposure to foreign currency risk
USD	16.87	-	16.87

Currency	As at 31st March, 2023		
	Trade payable and other payable	Hedges available	Net exposure to foreign currency risk
USD	177.18	-	177.18

**Sensitivity**

The sensitivity of profit or loss to changes in the exchange rates arises mainly from Unhedged foreign currency denominated financial instruments.

Particular	Impact on profit after tax	
	31st March, 2024	31st March, 2023
USD sensitivity		
INR/USD increases by 5%	8.70	254.40
INR/USD decreases by 5%	(8.70)	(254.40)
EUR sensitivity		
INR/EUR increases by 5%	488.37	-
INR/EUR decreases by 5%	(488.37)	-

**Capital Management**

52 Risk management

For the purpose of the company's capital management, equity includes equity share capital and all other equity reserves attributable to the equity holders of the Company. The Company manages its capital to optimise returns to the shareholders and makes adjustments to it in light of changes in economic conditions or its business requirements. The Company's objectives are to safeguard continuity, maintain a strong credit rating and healthy capital ratios in order to support its business and provide adequate return to shareholders through continuing growth and maximise the shareholders value. The Company funds its operation through internal accruals. The management and Board of Directors monitor the return on capital as well as the level of dividends to shareholders.

**53 Share-based payments**

(a) The share-based payment plan is an employee option plan. The options are equity settled options.

At the annual general meeting of company held on 30th September, 2020, member of the company passed the special resolution for introducing "Bharat Parenterals Employee Stock Option Plan 2020" of 2,00,000 options for the benefit of the employee of the company. The resolution also accorded approval for the Board of Directors, to formulate the Scheme as per broad parameters outlined in the resolution. Pursuant to Scheme framed, the company has granted options to eligible employees of the company under plan. Each options entitle for one equity share. The company granted 90,000 Stock Option to its employees by virtue of grant letter dated 12th, November, 2020 and 17th, June, 2022. The vesting conditions of which are as outlined in their grant letter. Necessary impact have been considered. Further, the company has not yet granted the 1,10,000 Stock Option to its employees. The options are exercisable at an exercise price of Rs. 99 per share (Face Value of Rs.10 per share).

**(b) Set out below is the summary of options**

Particular	Year ended 31st March 2024		Year ended 31st March 2023	
	Average exercise price/share in Rs.	No. of options	Average exercise price/share in Rs.	No. of options
Opening balance	99	45,000	-	-
Granted during the year	-	-	99	45,000
Exercised during the year	99	45,000	-	-
Forfeited during the year	-	-	-	-
<b>Closing balance</b>	-	-	<b>99</b>	<b>45,000</b>
<b>Vested and exercisable</b>	-	-	<b>99</b>	<b>45,000</b>

**(c) Share options outstanding at the end of the year have the following exercise period and exercise prices :**

Grant	Grant Date	Exercise period	Share Options as on 31 March 2024	Share Options as on 31 March 2023
Grant I - Exercise price Rs. 99.00	12-11-2020	1 years from the date of listing	-	-
Grant II - Exercise price Rs. 99.00	17-06-2022	1 years from the date of listing	-	-

**(d) No options expired during the year ended 31 March 2024 and 31 March 2023.**

**(e) Contractual life of options**

Grant	Grant Date	Expiry Date	Share Options as on 31st March 2024	Share Options as on 31st March 2023
Grant I - Exercise price Rs. 99.00	12-11-2020	11-11-2021	-	-
Grant II - Exercise price Rs. 99.00	17-06-2022	16-06-2023	-	-

The company has charged to statement of Profit and Loss as employee benefit expenses Rs. 13.96 Lakhs (P.Y. 53.09 Lakhs) by creating an Employee stock option reserve which is grouped under the head 'Other Equity'.

**54 Other disclosures**

(i) The Company do not have any Benami property, where any proceeding has been initiated or pending against The Company for holding any Benami property.

(ii) The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(iii) The Company have not traded or invested in Crypto currency or Virtual Currency during the year.

(iv) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(v) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that The Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(vi) The Company do not have any such transaction which is not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax

assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

(vii) The company holds all the title deeds of immovable property in its name.

(viii) The company is not declared as willful defaulter by any bank or financial Institution or other lender.

(ix) There is no Scheme of Arrangement approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.

55 The financial statements were authorized for issue in accordance with a resolution passed by the Board of Directors on 22nd May,2024. The financial statements as approved by the Board of Directors are subject to final approval by its Shareholders.

**56 Information on Dividend for the year ended 31st March, 2024**

Dividends proposed or declared after the balance sheet date but before the financial statements have been approved by the Board of Director for issue are not recognised as a liability at the balance sheet date.

The Board of Director recommended final dividend of Rs 1.00 per equity share for the financial year ended on 31st March, 2024. The payment is subject to approval of share holder in ensuing Annual General Meeting of the Company. (Previous year Rs. 0.75 per equity share).

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

**For C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhattbhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May , 2024

**INDEPENDENT AUDITOR'S REPORT****TO THE MEMBERS OF BHARAT PARENTERALS LIMITED****Report on the Audit of the Consolidated Financial Statements****Opinion**

We have audited the accompanying Consolidated Financial Statements of Bharat Parenterals Limited ("the Company"), its subsidiaries company (the Company and its subsidiaries together referred to as "the Group") which comprise the Consolidated Balance Sheet as at 31<sup>st</sup> March, 2024, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date and notes to the Consolidated Financial Statements, including a summary of material accounting policies and other explanatory information (hereinafter referred to as the "Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31<sup>st</sup> March, 2024, the consolidated profit and consolidated total comprehensive income, consolidated changes in equity and its consolidated cash flows for the year ended on that date.

**Basis for Opinion**

We conducted our audit of the Consolidated Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion on the Consolidated Financial Statements.

**Key Audit Matters**

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Consolidated Financial Statements of the current period. These matters were addressed in the context of our audit of the Consolidated Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

**Information other than the Consolidated Financial Statement and Auditor's Report thereon**

The Holding Company's Board of Directors is responsible for other information. The other information comprises the information included Board's Report including Annexures to that Board's Report, Corporate Governance and Shareholder's Information, but does not include the Consolidated Financial Statements and our auditor's report thereon.

Our opinion on the Consolidated Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Consolidated Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these Consolidated Financial Statements that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the Ind AS and other accounting principles generally accepted in India. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error;

In preparing the Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so;

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

**Auditor's Responsibilities for the Audit of Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's





report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Group has adequate internal financial controls system in place and the operating effectiveness of such controls;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation;
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the Consolidated Financial Statements of which we are the independent auditor. For the other entities included in the Consolidated Financial Statements, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion;

Materiality is the magnitude of misstatements in the Consolidated Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Statements may be influenced. We consider quantitative materiality and qualitative



factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Statements;

We communicate with those charged with governance of the company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit;

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards;

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### **Report on Other Legal and Regulatory Requirements**

1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements;
  - (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statements have been kept by the Group so far as it appears from our examination of those books and the reports of the other auditors;
  - (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including other comprehensive income), Consolidated Statement of Changes in Equity and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the Consolidated Financial Statements;
  - (d) In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act;
  - (e) On the basis of the written representations received from the directors of the Company as on 31<sup>st</sup> March, 2024 taken on record by the Board of Directors of the company and the report of the statutory auditors of its subsidiary company, incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on 31<sup>st</sup> March, 2024 from being appointed as a director in terms of Section 164(2) of the Act;
  - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate Report in "Annexure A";
  - (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:



In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act; and

- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Consolidated Financial Statements disclosed the impact of pending litigations on its financial position of the Group– Refer Note 38 to the Consolidated Financial Statements;
  - ii. The Group did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses;
  - iii. The Group is not required to transfer any amount to the Investor Education and Protection Fund by the Company.
  - iv.
    - i. The Management has represented that, to the best of it's knowledge and belief that no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
    - ii. The Management has represented that , to the best of it's knowledge and belief that no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
    - iii. Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
  - v. The final dividend paid, by the Holding Company during the year in respect of dividend declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.
  - vi. As stated in note no. 55 to the Consolidated Financial Statements, the respective Board of Directors of the Holding Company have proposed final dividend for the year which is subject to the approval of the members of the respective co respective ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend.



- vii. Based on our examination, which included test checks, that performed by us on the Holding Company and its associates which are companies incorporated in India whose financial statements have been audited under the Act, the Holding Company and associates have used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective software except in case of subsidiaries in which audit trail (edit log) facility has not been available from 1<sup>st</sup> April, 2023 to 18<sup>th</sup> June, 2023. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with.
2. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 (the "Order"/ "CARO") issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanations given to us, and based on the CARO reports issued by us for the Company and its subsidiaries included in the consolidated financial statements of the Company, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in these CARO reports.

For **CNK & Associates LLP**  
Chartered Accountants  
Firm Registration No. 101961W/W-100036

**Rachit Sheth**  
Partner  
Membership No. 158289  
Place: Vadodara  
Date: 22<sup>nd</sup> May 2024  
UDIN: 24158289BKAQIE1213

**ANNEXURE “A” TO THE INDEPENDENT AUDITOR’S REPORT****Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **BHARAT PARENTERALS LIMITED** (“the Company”) and in respect of its subsidiaries wherein such audit of internal financial controls over financial reporting was carried out by us and have been appropriately dealt with by us in making this report as on 31<sup>st</sup> March, 2024 in conjunction with our audit of the Consolidated Financial Statements of the Company for the year ended on that date.

**Management’s Responsibility for Internal Financial Controls**

The respective Board of Directors of the Company and its subsidiary company, which are companies incorporated in India are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of internal financial controls with reference to financial statements of the Company that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditors’ Responsibility**

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company, its subsidiary company, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by the Institute of Chartered Accountants of India and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Control and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements of the Company were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the internal financial controls with reference to financial statements of the company and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error.



We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls over Financial Reporting**

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company, its subsidiary company has, in all material respects, an internal financial controls with reference to financial statements of the Company and such internal financial controls over financial reporting were operating effectively as at 31<sup>st</sup> March, 2024, based on the internal control over financial reporting criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **CNK & Associates LLP**  
Chartered Accountants  
Firm Registration No. 101961W/W-100036

**Rachit Sheth**  
Partner  
Membership No. 158289  
Place: Vadodara  
Date: 22<sup>nd</sup> May 2024  
UDIN: 24158289BKAQIE1213

**BHARAT PARENTERALS LIMITED****NOTES FORMING PART OF THE FINANCIAL STATEMENTS****1. COMPANY OVERVIEW AND MATERIAL ACCOUNTING POLICIES:****1.1 Description of Business**

The Company is a Public Limited Company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on one recognised stock exchanges in India. The registered office of the Company is located at Vill.- Haripura, Savli, Baroda - 389 330. The Company is dealing in Manufacturing of Pharmaceutical Formulations.

**1.2 Basis of Preparation of Financial Statements**

- i. The Financial statements of the subsidiary used in the consolidation are drawn up to the same reporting date as that of the Bharat Parenterals Limited ("the Holding company") i.e. 31st March, 2024.

The Financial statements of the group have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Act to be read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the relevant amendment rules issued thereafter.

**ii. Principles of consolidation**

The Consolidated statement consist of Bharat Parenteral limited ("the Holding Company") and its subsidiary (collectively referred as "the Group"). The consolidated financial statements have been prepared on the following basis:

The Financial Statements of the holding company and its subsidiary have been consolidated on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after eliminating intra-group balances and intra-group transection resulting in unrealised profits or loss.

**iii. Composition of Consolidated Financial Statements**

The Consolidated financial statements are drawn up in Indian Rupee, the functional currency of the group, and in accordance with Ind AS presentation. The financial statements comprise:

- Balance Sheet
- Statement of Profit and Loss
- Statement of Changes in Equity
- Statement of Cash Flow
- Notes to Financial Statements

**2. Material Accounting Policies and Other Explanatory Notes**

The Material Accounting Policies of the holding company and its subsidiaries are similar Refer Note No. 2 of Standalone Financial Statements.



**BHARAT PARENTERALS LIMITED**  
**CIN:L24231GJ1992PLC018237**  
**CONSOLIDATED BALANCE SHEET AS AT 31st MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

Sr. No.	Particulars	Note No	As at 31st March, 2024	As at 31st March, 2023
	<b>ASSETS</b>			
(1)	<b>Non current Assets</b>			
	(a) Property, Plant and Equipment	3	20,947.98	4,119.04
	(b) Capital work-in-progress	4	2,389.16	9,901.43
	(c) Intangible under development	5	104.47	-
	(d) Investment Properties	6	89.46	98.52
	(e) <u>Financial Assets</u>			
	(i) Other Financial assets	7	309.22	321.26
	(f) Deferred tax assets (net)	8	11.67	-
	(g) Other Non Current Assets	9	539.37	2,165.69
(2)	<b>Current assets</b>			
	(a) Inventories	10	6,146.77	3,784.22
	(b) <u>Financial Assets</u>			
	(i) Trade receivables	11	14,142.11	11,240.68
	(ii) Cash and cash equivalents	12	870.96	785.23
	(iii) Bank Balances other than Cash and cash equivalents	13	338.45	212.96
	(iv) Loans	14	10.73	6.57
	(v) Other financial assets	15	397.41	376.79
	(c) Other current assets	16	4,057.00	2,021.87
	(d) Current tax Assets		27.50	-
	<b>Total Assets</b>		<b>50,382.27</b>	<b>35,034.25</b>
	<b>EQUITY AND LIABILITIES</b>			
(1)	<b>Equity</b>			
	(a) Equity Share capital	17	581.97	577.47
	(b) Other Equity	18	19,144.72	17,702.16
	(c) Non-Controlling Interest		4,090.71	3,510.27
	<b>Total equity attributable to equity holders of the Company</b>		<b>23,817.40</b>	<b>21,789.90</b>
(2)	<b>LIABILITIES</b>			
	<b>Non-Current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings	19	7,316.22	1,092.02
	(b) Provisions	20	210.29	132.66
	(c) Deferred tax liabilities (Net)	8	-	39.88
(3)	<b>Current liabilities</b>			
	(a) <u>Financial Liabilities</u>			
	(i) Borrowings	21	8,441.80	3,882.43
	(ii) Trade payables	22		
	a) total outstanding dues of Micro Enterprises and Small Enterprises		102.71	401.79
	b) total outstanding dues of creditors other than Micro Enterprises and Small Enterprises		5,900.52	4,732.54
	(iii) Other financial liabilities	23	2,235.00	1,711.82
	(b) Other current liabilities	24	2,178.65	1,090.92
	(c) Provisions	25	179.70	107.15
	(d) Current Tax Liability (Net)		-	53.17
	<b>Total Liabilities</b>		<b>26,564.87</b>	<b>13,244.36</b>
	<b>Total Equity and Liabilities</b>		<b>50,382.27</b>	<b>35,034.25</b>

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

**For C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May, 2024

Place: Vadodara  
Date: 22nd May, 2024



<b>BHARAT PARENTERALS LIMITED</b> <b>CIN:L24231GJ1992PLC018237</b> <b>CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH, 2024</b> <b>ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED</b>				
Sr. No.	Particulars	Note No.	Year ended 31st March, 2024	Year ended 31st March, 2023
I	Revenue From Operations	26	25,736.07	21,798.15
II	Other Income	27	859.20	1,173.91
III	<b>Total Income (I+II)</b>		<b>26,595.27</b>	<b>22,972.05</b>
IV	<b>EXPENSES</b>			
	Cost of materials consumed	28	17,316.50	14,606.93
	Purchase of Stock-in-Trade	29	37.64	116.48
	Changes in Inventories of Finished goods, Stock-in-Trade and work-in-progress	30	(1,518.97)	(975.33)
	Employee benefits expense	31	2,278.22	1,799.59
	Finance costs	32	322.49	218.59
	Depreciation and amortization expense	3 & 6	902.05	588.24
	Other expenses	33	5,385.16	4,262.85
	<b>Total expenses (IV)</b>		<b>24,723.10</b>	<b>20,617.34</b>
V	<b>Profit/(Loss) before tax (III-IV)</b>		<b>1,872.17</b>	<b>2,354.71</b>
VI	<b>Tax expense:</b>	34		
	(1) Current tax		868.89	840.32
	(2) Deferred tax		(44.87)	(57.08)
	(3) Short / (Excess) provision of tax in respect of earlier years		(3.29)	-
VII	<b>Profit / (Loss) for the period (V-VI)</b>		<b>1,051.44</b>	<b>1,571.47</b>
VIII	<b>Other Comprehensive Income</b>			
	(i) Items that will not be reclassified to profit or loss			
	- Remeasurement of Defined benefit plans		(26.54)	5.75
	- Income tax relating to Remeasurement of Defined benefit plans		6.68	(1.45)
	<b>Total other comprehensive income (VIII)</b>		<b>(19.86)</b>	<b>4.30</b>
IX	<b>Total comprehensive income for the period (VII+VIII)</b>		<b>1,031.59</b>	<b>1,575.78</b>
	<b>Net Profit attributable to:</b>			
	Owners of the company		1,451.71	1,644.04
	Non Controlling Interest		(400.27)	(68.36)
	<b>Other Comprehensive Income attributable to:</b>			
	Owners of the company		(19.86)	4.30
	Non Controlling Interest		-	-
	<b>Total Comprehensive Income for the period</b>			
	Owners of the company		1,431.85	1,648.34
	Non Controlling Interest		(400.27)	(68.36)
X	<b>Earnings per equity share:</b>	35		
	(1) Basic		24.94	28.40
	(2) Diluted		24.94	28.40

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

**For C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May , 2024

Place: Vadodara  
Date: 22nd May , 2024

BHARAT PARENTERALS LIMITED  
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31st MARCH, 2024  
ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED

a. Equity Share Capital:

Particular	As at 31st March, 2024		As at 31st March, 2023	
	Nos.	Rs. In Lakhs	Nos.	Rs. In Lakhs
Balance at the 01st April, 2023	5,774,666	577.47	5,774,666	577.47
Changes in Equity Share Capital due to prior period errors	-	-	-	-
Restated balance at the 01st April, 2023	-	-	-	-
Changes in equity share capital during the current year	45,000	4.50	-	-
<b>Balance at the 31st March, 2024</b>	<b>5,819,666</b>	<b>581.97</b>	<b>5,774,666</b>	<b>577.47</b>

b. Other Equity:

(1) Current reporting period

Particular	Reserves and Surplus				Total
	General Reserve	Security Premium reserve	Employee Stock Option Reserve	Retained Earnings	
Balance at the 01st April, 2023	3.99	152.37	53.09	17,492.72	17,702.16
Changes in accounting policy or prior period errors	-	-	-	-	-
Restated balance at the 01st April, 2023	-	-	-	-	-
Total Comprehensive Income for the current year	-	-	-	1,451.71	1,451.71
Addition during the year	-	-	59.28	-	59.28
Transfer during the year	-	107.10	(112.37)	(43.31)	(48.58)
Remeasurement of the Net Defined benefit liability/asset, net of tax effect	-	-	-	(19.86)	(19.86)
<b>Balance at the 31st March, 2024</b>	<b>3.99</b>	<b>259.47</b>	<b>0.00</b>	<b>18,881.27</b>	<b>19,144.72</b>

(2) Previous reporting period

Particular	Reserves and Surplus				Total
	General Reserve	Security Premium reserve	Employee Stock Option Reserve	Retained Earnings	
Balance at the 01st April, 2022	3.99	152.37	-	15,848.68	16,005.03
Changes in accounting policy or prior period errors	-	-	-	-	-
Restated balance at the 01st April, 2022	-	-	-	-	-
Total Comprehensive Income for the current year	-	-	-	1,639.74	1,639.74
Addition during the year	-	-	53.09	-	53.09
Transfer during the year	-	-	-	-	-
Remeasurement of the Net Defined benefit liability/asset, net of tax effect	-	-	-	4.30	4.30
<b>Balance at the 31st March, 2023</b>	<b>3.99</b>	<b>152.37</b>	<b>53.09</b>	<b>17,492.72</b>	<b>17,702.16</b>

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

For C N K & Associates LLP  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhattbhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May, 2024

Place: Vadodara  
Date: 22nd May, 2024

	Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
<b>A</b>	<b>Cash flow from operating activities</b>		
	Profit before income tax	1,872.17	2,354.71
	<b>Adjustments for :</b>		
	Share of (Profit)/Loss to minority	400.27	68.36
	Depreciation and amortisation expense	902.05	588.24
	(Gain) / Loss on Sales of Property, Plant and Equipments (Net)	8.46	9.13
	Fair valuation of Investments through FVTPL	-	20.50
	Amount no longer payable written back	16.74	-
	(Gain) / Loss on Sales of Investment (Net)	-	(54.78)
	Share Based Payment	13.96	53.09
	Finance Cost	322.49	218.59
	Unrealised Foreign exchange fluctuation	(89.01)	11.21
	Interest Income	(42.04)	(33.81)
	<b>Operating profit before working capital changes</b>	<b>3,405.09</b>	<b>3,235.24</b>
	<b>Movements in working capital:</b>		
	<b>Assets</b>		
	(Increase) / Decrease in trade receivables	(2,799.38)	(3,915.78)
	(Increase) / Decrease in inventories	(2,362.55)	(1,708.18)
	(Increase) / Decrease in other financial assets	21.61	1,932.41
	(Increase) / Decrease in Loans	(4.16)	6.51
	(Increase) / Decrease in other current assets	(2,035.13)	(1,119.60)
	(Increase) / Decrease in other non current assets	1,626.32	58.61
	<b>Liabilities</b>		
	Increase / (Decrease) in trade payables	862.81	3,463.88
	Increase / (Decrease) in provisions	150.17	45.14
	Increase / (Decrease) in other current liabilities	1,087.74	658.26
	Increase / (Decrease) in other financial liabilities	523.19	389.07
	<b>Cash generated from operations :</b>	<b>475.70</b>	<b>3,045.58</b>
	Direct taxes paid (net)	946.27	879.19
	<b>Net cash from operating activities (A)</b>	<b>(470.57)</b>	<b>2,166.38</b>
<b>B</b>	<b>Cash flows from investing activities</b>		
	Purchase of Property, plant and equipment's (Including Capital work in progress Including capital Advance & Intangible under development)	(10,430.21)	(9,160.08)
	Proceeds of sale of Property, plant and equipment's	70.09	150.88
	(Purchase)/Sale of investments	-	1,182.44
	(Increase) / Decrease Bank Balances other than Cash and cash equivalents	(125.49)	(84.85)
	Interest Received	7.21	129.66
	<b>Net cash (used) in Investing activities (B)</b>	<b>(10,478.40)</b>	<b>(7,781.94)</b>
<b>C</b>	<b>Cash flow from financing activities :</b>		
	Proceeds from issue of shares	44.55	-
	Dividend Paid	(43.31)	-
	Proceeds/(Repayment) of long term Borrowings	6,224.20	(124.38)
	Proceeds/ (Repayment) of short term Borrowings	4,559.37	3,324.27
	Finance Cost	(322.49)	(218.59)
	Increase / (Decrease) in Non controlling Interest	580.45	3,078.49
	<b>Net cash (used) in financing activities (C)</b>	<b>11,042.76</b>	<b>6,059.79</b>
	<b>NET INCREASE IN CASH AND CASH EQUIVALENTS [(A) + (B) + (C)]</b>	<b>93.80</b>	<b>444.24</b>
	<b>CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR</b>	<b>784.11</b>	<b>339.87</b>
	<b>Balances with banks</b>		
	(a) In current accounts	868.44	716.89
	(b) In Cash Credit Account	-	65.76
		<b>868.44</b>	<b>782.66</b>
	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	6.95	(1.12)
		<b>875.39</b>	<b>781.53</b>
	Cash on Hand	2.53	2.57
	<b>CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR</b>	<b>877.91</b>	<b>784.11</b>

**NOTES:**

- (i) The above cash flow Statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standards - 7, "Statement of Cash Flow".  
(ii) Figures in bracket indicate Cash Outflow.

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

**For C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Rachit Sheth**  
Partner  
Membership No.: 158289

**Krutika Bhatbhatt**  
Company Secretary

**Jignesh Shah**  
Chief Financial Officer

Place: Vadodara  
Date: 22nd May, 2024

Place: Vadodara  
Date: 22nd May, 2024

**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**3 Property, Plant and Equipment**

Particulars	Land - Freehold	Windmill	Electrical Installation	Factory Building	Building - Others	Plant and Equipment	Furniture and Fixtures	Vehicles	Computers	Capital work-in-progress	Total
<b>Gross carrying amount As at 31st March, 2023</b>	518.38	234.63	331.57	1,120.20	496.33	4,134.70	553.72	504.90	112.15	9,901.43	17,908.01
Additions	4.95	-	-	139.27	5,704.31	11,273.75	538.98	-	176.77	-	17,838.02
Disposals	-	81.06	-	-	-	107.70	-	56.66	-	9,901.43	245.43
Other adjustment/transfer	41.55	-	-	-	-	-	-	-	-	-	9,942.98
<b>Gross carrying amount As at 31st March, 2024</b>	481.78	153.57	331.57	1,259.47	6,200.63	15,300.74	1,092.69	448.24	288.92	-	25,557.61
<b>Accumulated depreciation as at 31st March, 2023</b>	-	136.68	217.60	309.06	237.71	2,198.00	346.07	354.97	87.45	-	3,887.53
Charge for the year	-	9.42	29.53	84.26	62.71	532.56	67.87	42.96	63.69	-	893.00
Disposals	-	29.95	-	-	-	100.67	-	40.28	-	-	170.90
<b>Accumulated depreciation as at 31st March, 2024</b>	-	116.15	247.13	393.32	300.42	2,629.89	413.94	357.65	151.14	-	4,609.63
<b>Net carrying amount</b>											
As at 31st March, 2024	481.78	37.42	84.44	866.15	5,900.21	12,670.85	678.75	90.59	137.79	-	20,947.98
As at 31st March, 2023	518.38	97.95	113.97	811.14	258.62	1,936.69	207.65	149.93	24.71	-	14,020.47

Particulars	Land - Freehold	Windmill	Electrical Installation	Factory Building	Building - Others	Plant and Equipment	Furniture and Fixtures	Vehicles	Computers	Capital work-in-progress	Total
<b>Gross carrying amount As at 1st April, 2022</b>	415.34	234.63	327.80	970.98	496.33	3,796.16	510.47	457.61	88.33	2,565.42	9,863.06
Additions	155.55	-	7.08	149.22	211.84	393.70	43.25	47.29	23.82	7,398.12	8,218.02
Disposals	-52.50	-	-3.30	-	-	-55.16	-	-	-	-62.10	-173.07
<b>Gross carrying amount As at 31st March, 2023</b>	518.38	234.63	331.57	1,120.20	496.33	4,134.70	553.72	504.90	112.15	9,901.43	17,908.01
<b>Accumulated depreciation as at 1st April, 2022</b>	-	124.05	188.66	240.04	211.84	1,876.60	303.30	303.41	74.32	-	3,322.21
Charge for the year	-	12.63	32.12	69.02	25.87	331.29	42.77	51.56	13.12	-	578.38
Disposals	-	-	-3.18	-	-	-9.88	-	-	-	-	-13.06
<b>Accumulated depreciation as at 31st March, 2023</b>	-	136.68	217.60	309.06	237.71	2,198.00	346.07	354.97	87.45	-	3,887.53
<b>Net carrying amount</b>											
As at 31st March, 2023	518.38	97.95	113.97	811.14	258.62	1,936.69	207.65	149.93	24.71	9,901.43	14,020.47
As at 31st March, 2022	415.34	110.59	139.14	730.94	284.49	1,919.56	207.17	154.20	14.01	2,565.42	6,540.85

**Notes:**

1. Assets pledged as security :  
The free hold Land and Buildings, all movables and other assets are pledged as security on pari passu basis to the bankers under a mortgage. The Company is not allowed to sell these assets to other entity.

**4 Capital work-in-progress**

Particulars	As at 31st March, 2024	As at 31st March, 2023
Capital Work in Progress	2,389.16	9,901.43
<b>Total</b>	<b>2,389.16</b>	<b>9,901.43</b>

**4.1 Capital Work-In-Progress ageing**

CWIP	Amount in CWIP				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Year	
<b>As at 31st March, 2024</b>					
Projects in progress	390.63	2,028.31	-	-	2,418.94
Projects temporarily suspended	-	-	-	-	-
<b>As at 31 March 2023</b>					
Projects in progress	7,400.39	2,501.04	-	-	9,901.43
Projects temporarily suspended	-	-	-	-	-

Note 1: There are no Projects whose completion is overdue or has exceeded its cost.

Note 2: Borrowing cost capitalised during the year is Rs. 245.41 lakhs (P.Y. Nil)

**5 Intangible under development**

Particulars	As at 31st March, 2024	As at 31st March, 2023
Intangible under development	104.47	-
<b>Total</b>	<b>104.47</b>	<b>-</b>

**5.1 Intangible under development ageing**

CWIP	Amount in CWIP				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Year	
<b>As at 31st March, 2024</b>					
Projects in progress	79.20	25.27	-	-	104.47
Projects temporarily suspended	-	-	-	-	-
<b>As at 31 March 2023</b>					
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-

**6 Investment Properties**

<b>Particulars</b>	<b>As at 31st March, 2024</b>	<b>As at 31st March, 2023</b>
<b>INVESTMENT PROPERTY (at cost less accumulated depreciation)</b>		
<b>Building given on Operating Lease</b>		
Opening Gross Block	149.93	149.93
Additions	-	-
Closing Gross Block	<b>149.93</b>	<b>149.93</b>
<b>Less :</b>		
Opening Accumulated Depreciation	51.41	41.55
Add : Depreciation for the year	9.06	9.86
Closing Accumulated Depreciation	<b>60.47</b>	<b>51.41</b>
<b>Total</b>	<b>89.46</b>	<b>98.52</b>

Note : Refer note (45) for other disclosure.

**BHARAT PARENTERALS LIMITED**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024

ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED

**7 Other Financial Assets**

Particulars	As at 31st March, 2024	As at 31st March, 2023
(i) Bank deposits with more than 12 months of original maturity	242.31	254.35
(ii) Deposits	66.91	66.91
<b>Total</b>	<b>309.22</b>	<b>321.26</b>

**8 Deferred tax assets (net)**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Deferred Tax Assets</b>		
<b>The balance comprises temporary differences attributable to:</b>		
Provision For Employee Benefit	92.76	56.99
Remeasurements of the defined benefit plans	-	3.36
Others	52.45	42.38
<b>Total DTA</b>	<b>145.21</b>	<b>102.74</b>
<b>Deferred Tax Liability</b>		
<b>The balance comprises temporary differences attributable to:</b>		
Property, Plant & Equipment's	130.22	142.61
Remeasurements of the defined benefit plans	3.31	-
<b>Total DTL</b>	<b>133.54</b>	<b>142.61</b>
<b>Net Deferred Tax (Asset)/Liability</b>	<b>(11.67)</b>	<b>39.88</b>

**9 Other Non - Current Assets**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Unsecured, considered good</b>		
(a) Capital Advances	439.61	2,065.93
(b) Balance with Government Authorities	99.76	99.76
<b>Total</b>	<b>539.37</b>	<b>2,165.69</b>

10 Inventories

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Inventories (lower of cost and net realised value)</b>		
Raw Materials	2,107.23	2,225.20
Consumables	532.06	-
Packing Material	171.54	-
Raw Material (F&D)	34.34	34.78
Work-in-Progress	436.90	422.44
Finished goods	2,488.86	984.36
Goods in Transit (Raw materials)	375.83	117.44
<b>Total</b>	<b>6,146.77</b>	<b>3,784.22</b>

11 Trade Receivables

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Trade Receivables considered Good-Secured</b>		
<b>Trade Receivables considered Good-Unsecured</b>		
- Receivable from Related Parties (Refer Note 37(d))	1,292.42	1,138.46
- Others	13,020.02	10,248.26
	<b>14,312.44</b>	<b>11,386.72</b>
<b>Trade Receivable which have significant increase in credit risk</b>	38.04	22.33
<b>Trade Receivables credit impaired</b>	-	-
<b>Total</b>	<b>14,350.48</b>	<b>11,409.05</b>
Less : Expected Credit Loss Allowance	(208.37)	(168.37)
<b>Total</b>	<b>14,142.11</b>	<b>11,240.68</b>

Note: Refer Note 46 for Aging of Trade Receivable.

12 Cash and cash equivalents

Particulars	As at 31st March, 2024	As at 31st March, 2023
Balances with banks		
(a) In current accounts	868.44	716.89
(b) In cash credit accounts (Refer note 21 (i))	-	65.76
Cash on Hand	2.53	2.57
<b>Total</b>	<b>870.96</b>	<b>785.23</b>

13 Bank Balances

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Other Bank Balances</b>		
(a) Term deposits with original maturity for more than 3 months but less than 12 months	216.73	107.11
(b) Balances held as Margin Money	117.88	105.85
(c) In earmarked accounts		
- Balances held in unpaid dividend accounts	3.84	-
<b>Total</b>	<b>338.45</b>	<b>212.96</b>

14 Loans

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Loans to Employees	10.73	6.57
<b>Total</b>	<b>10.73</b>	<b>6.57</b>

15 Other Financial Assets

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Interest accrued on deposits	108.85	74.01
(b) Security and other deposits	288.06	302.28
(c) Term deposits	0.50	0.50
<b>Total</b>	<b>397.41</b>	<b>376.79</b>

16 Other Current Assets

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Advance to Suppliers	283.92	324.05
(b) Advance to employees	266.29	0.12
(c) Expenses paid in advance	154.87	133.83
(d) Balances with government authorities	3,351.92	1,563.87
<b>Total</b>	<b>4,057.01</b>	<b>2,021.87</b>



17 Share Capital

Authorised Equity Share Capital

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>a) Authorised</b> 63,00,000 - Equity shares of Rs. 10/- each	630.00	630.00
	<b>630.00</b>	<b>630.00</b>
<b>b) Shares issued, subscribed and fully paid</b> C.Y. 58,19,666 (P.Y. 57,74,666) - Equity shares of Rs. 10/- each	581.97	577.47
	<b>581.97</b>	<b>577.47</b>
<b>c) Shares fully paid</b> C.Y. 58,19,666 (P.Y. 57,74,666) - Equity shares of Rs. 10/- each	581.97	577.47
	<b>581.97</b>	<b>577.47</b>

d) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period.

Particulars	As at 31st March, 2024		As at 31st March, 2023	
	Numbers	Rs. in Lakhs	Numbers	Rs. in Lakhs
At the beginning of the period	5,774,666	577.47	5,774,666	577.47
Add / (Less) : Changes during the year (refer note No. 53)	45,000	4.50	-	-
At the end of the period	<b>5,819,666</b>	<b>581.97</b>	<b>5,774,666</b>	<b>577.47</b>

e) Terms & Rights attached to each class of shares;

The Company has only one class of equity shares having par value of Rs. 10 per share. Each holder of equity shares is entitled to one vote per share. In the event of the liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company. The distribution will be in proportion to the number of equity shares held by the shareholders.

f) Shares reserved for issue under options

Pursuant to approved employee stock option scheme "Bharat Parenterals Employee Stock Option Plan 2020", the Company has granted 2,00,000 nos of employees stock options of which 45,000 (31 March 2023: NIL) of the options have been exercised (also refer note 53).

f) Shareholding of promoters;

Promoter Name	As at 31st March, 2024			As at 31st March, 2023		
	No of shares	% of total shares	% change during the year	No of shares	% of total shares	% change during the year
Bharat R. Desai	741,515	12.74%	-0.10%	741,515	12.84%	0.00%
Hima B. Desai	783,430	13.46%	-0.10%	783,430	13.57%	0.00%
Pooja P. Shah	500	0.01%	0.00%	500	0.01%	0.00%
Shailesh G. Desai	2,600	0.04%	0.00%	2,500	0.04%	0.00%
Bhahim B. Desai	1,699	0.03%	-0.01%	2,500	0.04%	0.00%
Lataben S. Parikh	2,000	0.03%	0.00%	2,000	0.03%	0.00%
Desai shares and stock Private Limited	2,731,536	46.94%	-0.37%	2,731,536	47.30%	0.00%

g) Shares held by shareholders each holding more than 5% of the shares

Shareholders	As at 31st March, 2024		As at 31st March, 2023	
	No. of shares	Percentage	No. of shares	Percentage
<b>Equity shares with voting rights</b>				
Bharat R. Desai	741,515	12.74%	741,515	12.84%
Hima B. Desai	783,430	13.46%	783,430	13.57%
Desai shares and stock Private Limited	2,731,536	46.94%	2,731,536	47.30%
Asoj Soft Caps Private Limited (Anchor)	340,130	5.84%	340,130	5.89%
<b>Total</b>	<b>4,596,611</b>	<b>78.98%</b>	<b>4,596,611</b>	<b>79.60%</b>

18 Other Equity

Particulars	As at 31st March, 2024	As at 31st March, 2023
General Reserve	3.99	3.99
Employee Stock Option Reserve	0.00	53.09
Security Premium reserve	259.47	152.37
Retained Earnings	18,881.25	17,492.71
<b>Total</b>	<b>19,144.72</b>	<b>17,702.16</b>

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>General Reserve</b>		
As per last Balance Sheet	3.99	3.99
	<b>3.99</b>	<b>3.99</b>
<b>Employee Stock Option Reserve</b>		
Balance as per the last financial statements	53.09	-
Add: Reserve Created during the year	59.28	53.09
Less: Reserve Utilised during the year	112.37	-
<b>Total</b>	<b>0.00</b>	<b>53.09</b>
<b>Security Premium reserve</b>		
Balance as per the last financial statements	152.37	152.37
Add: Utilised during the year	107.10	-
<b>Total</b>	<b>259.47</b>	<b>152.37</b>
<b>Retained Earnings</b>		
Balance as per the last financial statements	17,492.71	15,848.67
Add: Profit for the year as per Statement of Profit and Loss	1,451.71	1,639.74
Less: Equity Dividend	(43.31)	-
<b>Items of Other Comprehensive Income</b>		
Remeasurement of the Net Defined benefit liability/asset, net of tax effect	(19.86)	4.30
<b>Total</b>	<b>18,881.25</b>	<b>17,492.71</b>

18.1 The General Reserve is used from time to time to transfer profits from retained earnings for appropriation purposes. As the General Reserve is created by a transfer from one component of equity to another and is not an item of other comprehensive income, items included in the general reserve is not reclassified subsequently to the Statement of Profit and Loss.

18.2 Employee Stock Option Reserve is used to recognise the fair value of equity settled share based payment transactions.

18.3 Security premium reserve is used to record the premium on issue of equity share under ESOP scheme. The reserve is utilised in accordance with the provision of the Companies Act, 2013.

**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**19 Borrowings**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Secured - at amortized cost</b>		
(a) Term Loans		
- from Banks (Refer below note (i) and (ii))	7,025.23	685.83
-Vehicle Loans (Refer below note (iii))	40.90	3.12
<b>- Inter Corporate Deposits (Refer note (iv))</b>		
(i) Seven oaks Lifesciences LLP	-	403.07
-Deposits from Directors	250.10	-
(To be repaid after 2 years and rate of Interest is 7% P.a.)		
<b>Total</b>	<b>7,316.22</b>	<b>1,092.02</b>

(i) The above Term loans are secured by first charge by way of hypothecation of all the movable machinery financed or to be financed under the said term loans by the respective banks. The above Term Loan also includes hypothecation of entire Plant & Machinery (excluding Plant & Machinery covered under Primary Security) of the Company Situated at Survey No. 144 & 146, Jarod Samlaya Road, Haripura Village, Savli, Vadodara (Both Present & Future).

Interest rate on term loan is 1 Y MCLR (Presently 1 Y MCLR is 8.60%) + 0.60% p.a. i.e. 9.20% p.a. The Loan is repayable in 60 Equated monthly installment of Rs. 18.75 lakhs.

Interest rate on ECLGS loan is Repo + 2.4% presently 8.9% p.a. The Loan is repayable in 36 Equated monthly installment after the end of 24 months of moratorium.

**(ii) Maturity profile of Secured Term loans are set out below:**

Particulars	Amount
0-1 year	356.92
1-2 years	263.26
2-3 years	6,405.05

(iii) The above Vehicle Loans are secured by way of Hypothecation of respective Vehicles.

(iv) The rate of interest for the above loan is ranging from 6% p.a. to 7% p.a. and repayable within 9 years.

**20 Provisions**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>a) Provision for employee benefits</b>		
Provision for Compensated absences	91.68	70.55
Provision for Gratuity (Refer Note 36)	118.60	62.10
<b>Total</b>	<b>210.29</b>	<b>132.66</b>

**21 Borrowings**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Secured</b>		
a) Current Maturities On Long Term Debt (Refer note 19 (i) & (ii))	356.92	280.26
b) Loans repayable on demand (Refer below note) - Working capital loan and Packing Credit	8,084.87	3,602.17
<b>Total</b>	<b>8,441.80</b>	<b>3,882.43</b>

Note: (i) The above loan exclusively hypothecated against the entire current asset and entire movable fixed assets including plant and machinery (Present & Future) of the company, Further, the above loan is guaranteed by Mr. Bharat Desai & Mr. Hima Desai. Rate of interest on the above cash credit facility ranges from 8% to 8.74 % P.a.

Note: (ii) The company has borrowings from banks secured against the current asset and quarterly returns filled for the same with the banks are in agreement with the books of accounts of the company.

**22 Trade Payables**

Particulars	As at 31st March, 2024	As at 31st March, 2023
Total outstanding due to Micro and Small Enterprises	102.71	401.79
Total outstanding due to other than Micro and Small Enterprises	5,900.52	4,732.54
<b>Total</b>	<b>6,003.22</b>	<b>5,134.32</b>

Note: Refer Note 47 for Aging of Trade Payable.

**BHARAT PARENTERALS LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**

ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED

**23 Other Financial Liabilities**

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Security Deposits	27.10	29.66
(b) Other payable*	1,494.58	979.27
(c) Unpaid Dividend	3.84	-
(d) Payable for Fixed Asset	709.48	702.89
<b>Total</b>	<b>2,235.00</b>	<b>1,711.82</b>

\*Include Commission payable pertains to Sales.

**24 Other Current Liabilities**

Particulars	As at 31st March, 2024	As at 31st March, 2023
(a) Advances from Customers	1,431.77	746.13
(b) Statutory Dues	170.53	74.60
(c) Salary and Wages Payable	224.96	170.85
(d) Other payable	351.39	99.33
<b>Total</b>	<b>2,178.65</b>	<b>1,090.92</b>

**25 Provisions**

Particulars	As at 31st March, 2024	As at 31st March, 2023
<b>Provision for employee benefits</b>		
(a) Provision for compensated absences	4.65	2.66
(b) Provision for Gratuity (Refer Note 36)	16.51	7.08
(c) Provision for Bonus	158.53	97.41
<b>Total</b>	<b>179.70</b>	<b>107.15</b>

**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**26 Revenue from Operations**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Sale of Products	25,372.38	21,750.13
Sale of services	323.40	-
Other Operating Revenue	40.28	48.02
<b>Total</b>	<b>25,736.07</b>	<b>21,798.15</b>

**26.1 Sale of Products comprises of :**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Domestic Sales	7,704.61	8,148.19
Export Sales	15,742.92	10,863.75
Deemed Export	1,924.86	2,738.19
<b>Total</b>	<b>25,372.38</b>	<b>21,750.13</b>

**26.2 Other operating revenue comprises of :**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Sale of Scrap	31.56	41.88
Services Income - Job work	8.72	6.14
<b>Total</b>	<b>40.28</b>	<b>48.02</b>

**27 Other Income**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Interest Income	42.04	33.81
Fair Value change of investment held for trading	-	(20.50)
Gain / (Loss) on sale of investments (Net)	-	54.78
Export Incentives	204.82	132.21
Gain/(loss) on sale of Property, Plant and Equipments (Net)	-	(9.13)
Net gain on foreign currency transactions/translations	333.03	469.85
Bad Debts Recovered	66.00	18.00
Amount no longer payable written back	16.74	-
Recovery of freight and other charges	123.89	433.71
Non operating income	72.69	61.17
<b>Total</b>	<b>859.20</b>	<b>1,173.91</b>

**28 Cost of Raw Material and Components**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Cost of Raw Material Consumed	17,316.50	14,606.93
<b>Total</b>	<b>17,316.50</b>	<b>14,606.93</b>

**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**29 Purchase of Traded goods**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Purchase of Traded goods	37.64	116.48
<b>Total</b>	<b>37.64</b>	<b>116.48</b>

**30 Changes in inventories of finished goods, work-in-progress and stock-in-trade**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Inventories at the end of the year:		
Finished Goods	2,488.86	984.36
Work-in-Progress	436.90	422.44
	<b>2,925.77</b>	<b>1,406.80</b>
Inventories at the beginning of the year:		
Finished Goods	984.36	249.94
Work-in-Progress	422.44	181.53
	<b>1,406.80</b>	<b>431.47</b>
<b>Net (increase) / decrease</b>	<b>(1,518.97)</b>	<b>(975.33)</b>

**31 Employee benefits expense**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Salaries, Wages and Bonus	2,055.03	1,628.15
Share Based Payment	13.96	53.09
Contributions to Provident Fund and Other Funds	172.99	105.50
Staff Welfare Expenses	36.25	12.85
<b>Total</b>	<b>2,278.22</b>	<b>1,799.59</b>

**32 Finance costs**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Interest expense on borrowings	317.51	213.77
Interest due to MSME Vendors	4.99	4.82
<b>Total</b>	<b>322.49</b>	<b>218.59</b>

**BHARAT PARENTERALS LIMITED**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**

**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**33 Other Expenses**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Power and Fuel	469.49	375.44
Consumption of Stores and spares	355.04	282.15
Manufacturing Processing cost	633.99	527.48
Carting, Freight, Octroi Inwards	11.96	13.06
<b>Repairs &amp; Maintenance</b>		
-Machinery	105.73	81.96
-Building	87.03	89.89
-Others	18.28	16.17
Sales promotion and advertisement Expenses	175.49	76.72
Legal and Professional Fees	363.79	237.85
Freight / Clearing and Forwarding Charges on Sales	729.62	740.47
Payments to Auditors (Refer note 41)	8.35	4.76
Corporate Social Responsibility Expenses (Refer Note 42)	56.75	65.59
Travelling Expense	116.43	135.27
Research and development expenses	103.32	104.91
Commission on sales	868.26	816.74
Provision for Expected Credit Loss	40.00	42.25
Bank charges	84.09	40.97
Bad debts	85.20	-
Loss on discard of Property, Plant & equipments (Net)	8.46	-
Rates and Taxes	110.38	1.76
Donation	0.69	0.67
Insurance Expense	241.33	241.03
Deduction and Damages Expenses	163.01	7.52
Miscellaneous Expenses	548.48	360.20
<b>Total</b>	<b>5,385.16</b>	<b>4,262.85</b>

**BHARAT PARENTERALS LIMITED**
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**
**34 TAX EXPENSE**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>(a) Income tax expense</b>		
<i>Current tax</i>	868.89	840.32
Short/ (Excess) provision of earlier year	(3.29)	-
(i) <i>Total Current tax expenses</i>	865.60	840.32
(ii) <i>Total Deferred tax expenses (Benefits)</i>	(44.87)	(57.08)
	(44.87)	(57.08)
Total Income tax expenses (i + ii)	820.72	783.24
<b>(b) Reconciliation of tax expense and the accounting profit multiplied by India's tax rate</b>		
Profit before income tax expense	1,872.17	2,354.71
<b>Tax at the Indian tax rate of 25.17% (2022-2023 - 25.17%)</b>	471.19	592.63
Tax effect of amounts which are not deductible / (taxable) in calculating taxable income:		
Income considered separately	-	114.63
Non-deductible tax expenses (Disallowances u/s 43B etc)	31.78	-
deductible tax expenses (allowances u/s 35)	-	(1.95)
Short/ (Excess) provision of earlier year	(3.29)	-
Others (including Deferred tax)	321.05	77.92
<b>Income Tax Expense</b>	<b>820.72</b>	<b>783.23</b>

**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**35 Earnings per share (EPS)**

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the Company by the weighted average number of Equity shares outstanding during the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of Equity shares outstanding during the year.

**i. Profit attributable to Equity holders of Company**

Particulars	31st March, 2024	31st March, 2023
Profit attributable to equity holders of the Company for basic and diluted earnings per share	1,451.71	1,639.74

**ii. Weighted average number of ordinary shares**

Particulars	31st March, 2024	31st March, 2023
Issued ordinary shares(in Nos)	5,819,666	5,774,666
Weighted average number of shares at March 31 for basic and diluted earnings per shares	5,821,633	5,774,666
<b>Basic earnings per share</b>	<b>24.94</b>	<b>28.40</b>



**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**36 Disclosure as required under Ind AS 19 - Employee Benefits**

**[A] Defined contribution plans:**

The Group makes contributions towards provident fund to defined contribution retirement benefit plan for qualifying employees. The provident fund contributions are made to Government administered Employees Provident Fund. Both the employees and the Company make monthly contributions to the Provident Fund Plan equal to a specified percentage of the covered employee's salary.

The Group recognised Rs. 109.83 lakhs (P.Y : Rs. 75.21 lakhs ) for provident fund contributions in the Statement of Profit and Loss.

**[B] Defined benefit plan:**

The Holding company makes contributions to Gratuity Fund managed by ICICI Prudential life insurance, a funded defined benefit plan for qualifying employees. The scheme provides for payment to vested employees as under:

i) On normal retirement / early retirement / withdrawal / resignation: As per the provisions of Payment of Gratuity Act, 1972 with vesting period of 5 years of service.

ii) On death in service: As per the provisions of Payment of Gratuity Act, 1972 without any vesting period.

The following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at 31st March, 2023.

**Defined benefit plans- As per actuarial valuation**

a) Reconciliation in present value of obligations (PVO) - Defined Benefit Obligation:	Gratuity Funded	
	31st March, 2024	31st March, 2023
Present value of Benefit Obligations at the beginning of the period	215.63	204.27
Current Service Cost	34.31	26.22
Interest Cost	15.31	15.12
Benefits paid	(4.71)	(16.94)
Actuarial (Gains) / Losses due to change in assumptions	39.75	(13.04)
<b>Present value of Benefit Obligations at the end of the period</b>	<b>300.29</b>	<b>215.63</b>

b) Change in fair value of plan assets:	Gratuity Funded	
	31st March, 2024	31st March, 2023
Fair value of Plan assets at the beginning of the year	146.45	159.50
Expected Return on plan assets	10.23	11.18
Benefits paid	(4.71)	(16.94)
Actuarial Gains and (Losses)	13.21	(7.29)
<b>Fair value of Plan assets at the end of the year</b>	<b>165.19</b>	<b>146.45</b>

c) Reconciliation of PVO and fair value of plan assets:	Gratuity Funded	
	31st March, 2024	31st March, 2023
Present value of Benefit Obligations at the end of the period	300.29	215.63
Fair value of Plan assets at the end of the year	165.19	146.45
<b>Net (Asset) / Liability recognised in Balance sheet</b>	<b>135.11</b>	<b>69.18</b>

d) Net Expenses recognised in the statement of Profit and Loss accounts	Gratuity Funded	
	31st March, 2024	31st March, 2023
Net Interest Cost	5.08	3.94
Current Service Cost	34.31	26.22
<b>Total</b>	<b>39.39</b>	<b>30.16</b>

e) Amount recognised in Other comprehensive income Remeasurements:	Gratuity Funded	
	31st March, 2024	31st March, 2023
Actuarial (Gains) / Losses	26.54	(5.75)

f) Assumptions used in the accounting for the gratuity plan:	Gratuity Funded	
	31st March, 2024	31st March, 2023
Discount Rate (%)	7.10%	7.40%
Salary escalation rate (%)	7.00%	7.00%
Mortality* :		
* Indian Assured Lives Mortality (2012-14) Ult.		

37 Related Party Disclosures

a) Name of the related party and nature of relationship: -

Sr No	Particulars	Relationship
<b>I</b>	<b>Key Managerial Personnel / Directors:</b> Mr. Bharat Desai Mr. Hemang J. Shah Mr. Shaileshkumar Ghabhawala Mrs. Zankhana Sheth Mr. Mukeshbhai Jivrajbhai Patel Mr. Sanjay Parasmal Shah Mr. Jignesh Shah Mr. Shyam Rajpurohit Krutika Bhatt	Managing Director Executive Director Independent Director Independent Director Independent Director Non Executive Director Chief Financial Officer Company secretary (Upto 02.10.2023) Company secretary (w.e.f 02.10.2023)
<b>II</b>	<b>Relatives of Key Managerial Personnel / Directors:</b> Mrs. Shital H. Shah Mr. Bahim B Desai Mrs. Nikita Shah Mrs. Himaben b. Desai Mr. Keval Shah	Relatives of Director Relatives of Director Relatives of Director Relatives of Director Relatives of Director
<b>III</b>	<b>Enterprise in which is director or his relatives are interested or director</b> Varenyam Healthcare Private Limited	Enterprise in which is director or his relatives are interested or director

b) Key Managerial Personnel Compensation

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Short-term employee benefits	204.87	183.82
Terminal Benefits	2.59	1.30
<b>Total Compensation</b>	<b>207.46</b>	<b>185.12</b>

c) Transactions with Related Parties:

During the year, the following transactions were carried out with related parties and relative of Key Managerial Personnel in the ordinary course of the business.

Sr No	Particular	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>a)</b>	<b>Enterprise in which is director or his relatives are interested or director</b>		
1	<b>Varenyam Healthcare Private Limited</b>		
i)	Sale of Goods	2,405.34	1,250.79
ii)	Purchase of Goods	18.13	82.29

**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**d) Outstanding Balances**

Sr No	Key Managerial Personnel and their relatives	Name of Parties	Year ended 31st March, 2024	Year ended 31st March, 2023
1	<b>Key Managerial Personnel</b> Remuneration	Mr. Bharat Desai	143.11	143.17
		Mr. Hemang J. Shah	40.24	25.71
		Mr. Jignesh Shah	15.22	10.33
		Mr. Shyam Rajpurohit	4.17	3.07
		Ms. Krutika Bhatt	4.72	-
2	Sitting Fees to Directors	Mr. Shaileshkumar Ghabhawala	0.10	0.20
		Mrs. Zankhana Sheth	0.10	0.20
		Mr. Bharat Desai	0.10	0.20
		Mr. Hemang J. Shah	0.10	0.20
		Mr. Mukeshbhai J. Patel	0.10	0.20
		Mr. Sanjay P. Shah	0.10	0.20
3	Sale of Property Plant and Equipment's	Mr. Bharat Desai	-	32.61
4	<b>Relatives of Key Managerial Personnel</b> Remuneration/Perquisite	Mr. Bhahim B Desai	74.73	67.88
		Mrs. Nikita Shah	39.96	36.01
		Mrs. Himaben b. Desai	171.84	173.65
5	Consultancy Expenses	Mrs. Shital H. Shah	11.00	9.00

**e) Outstanding Balances**

Sr No	Particulars	As at 31st March, 2024	As at 31st March, 2023
1	<b>Key Managerial Personnel and relatives</b>		
	Mr. Bharat Desai	11.50	11.50
	Mrs. Himaben b. Desai	9.44	9.44
	Mr. Hemang J. Shah	2.24	2.09
	Mr. Jignesh Shah	1.03	0.82
	Mr. Bhahim B Desai	1.56	0.92
	Mrs. Nikita Shah	0.83	0.52
	Mr. Shyam Rajpurohit	-	0.5
Ms. Krutika Bhatt	0.84		
2	<b>Enterprise in which is director or his relatives are interested or director</b>		
	Varenyam Healthcare Private Limited	1,288.60	1,138.46

**38 Contingent Liabilities**

Sr No	Particulars	As at 31 March, 2024	As at 31 March, 2023
<b>(i)</b>	<b>Contingent liabilities</b>		
	a) Liabilities Disputed in appeals		
	- Income Tax	86.14	86.14
	- Service Tax	10.75	10.75
	b) Letter of Credit, Bank Guarantees and corporate Guarantees	2,136.91	2,571.84
	<b>Total</b>	<b>2,233.81</b>	<b>2,668.73</b>
<b>(ii)</b>	<b>Commitments</b>		
	Estimated amount of contracts remaining to be executed on capital account & not provided for:		
	-Tangible Assets	1,879.47	81.71

**39 Disclosure pursuant to leases**

**As Lessee:**

**Short term Leases:**

The Group has obtained premises for its business operations under operating lease or leave and license agreements. These are not non-cancellable and are renewable by mutual consent on mutually agreeable terms.

Lease payments are recognised in statement of Profit and Loss under the head "Rent Expense" in note no 33.

**40 Disclosure related to Micro and Small Enterprises**

On the basis of confirmation obtained from the supplier who have registered themselves under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006) and based on the information available with the Group, the following are the details:

Particulars	As at 31 March, 2024	As at 31 March, 2023
(a) the principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year (Refer below notes)	102.71	401.79
(b) the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	4.99	-
(c) the amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;	-	4.82
(d) the amount of interest accrued and remaining unpaid at the end of each accounting year; and	-	12.11
(e) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises	-	-

41 Auditor's Remuneration

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>Statutory Auditors</b>		
Audit Fees (including for quarterly limited review)	4.55	4.55
For certification	1.31	0.21
For other matters	2.49	-
<b>Total</b>	<b>8.35</b>	<b>4.76</b>

42 Corporate Social Responsibility (CSR)

As per section 135 of the Companies Act, 2013, a CSR committee has been formed by the holding company. The areas for CSR activities are promoting education, art and culture, healthcare, destitute care and rehabilitation and rural development projects as specified in Schedule VII of the Companies Act, 2013. The details of amount required to be spent and actual expenses spent during the year is as under:

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
(a) Gross amount required to be spent by the holding company during the year	53.85	59.51
<b>(b) Amount spent during the year on</b>		
<b>1. Construction / Acquisition of Assets</b>		
- In cash	-	-
- Yet to be paid in cash	-	-
<b>2. On purpose other than (i) above</b>		
- In cash	56.75	65.59
- Yet to be paid	-	-
(c) Shortfall at the end of the year	-	-
(d) Total of previous years shortfall	-	-
(e) Reason for shortfall		
	Rural Development, Health & Education promotion etc..	Rural Development, Health & Education promotion etc..
(f) Nature of CSR activities		
(g) Details of related party transactions		
<b>(h) Movements in the provision of CSR during the year</b>		
Balance at the beginning of the year	-	-
Provision made during the year	-	-
Provision utilised during the year	-	-
Balance at the end of the year	-	-

**43 Operating Segments**

The activities of the Group relate to only one segment i.e. Manufacturing of Pharmaceuticals Formulations

**Geographical Information**

The analysis of geographical information is based on the geographical location of the customers. The geographical information considered for disclosure are as follows:

**Revenue by Geography**

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Within India	9,629.47	10,886.38
Outside India	16,066.32	10,863.75

**Carrying value of segment assets**

Particulars	As at 31st March, 2024	As at 31st March, 2023
Within India	40,028.85	29,142.22
Outside India	10,353.43	5,892.03

**Property, Plant & Equipment by Geographical Locations**

The Group has common PPE for producing goods for domestic as well as overseas market. There are no PPE situated outside India. Hence, additional segment-wise information for PPE / additions to PPE has not been furnished.

**44 Expenditure on Formulation and Development (R&D)**

The Group's F&D center as certified by Department of Scientific and Industrial Research function at survey No. 144/146 Jarod - Samlaya road, Village Haripura, Vadodara

Expenditure incurred in the F&D center during the financial year 2023-24 & 2022-23 are given below

Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Capital Expenditure	-	1.95
Recurring Expenditure	106.07	137.78
<b>Total Expenditure</b>	<b>106.07</b>	<b>139.73</b>

**45 Investment Property:**

(i) Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
Amount recognised in Statement of Profit or Loss for investment properties Rental Income	-	-
Direct operating expenses from property that generated rental income	-	-
Depreciation	(9.06)	(9.86)
<b>Profit from Investment Property</b>	<b>(9.06)</b>	<b>(9.86)</b>

(ii) Particulars	Year ended 31st March, 2024	Year ended 31st March, 2023
<b>Fair Value</b>		
Investment Properties	193.54	193.54
<b>Total</b>	<b>193.54</b>	<b>193.54</b>

Estimation of fair value: Method of Estimation

In the absence of valuation reports, the Group has used the government registration rates for the purpose of determining the fair value of Land and Buildings.

**BHARAT PARENTERALS LIMITED**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2024**  
**ALL AMOUNTS ARE IN RS. LAKHS UNLESS OTHERWISE STATED**

**46 Trade receivables aging**

Particulars	Outstanding for following periods from due date of Payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
<b>As at 31st March, 2024</b>						
(i) Undisputed Trade receivables – considered good	11,072.7	1,920.64	905.18	358.52	214.45	14,312.44
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	38.04	38.04
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
Less : Expected Credit Loss Allowance	(65.04)	(11.72)	(45.26)	(35.85)	(50.50)	(208.37)
% Expected Credit Loss Allowance to Trade Receivable	-0.59%	-0.61%	-5.00%	-10.00%	-20.00%	
<b>Total</b>	<b>11,007.61</b>	<b>1,908.92</b>	<b>859.92</b>	<b>322.66</b>	<b>201.99</b>	<b>14,142.11</b>
<b>As at 31st March, 2023</b>						
(i) Undisputed Trade receivables – considered good	9,283.28	1,073.06	671.40	112.47	246.50	11,386.72
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	22.33	22.33
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables–considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
Less : Expected Credit Loss Allowance	(62.59)	(7.19)	(33.57)	(11.25)	(53.77)	(168.37)
% Expected Credit Loss Allowance to Trade Receivable	-0.67%	-0.67%	-5.00%	-10.00%	-20.00%	
<b>Total</b>	<b>9,220.69</b>	<b>1,065.87</b>	<b>637.83</b>	<b>101.22</b>	<b>215.07</b>	<b>11,240.68</b>

**47 Trade Payable Aging**

Particulars	Outstanding for following periods from due date of Payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at 31st March, 2024</b>					
(i) MSME	87.70	8.05	6.96	-	102.71
(ii) Others	5,778.56	50.91	7.08	63.96	5,900.51
(iii) Disputed dues – MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
<b>Total</b>	<b>5,866.26</b>	<b>58.96</b>	<b>14.04</b>	<b>63.96</b>	<b>6,003.22</b>
<b>As at 31st March, 2023</b>					
(i) MSME	394.53	7.26	-	-	401.79
(ii) Others	4,534.62	21.57	9.05	167.27	4,732.51
(iii) Disputed dues – MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
<b>Total</b>	<b>4,929.15</b>	<b>28.83</b>	<b>9.05</b>	<b>167.27</b>	<b>5,134.30</b>

48 Fair Value Measurements

Financial instruments by category

Particulars	As at 31st March, 2024			As at 31st March, 2023		
	FVTPL	FVOCI	Amortized Cost	FVTPL	FVOCI	Amortized Cost
<b>Financial Assets</b>						
Trade Receivables	-	-	14,142.11	-	-	11,240.68
Cash and Cash Equivalents	-	-	870.96	-	-	785.23
Bank balances other than above	-	-	338.45	-	-	212.96
Loans	-	-	10.73	-	-	6.57
Other Financial Assets	-	-	706.63	-	-	698.04
<b>Total Financial Assets</b>	-	-	<b>16,068.89</b>	-	-	<b>12,943.48</b>
<b>Financial Liabilities</b>						
Borrowings	-	-	15,758.02	-	-	4,974.45
Other current financial Liabilities	-	-	2,235.00	-	-	1,711.82
Trade payables	-	-	6,003.22	-	-	5,134.32
<b>Total Financial Liabilities</b>	-	-	<b>23,996.24</b>	-	-	<b>11,820.60</b>

(i) Fair value hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are (a) recognized and measured at fair value. To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

**Level 1:** Level 1 hierarchy includes financial instruments measured using quoted prices.

**Level 2:** The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

**Level 3:** If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

There are no transfers between levels 1 and 2 during the year.

The Company's policy is to recognise transfers into and transfers out of fair value hierarchy levels at the end of the reporting period.

(ii) Valuation technique used to determine fair value

Specific valuation techniques used to value financial instruments include:

- the use of quoted market prices or dealer quotes for similar instruments
- the fair value of the remaining financial instruments is determined using discounted analysis(if any).



#### 49 Financial Risk Management

The Group's Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework.

The Group's risk management policies are established to identify and analyse the risks faced by the Group, to set appropriate risk limits and controls and to monitor risks. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group's activities.

##### (A) Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group's receivables from customers, loans and investments. Credit risk is managed through continuous monitoring of receivables and follow up for overdues.

##### (i) Investments

The Group limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Group does not expect any losses from non-performance by these counter parties, and does not have any significant concentration of exposures to specific industry sector or specific country risks.

##### (ii) Trade Receivables

The Group has used Expected Credit Loss (ECL) model for assessing the impairment loss. For the purpose, the Group uses a provision matrix to compute the expected credit loss amount. The provision matrix takes into account external and internal risk factors and historical data to credit losses from various customers.

Reconciliation of loss allowance provision – Trade receivables

Particulars	(Rs. In Lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
Balance at the beginning of the year	168.37	126.12
Changes in loss allowance	40.00	42.25
Balance at the end of the year	208.37	168.37

Other than trade and other receivables, the Group has no other financial assets that are past due but not impaired.

##### (B) Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The responsibility for liquidity risk management rests with the board of directors, which has established an appropriate liquidity risk management framework for the management of the Group's short-term, medium-term and long-term funding and liquidity management requirements. The Group manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities.

##### (i) Maturities of financial liabilities

The tables herewith analyse the Group's financial liabilities into relevant maturity groupings based on their contractual maturities for:

The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

##### Contractual maturities of financial liabilities

Particulars	Less than 1 year	More than 1 year	Total
<b>As at 31st March, 2024</b>			
<b>Non-derivatives</b>			
Borrowings	8,441.80	7,316.22	15,758.02
Trade payables	6,003.22	-	6,003.22
Other financial liabilities	2,235.00	-	2,235.00
<b>Total Non-derivative liabilities</b>	<b>16,680.02</b>	<b>7,316.22</b>	<b>23,996.24</b>
<b>As at 31st March, 2023</b>			
<b>Non-derivatives</b>			
Borrowings	3,882.43	1,092.02	4,974.45
Trade payables	5,134.32	-	5,134.32
Other financial liabilities	1,711.82	-	1,711.82
<b>Total Non-derivative liabilities</b>	<b>10,728.58</b>	<b>1,092.02</b>	<b>11,820.60</b>

(C) Market risk

(i) Price Risk

The Group is mainly exposed to the price risk due to its investments in securities. The price risk arises due to uncertainties about the future market values of these investments. The above instruments risk are arises due to uncertainties about the future market values of these investments.

**Management Policy**

The Group maintains its portfolio in accordance with the framework set by the Risk management Policies.

(ii) Foreign Currency Risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

The risk is measured through a forecast of foreign currency for the Group's operations.

The Group's exposure to foreign currency risk at the end of the reporting period expressed in Indian Rupee, are as follows:

(i) Trade receivable and other Receivable

Currency	As at 31st March, 2024		
	Trade receivable and other Receivable	Hedges available	Net exposure to foreign currency risk
USD	190.79	-	190.79
EURO	9,767.50	-	9,767.50

Currency	As at 31st March, 2023		
	Trade receivable and other Receivable	Hedges available	Net exposure to foreign currency risk
USD	5,265.14	-	5,265.14
EURO	-	-	-

(ii) Trade payable and other payable

Currency	As at 31st March, 2024		
	Trade payable and other payable	Hedges available	Net exposure to foreign currency risk
USD	16.87	-	16.87

Currency	As at 31st March, 2023		
	Trade payable and other payable	Hedges available	Net exposure to foreign currency risk
USD	177.18	-	177.18

**Sensitivity**

The sensitivity of profit or loss to changes in the exchange rates arises mainly from Unhedged foreign currency denominated financial instruments.

Particular	Impact on profit after tax	
	31st March, 2024	31st March, 2023
USD sensitivity		
INR/USD increases by 5%	8.70	254.40
INR/USD decreases by 5%	(8.70)	(254.40)
EUR sensitivity		
INR/EUR increases by 5%	488.37	-
INR/EUR decreases by 5%	(488.37)	-

**Capital Management**

50 Risk management

For the purpose of the Group's capital management, equity includes equity share capital and all other equity reserves attributable to the equity holders of the Group. The Group manages its capital to optimise returns to the shareholders and makes adjustments to it in light of changes in economic conditions or its business requirements. The Group's objectives are to safeguard continuity, maintain a strong credit rating and healthy capital ratios in order to support its business and provide adequate return to shareholders through continuing growth and maximise the shareholders value. The Group funds its operation through internal accruals. The management and Board of Directors monitor the return on capital as well as the level of dividends to shareholders.

**51 Share-based payments**

(a) The share-based payment plan is an employee option plan. The options are equity settled options.

At the annual general meeting of holding company held on 30th September, 2020, member of the company passed the special resolution for introducing "Bharat Parenterals Employee Stock Option Plan 2020" of 2,00,000 options for the benefit of the employee of the company. The resolution also accorded approval for the Board of Directors, to formulate the Scheme as per broad parameters outlined in the resolution. Pursuant to Scheme framed, the company has granted options to eligible employees of the company under plan. Each options entitle for one equity share. The company granted 90,000 Stock Option to its employees by virtue of grant letter dated 12th, November, 2020 and 17th, June, 2022. The vesting conditions of which are as outlined in their grant letter. Necessary impact have been considered. Further, the company has not yet granted the 1,10,000 Stock Option to its employees. The options are exercisable at an exercise price of Rs. 99 per share (Face Value of Rs.10 per share).

**(b) Set out below is the summary of options**

Particular	Year ended 31 March 2024		Year ended 31 March 2023	
	Average exercise price/ share in Rs.	No. of options	Average exercise price/ share in Rs.	No. of options
Opening balance	99	45,000	-	-
Granted during the year	-	-	99	45,000
Exercised during the year	99	45,000	-	-
Forfeited during the year	-	-	-	-
<b>Closing balance</b>	-	-	<b>99</b>	<b>45,000</b>
<b>Vested and exercisable</b>	-	-	<b>99</b>	<b>45,000</b>

**(c) Share options outstanding at the end of the year have the following exercise period and exercise prices :**

Grant	Grant Date	Exercise period	Share Options as on 31 March 2024	Share Options as on 31 March 2023
Grant I - Exercise price Rs. 99.00	12-11-2020	1 years from the date of listing	-	-
Grant II - Exercise price Rs. 99.00	17-06-2022	1 years from the date of listing	-	-

**(d) No options expired during the year ended 31 March 2024 and 31 March 2023.****(e) Contractual life of options**

Grant	Grant Date	Expiry Date	Share Options as on 31 March 2024	Share Options as on 31 March 2023
Grant I - Exercise price Rs. 99.00	12-11-2020	11-11-2021	-	-
Grant II - Exercise price Rs. 99.00	17-06-2022	16-06-2023	-	-

The holding company has charged to statement of Profit and Loss as employee benefit expenses Rs. 13.96 Lakhs (P.Y. 53.09 Lakhs) by creating an Employee stock option reserve which is grouped under the head 'Other Equity'.

**52 Other disclosures**

(i) The Group do not have any Benami property, where any proceeding has been initiated or pending against The Group for holding any Benami property.

(ii) The Group do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(iii) The Group have not traded or invested in Crypto currency or Virtual Currency during the year.

(iv) The Group have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (Ultimate Beneficiaries) or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(v) The Group have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that The Group shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

vi) The Group do not have any such transaction which is not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax

assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)

vii) The Group holds all the title deeds of immovable property in its name.

viii) The Group is not declared as willful defaulter by any bank or financial Institution or other lender.

ix) There is no Scheme of Arrangement approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.

**53 Other Disclosures as per Schedule - III**

Name of the company	Net Assets, i.e. total assets minus total liabilities		Share in Profit or loss	
	As % of consolidated net assets	Amount	As % of consolidated Profit and Loss	Amount
<b>Parent</b>				
Bharat Parenterals Limited	85.03%	20,252.97	179.59%	1,852.61
(Previous Year)	84.37%	18,385.16	108.96%	1,717.01
<b>Subsidiaries</b>				
Varenyam Biolifesciences Private Limited	-0.08%	(19.19)	-1.32%	(13.57)
(Previous Year)	-0.03%	(5.63)	-0.36%	(5.63)
Innoxel Lifesciences Private Limited	-2.13%	(507.09)	-39.47%	(407.19)
(Previous Year)	-0.46%	(99.90)	-4.27%	(67.25)
Minority Interest in subsidiary	17.18%	4,090.71	-38.80%	(400.27)
(Previous Year)	16.11%	3,510.27	-4.34%	(68.36)
<b>Total</b>	<b>100.00%</b>	<b>23,817.40</b>	<b>100.00%</b>	<b>1,031.59</b>
(Previous Year)	100.00%	21,789.90	100.00%	1,575.78

**54** The consolidated financial statements were authorized for issue in accordance with a resolution passed by the Board of Directors on 22nd May,2024. The financial statements as approved by the Board of Directors are subject to final approval by its Shareholders.

**55 Information on Dividend for the year ended 31st March, 2024**

Dividends proposed or declared after the balance sheet date but before the financial statements have been approved by the Board of Director of the holding company for issue are not recognised as a liability at the balance sheet date.

The Board of Director recommended final dividend of Rs 1.00 per equity share for the financial year ended on 31st March, 2024. The payment is subject to approval of share holder in ensuing Annual General Meeting of the Company. (Previous year Rs. 0.75 per equity share).

The accompanying notes are an integral part of the financial statements.  
As per our Report of even date

**For C N K & Associates LLP**  
Chartered Accountants  
Firm Registration No.: 101961W/W-100036

For and on behalf of Board of Directors of  
**BHARAT PARENTERALS LIMITED**

**Rachit Sheth**  
Partner  
Membership No.: 158289

Place: Vadodara  
Date: 22nd May , 2024

**Bharat R Desai**  
Managing Director  
DIN: 00552596

**Hemang Shah**  
Director  
DIN: 03024324

**Krutika Bhatt**  
Company Secretary  
Place: Vadodara  
Date: 22nd May , 2024

**Jignesh Shah**  
Chief Financial Officer